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Signalling molecules and cell-cell communication in bacteria 
In bacteria, the major cell-cell communication is carried out by signalling molecules (Ryan 
and Dow, 2008). This communication involves the production and release of small molecules 
that are detected by their cognate receptors. This process, in most cases, requires a certain 
amount of cells to generate enough signalling molecules which in turn generates 
population-wide alterations in gene expression. Through this signalling molecule, the bacteria 
are able to monitor their population density and respond to the environment in a multi-cellular 
manner which is known as quorum sensing (Waters and Bassler, 2005). These cell-cell 
communications are interesting in several aspects. For example: (1) These signals are often 
required or involved in the biofilm formation which are associated with many diseases, 
especially those in humans (Costerton et al., 1999). By studying signalling mechanisms, it is 
possible to find ways to interfere with the formation of biofilms and thus to develop 
anti-microbial therapies (Welch et al., 2005). (2) The regulatory networks of the signalling 
molecules can be used for controlling recombinant gene expression (Bulter et al., 2004 and 
Weber et al., 2003). (3) Some signals and their regulatory pathways are being intensively 
studied because of their ability to elicit the production of valuable secondary metabolites such 
as antibiotics (Takano et al., 2006). To block cell-cell communication and to control antibiotic 
production, it is necessary to fully understand the signalling mechanism. 
In Gram-negative bacteria, N-acylhomoserine lactones (N-AHLs) are mainly used as the 
signals (Fuqua et al., 2001), although other factors such as fatty acid derivatives and cyclic 
dipeptides also can be used (Fig. 1; Ryan and Dow, 2008). In contrast, many Gram-positive 
bacteria use peptides or modified peptides as signals (Fig. 1; Lyon and Novick, 2004). However, 
signalling molecules which have a structure similar to N-AHL are also found in Gram-positive 
bacteria, namely γ-butyrolactones, produced by and studied extensively in Streptomyces (Fig. 1; 
Takano, 2006).  
In Gram-negative bacteria, the most intensively investigated signalling molecules are 
N-AHLs (Ryan and Dow, 2008). Generally, N-AHL is synthesized by an N-AHL synthase and 
binds to its cognate receptor only on reaching a critical threshold concentration. The bound 
complex, N-AHL and its receptor, then binds upstream of, and activates the transcription of, 
target gene(s), which in some cases can include N-AHL synthase, establishing a positive 
feedback loop for N-AHL synthesis (Fuqua et al., 2001). The diverse acyl chains of N-AHLs 
derived from fatty acid intermediates are crucial for signalling specificity (Fig 1; Fuqua and 
Eberhard, 1999). The N-AHL receptors possessing specific acyl-binding pockets can only bind 
and be activated by their cognate signals (Vannini et al., 2002). Therefore, each species is able 
to distinguish and respond to its own signals in a mixed-species environment in which multiple 





without an N-AHL synthase homologue are able to detect N-AHLs produced by other bacterial 
genera (Michael et al., 2001), which in some cases can lead to the death of one bacterial genus. 
As the N-AHLs are produced in a biofilm environment, this mechanism becomes very effective 
at low concentrations of the signalling molecules (Welch et al., 2005). N-AHL switches on 
mechanisms which are involved in bioluminescence, biofilm formation, antibiotic biosynthesis, 
plasmid conjugal transfer and other physiological changes (Fuqua et al., 2001).  
 
Figure 1. Chemical structures of signalling molecules produced by Gram-positive and Gram-negative bacteria. 
The names of the signalling molecules are indicated, with the producing strain listed in brackets under the 
chemical structures. Adapted with permission from Ryan and Dow, 2008.   
 
In Gram-positive bacteria, most peptide signals are cleaved from larger precursor peptides, 
which subsequently are modified to contain lactone and thiolactone rings, isoprenyl groups and 
lanthionines (Fig. 1; Waters and Bassler, 2005). Peptide signals are exported out of the cell and 
detected by their receptors which are the two-component type histidine kinases. A 
phosphorylation cascade resulting from the binding of the signalling peptide regulates the 





2002) and competence (Hamoen et al., 2003). Similar to the N-AHL system, signalling 
peptides are mainly recognized by their cognate species and, in some cases, by different strains 
of the same or related species. In the latter cases, the interspecies signalling can either activate 
or repress the target gene expression (Lyon et al., 2002). There are distinct differences between 
the N-AHL system in Gram-negative bacteria and the modified peptide system in 
Gram-positive bacteria. For instance: N-AHL diffuses freely across the membrane while 
peptide signals need dedicated oligopeptide exporters for releasing the peptide outside the cell; 
the receptor of N-AHL is in the cytoplasm while that of peptide signals is located in the 
cytoplasmic membrane (Ryan and Dow, 2008). However, a modified peptide system is not the 
only signal used in Gram-positive bacteria: γ-butyrolactones, diffusible signalling molecules, 
are found and studied mainly in the genus Streptomyces.     
 
Streptomyces 
Streptomycetes belong to the phylum of Actinobacteria and are Gram-positive bacteria 
(Fig. 2). Streptomyces are found predominately in soil and their abundant presence is 
responsible for the earthy odour which results from the production of a volatile compound 
called geosmin (Gust et al., 2003). Streptomyces are infrequent pathogens, though a few species 
can cause parasitic plant disease or infection in humans. For instance, Streptomyces scabies 
infects the underground tubers of potatoes causing scab disease (Loria et al., 1997) and 
Streptomyces somaliensis can cause mycetoma in humans (el Hassan et al., 2001). 
 
Figure 2. Colonies of S. coelicolor grown on solid medium. The droplets visible on colonies contain an antibiotic 
(actinorhodin) secreted by S. coelicolor. 
 
The complete genome sequence of Streptomyces coelicolor, the best-studied species as 
well as the model organism of Streptomyces, was the first to be finished in Streptomyces and 
published in 2002 (Bentley et al., 2002). The genome sequences of Streptomyces avermitilis 





These complete sequences reveal that Streptomyces species possess, instead of a circular 
chromosome commonly seen in bacteria, a linear chromosome with a high GC content (~72%). 
The length of the genome (~8 Mb) and the gene number (e.g. 7825 genes in S. coelicolor ), 
which is nearly twice the size of Escherichia coli (~4.6 Mb and 4288 genes, Blattner et al., 
1997) and Bacillus subtilis (~4.2 Mb and 4100 genes, Kunst et al., 1997), make Streptomyces 
one of the largest bacterial genomes sequenced.  
Streptomyces are unique among bacteria with a distinct colony morphology and a complex 
life cycle more closely resembling that of filamentous fungi, or a multi-cellular eukaryotic 
organism (Chater and Losick, 1997). On solid medium, substrate mycelia are formed from a 
germinating spore which elongate and branch rapidly in the culture medium. Subsequently, 
specialized branches emerge from substrate mycelia and grow upward into the air to form aerial 
mycelia. Then, aerial hyphae are divided into chains of unigenomic compartments by spore 
septa, eventually developing into thick-walled spores (Flärdh and Buttner, 2009).  
Streptomyces are also well known for their production of a variety of secondary 
metabolites which cover almost 70% of commercially available antibiotics (Hopwood, 2007) 
including streptomycin produced by S. griseus which is the anti-tuberculosis antibiotic whose 
discovery won Selman A. Waksman the Novel Prize in 1952 (Smith, 2000) and 
chloramphenicol produced by Streptomyces venezuelae (Piraee et al., 2004) which is the first 
antibiotic to be manufactured synthetically. 
The production of secondary metabolites usually coincides with the early stages of 
morphological differentiation, e.g. the formation of aerial mycelia in solid medium or during 
the transition phase to the stationary phase in liquid medium (Takano, 2006). The biosynthesis 
of secondary metabolites is influenced by various physiological signals. These include: the 
highly phosphorylated guanosine nucleotide, ppGpp which triggers antibiotic production under 
conditions of nitrogen-limitation (Bibb, 2005), Factor C (a protein) which induces sporulation 
(Biro et al., 2000), the antibiotic pamamycin which is an aerial mycelium stimulator, and 
γ-butyrolactones (some examples are shown in Fig. 3). In the following sections I have focused 
on the biosynthesis and regulation of the γ-butyrolactone signalling molecules.  
 
γ-butyrolactones, the small signalling molecules 
γ-butyrolactones are low-molecular-weight compounds effective at extremely low 
concentrations (10-9M) and are required as intrinsic factors for triggering secondary metabolism 
and/or morphological differentiation (Takano et al., 2006). Eleven γ-butyrolactones have been 
structurally characterized to date: they have a 2,3-di-substituted γ-butyrolactone skeleton in 
common with minor differences in the carbon side chain. They can be classified into three 





A-factor in S. griseus (Mori 1983), (2) virginiae butanolide (VB) type possessing a 
1’-α-hydroxyl group: VB-A through VB-E produced by Streptomyces virginiae (Kondo et al., 
1989; Yamada et al., 1987) and Gräfe’s three factors produced by Streptomyces bikiniensis and 
Streptomyces cyaneafuscatus (Gräfe et al., 1983), (3) IM-2 type possessing a 1’-β-hydroxyl 
group: IM-2 identified from Streptomyces lavendulae (Sato et al., 1989) and SCB1 identified 
from S. coelicolor (Takano et al., 2000) (Fig. 3, see Chapter 2 for details).  
 
Figure 3. Chemical structures of γ-butyrolactones and other signalling factors from Streptomyces. The names of 
the signalling molecules are shown in bold, and the strain which produces them is listed underneath the chemical 
structures. Antibiotic synthesis and cellular development regulated by γ-butyrolactone are shown in brackets next 
to its name. 
 
The Streptomyces strains studied in most detail are known to produce one type of 
γ-butyrolactones. However there are also reports that a specific strain produces more than one 
type of γ-butyrolactones. For example, Streptomyces celluloflavus (an aureothricin producer), 
Streptomyce sclerogranulatus (a sclerothricin producer) and Streptomyces tubercidicus (a 
tubercidin producer) were shown to produce both IM-2- and VB-active signalling compounds, 
as determined by bioassays (Hashimoto et al., 1992). However, the structures of these 
compounds have not yet been determined. 
Streptomyces is not the only genus which produces γ-butyrolactones. VB type and IM-2 





actinomycetes, Actinoplanes teichomyceticus (a teicoplanin producer) and Amycolatopsis 
mediterranei (a rifamycin producer), respectively (Choi et al., 2003). On the other hand, 
signalling molecules other than γ-butyrolactones with the ability to elicit secondary metabolites 
were also reported in Streptomyces (Fig. 3). The recent examples are PI factor 
(2,3-diamino-2,3-bis(hydroxymethyl)-1,4-butanediol) which elicits pimaricin production in 
Streptomyces natalensis (Recio et al., 2004) and five methylenomycin furans (MMFs; 
2-alky-4-hydroxymethylfuran-3-carboxylic acids) which induce methylenomycin production in 
S. coelicolor (Corre et al., 2008).  
 
The biosynthesis of γ-butyrolactones and methylenomycin furans  
Several proteins involved in γ-butyrolactone biosynthesis have been identified. The most 
recent study in S. griseus strongly indicates that AfsA is the key A-factor biosynthesis enzyme 
and catalyzes the first condensation of dihydroxyacetone phosphate (DHAP) and a β-keto acid 
derivative (Kato et al., 2007; see chapter 4, for details on the A-factor biosynthetic pathway). 
Many AfsA homologues in Streptomyces, including the 3 genome sequenced strains, have been 
identified (Table 1), indicating that this protein family is widespread in Streptomyces. In the 
AfsA family, the afsA homologues studied in most detail are barX in S. virginiae and scbA in S. 
coelicolor. These two genes show variations in their mutant phenotypes when compared to the 
afsA mutant (Table 2). Moreover, BarX is thought to be a regulator and ScbA is suggested to 
have a regulatory and/or enzymatic function, suggesting that AfsA homologues play different 
roles in Streptomyces. 
The origin of the β-keto acid derivative, whose structure determines the variation in the 
C-2 side chain of γ-butyrolactones, has been determined. Recently, Corre and his colleagues 
reported that MmfL, the AfsA homologue encoded on SCP1 (S. coelicolor plasmid 1; Table 1), 
plays an important role in MMF biosynthesis (Corre et al., 2008). When MmfL was solely 
expressed in E. coli, only MMFs with linear C-2 side chains (MMF2 and MMF5; see Fig. 3) 
were produced whereas in S. coelicolor, with wild-type scbA, five MMFs with both linear and 
branched C-2 side chains were produced. This observation is consistent with the fact that E. 
coli only produces straight-chain fatty acids while Streptomyces produces both straight- and 
branched-chain fatty acids. This indicates that the precursors of MMFs are derived from fatty 
acid biosynthesis. 
Corre and colleagues suggested that, based on feeding experiments (Corre et al., 2008 and 
Hu et al., 2000), MMF is derived from three molecules of acetate, which are able to form a 
β-keto acid derivative, and one molecule of glycerol; this is very similar to γ-butyrolactone 
biosynthesis (Fig. 4; Kato et al., 2007 and Sakuda et al., 1992). Therefore, they propose that 





which then are modified by different proteins resulting in SCBs, possessing a lactone ring, and 
MMFs, possessing a furan ring, respectively (Corre et al., 2008). However, ScbA and MmfL 
only share 30% amino acid identity with each other (Table 1). Whether these two proteins are 
able to catalyze the same reaction is under considerable debate. SCB1 is involved in the direct 
regulation of CPK and also affects the production of actinorhodin (Act) and undecylprodigiosin 
(Red) (Takano et al., 2000 and 2005). MMFs only induce the production of one antibiotic, 
methylenomycin (O’Rourke et al., 2008), whose gene cluster is also located on SCP1 adjacent 
to mmfL, suggesting a more specific, and not a global regulatory role.     
  
Figure 4. Scheme for A-factor, SCB1 and MMF biosynthesis. Acetate produced via the fatty acid biosynthesis is 
used to form a β-keto acid derivative which is condensed with a glycerol derivative by AfsA to form A-factor. 
Similarly, SCBs are produced by ScbA and MMFs by MmfL. This scheme has been suggested by Corre et al. 
(2008). 
 
The regulation cascade of A-factor and the γ-butyrolactone receptors  
Along with the study of the A-factor biosynthetic pathway, the A-factor regulatory cascade 
in S. griseus has also been studied (Horinouchi, 2007). A-factor is produced in a 
growth-dependent manner and accumulates during growth. The A-factor receptor, ArpA, binds 
to the promoter of the key transcriptional activator, AdpA and represses its expression in the 
exponential phase when the concentration of A-factor is below the critical level. When the 
concentration of A-factor reaches the critical level, it binds to ArpA, thus inhibiting ArpA 





transcription of several genes to stimulate morphological differentiation and the production of 
streptomycin and grixazone (Ohnishi et al., 2005). AdpA also binds to its own operator sites 
and represses its own expression allowing self-control of its intracellular concentration (Fig. 5; 
Kato et al., 2005).   
 
Figure 5. The A-factor regulatory cascade in S. griseus. A-factor synthesized by AfsA, the key A-factor 
biosynthesis enzyme, binds and dissociates the A-factor receptor (ArpA) from the promoter region of adpA, 
encoding a central transcriptional activator. AdpA activates many genes required for the production of 
streptomycin and grixazone, and for morphological differentiation, by binding to their promoter regions. AdpA 
also autorepresses its own expression by binding to its operator sites. Arrows denote activation and lines with a bar 
denote repression. 
 
Many γ-butyrolactone receptor proteins have been identified which have a common 
activity as a DNA binding transcriptional regulator controlling secondary metabolism and/or 
morphological differentiation in Streptomyces with strict ligand specificity. For example, BarA 
as a VB-specific receptor in S. virginiae (Kinoshita et al., 1997), FarA as an IM-2-specific 
receptor in S. lavendulae (Kitani et al., 2001) and ScbR as a SCB-specific receptor in S. 
coelicolor (Takano et al., 2001). γ-butyrolactone receptor activity was also detected in the 
crude cell-free lysates of A. mediterranei, A. teichomyceticus and Micromonospora 
echinospora by an autoregulator-binding assay with tritium-labeled autoregulators as ligands 





identified and cloned and their ligand specificities were also resolved by the 
autoregulator-binding assay (Aroonsri et al., 2008). These data suggest that the 
γ-butyrolactone-receptor system also exists in non-Streptomyces actinomycetes. 
 
The regulation model of ScbA, ScbR and SCB1 
The SCB receptor, ScbR, binds to the promoter region, and represses the promoter activity, 
of scbR, where in the A-factor system the receptor, ArpA, does not autoregulate itself and has a 
different γ-butyrolactone regulation system compared to that of S. coelicolor. It also represses 
the pathway-specific regulatory gene, cpkO, which locates in and regulates the transcription of 
a type I polyketide CPK cluster (Fig. 6; Takano, 2006, Takano et al., 2005, Pawlik et al., 2007). 
When SCBs are present, ScbR cannot bind to its own promoter and that of cpkO, leading to 
transcription and translation of the corresponding genes (Fig. 6; Takano et al., 2001 and 2005).   
ScbR binding to the scbA promoter also occurred and the transcription of scbA was 
abolished in a scbR deletion mutant, suggesting that ScbR may be an activator instead of a 
repressor in the regulation of the scbA transcription (Takano et al., 2001). The transcription of 
scbA was barely detected in a scbA deletion mutant which still retained its promoter. And 
addition of exogenous SCB1 did not restore its expression, suggesting that ScbA may be 
required for its own transcription as well (Fig. 6 and Table 2; Takano et al., 2001). In addition, 
both the scbA mutant and the scbR mutant lost the ability to produce SCBs (Takano et al., 
2001), providing further support for the suggested involvement of ScbA in the synthesis of 
SCBs (see above), with a regulatory role for ScbR in scbA expression. These findings indicate a 
much more complex regulatory mechanism in S. coelicolor compared to the A-factor system in 
S. griseus where the synthase, AfsA, is not regulated by the receptor, ArpA. 
Although SCBs have been shown to elicit the precocious production of Act and Red 
(Takano et al., 2000), no direct link between ScbR and these two antibiotic gene clusters was 
found (Fig. 6; Takano, 2006). Besides those genes for secondary metabolism, ScbR was 
recently found to bind to the upstream region of glnR, a global regulator that controls genes 
involved in nitrogen metabolism, suggesting involvement of ScbR in primary metabolism 
(Yang et al., 2009). 
The detailed mechanisms of the SCB regulatory cascade and the biosynthetic pathway for 
SCBs are not fully established, but the SCB system already reveals a striking difference from 
the system discovered in S. griseus. Compared with other reports on γ-butyrolactone systems in 
different Streptomyces strains, the A-factor system appears different in many aspects (Takano, 
2006). For instance, A-factor is one of the few γ-butyrolactones controlling both antibiotic 
biosynthesis and cellular development. Though the A-factor system has been studied in most 





features, such as the complex transcriptional regulation of scbA and the unsolved link between 
SCBs and the production of Act and Red, are very interesting. A detailed study of the roles of 
the two key proteins, ScbA and ScbR, in the SCB system may result in elucidation of the 
mechanism of SCBs in S. coelicolor.  
Figure 6. The SCB1 regulatory pathway in S. coelicolor. ScbR (light-gray ovals) bind to 4 target sites as a dimer. 
ScbR binds to its own promoter (one site on scbRp) and cpkO promoter (two sites on cpkOp) as a repressor and 
this binding is released (black ovals with ligh-gray triangle) by having an interaction with SCB1 (light-gray 
triangles). ScbA (deep-gray circles) is involved in SCB1 synthesis and the transcription of scbA may require the 
involvement of ScbR, ScbA and SCB1 which is still under investigation (shown as “?”). ScbR may go through 
other genes to regulate the production of Act and Red. CpkO is a pathway-specific activator which can trigger the 
production of a type I polyketide encoded by the CPK gene cluster (Takano et al., 2005). scbAp indicates the 
promoter of scbA. Arrows denote activation and lines with a bar denote repression. Adapted with permission from 
Takano, 2006.   
 
The role of β-hydroxyacyl-ACP dehydratases (FabA and FabZ) in E. coli 
E. coli has a type II fatty acid biosynthetic pathway as found in most bacteria and plants 
(Fujita et al., 2007). Each of the individual steps is catalyzed by separate proteins. In some 
cases, multiple proteins are available for the same step. However, because of differences in 
substrate specificity, each of these play a unique role in the physiological regulation of the 





membrane bilayer. A core feature of the type II system is the fatty acid elongation cycle which 
requires four steps to complete one round: (1) condensation (2) ketone reduction (3) 
dehydration and (4) double-bond reduction. Each round extends the fatty acid chain by two 
carbons (Fujita et al., 2007). The key reaction point where unsaturated fatty acid biosynthesis 
diverges from saturated fatty acid biosynthesis is catalyzed by FabA, a β-hydroxyacyl-ACP 
dehydratase, acting in the dehydration step (Schujman and de Mendoza, 2005). FabA is a 
bifunctional enzyme that catalyzes the dehydration reaction of β-hydroxyacyl-ACPs to trans-2 
unsaturated acyl-ACP (step 3) and the isomerization of trans-2-decenoyl-ACP to 
cis-3-decenoyl-ACP (Schujman and de Mendoza, 2005). FabA is selective for, and introduces a 
cis-3-double bond into 10-carbon substrates, and this double bond is retained in the substrates, 
which hence are converted into unsaturated fatty acids playing crucial roles in the regulation of 
cellular membrane fluidity (Heath and Rock, 1996 and Aguilar and Mendoza, 2006). In a fabA 
mutant, no unsaturated fatty acid is produced but saturated fatty acid synthesis persists because 
of the presence of another β-hydroxyacyl-ACP dehydratase, FabZ which is only capable of 
dehydration and functions in the acyl chain elongation (Lu et al., 2004).   
FabA and FabZ homologues are found in many Gram-negative bacteria. Several of these 
proteins have been crystallized and the active site residues, an aspartate (Asp) in FabA and a 
glutamate (Glu) in FabZ, have been identified by analyzing their crystal structures with 
inhibitor added and also by mutagenesis (Kimber et al., 2004). Recently, our studies have 
shown that the regions around the FabA and FabZ active sites have a pronounced similarity to 
the two conserved repeats of ScbA, and these repeats are also and only conserved within the 
AfsA family. The catalytic active site residue for FabA and FabZ is well conserved in ScbA and 
the AfsA homologues, although the overall amino acid identities of ScbA to FabA and to FabZ 
are only 15% and 13%, respectively. It is not known whether these conserved residues are 
important, like in FabA/FabZ, for the function of ScbA and, if so, whether ScbA catalyzes a 
similar reaction as FabA and FabZ. 
 
Outline of this thesis 
Though the complex regulatory network of the SCB system has been reported, the precise 
enzymatic and regulatory function of ScbA and the ligand preference of ScbR have not been 
elucidated. These topics are studied and described in the following chapters of this thesis. 
 
Chapter 2 describes the isolation and identification of two new SCBs and a new 
γ-butyrolactone reporter system in S. coelicolor. The chemical structures of these two 
γ-butyrolactones, SCB2 and SCB3 were elucidated and their abilities to elicit the production of 





ScbR as a sensor for the butyrolactones and also the ScbR repressed promoter cpkO fused with 
the promoterless kanamycin resistant gene, was created. The binding affinity of three SCBs 
towards ScbR was resolved using this new bioassay and the ligand preference of ScbR was 
reported for the first time. This bioassay also has made it possible to screen for potential 
γ-butyrolactone producers.  
 
Chapter 3 describes the remote similarity of the active site of ScbA of S. coelicolor to that of 
FabA and FabZ in E. coli. This similarity between ScbA and FabA/FabZ was found by HHpred 
software. Putative active site residues were mutated and the mutant genes introduced into a 
scbA deletion mutant strain via an integrative plasmid. The resulting strains lost the ability to 
produce γ-butyrolactones, strongly suggesting that ScbA has an enzymatic role in 
γ-butyrolactone synthesis.  
 
Chapter 4 addresses the effect of the mutated active sites in ScbA, constructed in Chapter 3, on 
antibiotic production and morphological development by introducing the mutations into the 
chromosomal locus. A double glutamate point mutant, and an arginine point mutant, both had 
different antibiotic production profiles in solid and liquid media and the double-point mutant 
also showed a different morphological phenotype compared to the other mutants and the wild 
type, which may suggest a regulatory role of ScbA in both antibiotic production and 
development.  
 
Chapter 5 describes the attempts made for overexpression of ScbA in Streptomyces and E. coli. 
ScbA was overexpressed in Streptomyces and E. coli by six different expression constructs. 
With a specific anti-ScbA antibody, soluble forms of ScbA and a double glutamate point 
mutated ScbA were detected in the E. coli cell-free extract when using the pQE80 expression 
vector. 
 





Table 1. AfsA homologues from the NCBI database                                   
Protein Organism Amino acid Functionb References 
names  identitya(%)                                         
AfsA S. griseus 100% enzyme Ohnishi et al., 2008 
ScbA S. coelicolor 63% enzy/regu# Takano et al., 2001 
JadW1 S. venezuelae 43% regulator# Wang and Vining, 2003 
BarX S. virginiae 42% regulator Kawachi et al., 2000 
FarX S. lavendulae 42% ? Waki et al., 1997 
SSEG02733 S. sviceus 41% ? NCBI 
Lct9 S. rishiriensis 38% ? Zhang et al., 2008 
SngA S. natalensis 38% regulator# Lee et al., 2005 
SrrX S. rochei (pSLA2-L) 38% # Arakawa et al., 2007 
SSEG08179 S. viceus 38% ? NCBI 
SSAG03578 S. sp. Mg1 38% ? NCBI  
NcsR1 S. carzinosaticus  37% # Liu et al., 2005 
SSCG01266 S. clavuligerus 36% ? NCBI 
AvaA S. avermitillis  34% ? Ikeda et al., 2003 
SSBG01924 S. sp. SPB74 29% ? NCBI 
AfsA S. albulus 28% ? Yamanaka et al., 2008 
MmfL S. coelicolor (SCP1) 27% enzyme Corre et al., 2008 
SscA S. scabies 27% ? Kitani et al., 2008 
SAML0197 S. ambofaciens 26% ? Choulet et al., 2006           
a Amino acid identity with ScbA from BLAST searches performed at National Center for 
Biotechnology Information (NCBI). 
b The function of the protein as suggested by the reference.  
# The data is not sufficient to define whether this protein is a regulator or an enzyme. 
























































































































































































































































































































































































































































































































Analysis of two additional signalling molecules  
in Streptomyces coelicolor  
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γ-butyrolactone bacterial hormones regulate antibiotic production and morphological 
differentiation in Streptomyces species. One γ-butyrolactone, SCB1, has been previously 
characterized in Streptomyces coelicolor. Here we report the characterisation of two additional 
γ-butyrolactones named SCB2 (2-(1'-hydroxyoctyl)-3-hydroxymethylbutanolide) and SCB3 
(2-(1'-hydroxy-6'-methyloctyl)-3-hydroxymethylbutanolide), possessing an antibiotic 
stimulatory activity. To elucidate the specificity determinants of these ligands for the receptor 
protein, ScbR, thirty chemically synthesized γ-butyrolactone analogues were tested by utilizing 
the release of ScbR from the DNA upon binding to a γ-butyrolactone which can be detected by 
kanamycin resistance. The butyrolactone detection method developed here revealed that ScbR 
shows preference towards a ligand possessing a 7-10 carbon C-2 side chain, a C-1'-β-hydroxyl 
group and a C-6'-methyl branch which coincides with SCB3. Moreover, this method was 




Small extracellular signalling molecules called γ-butyrolactones, found mainly to be 
produced with the exception of furans (MMFs) (Corre et al., 2008) and is involved in the 
regulation of antibiotic production and, in some cases, morphological differentiation in the 
soil-dwelling Streptomyces (Takano, 2006). Regarded as bacterial hormones, the 
γ-butyrolactones are active at nanomolar concentrations and are thought to diffuse freely in and 
out of the cell. Twelve γ-butyrolactones, which have a 2,3-di-substituted γ-butyrolactone 
skeleton in common, have been identified to date. These have been classified into the following 
three groups based on their structural differences (Fig. 1): (1) A-factor type, possessing a 
1’-keto group; (2) virginiae butanolide (VB) type, possessing a 1’-α-hydroxyl group; and (3) 
IM-2 type, possessing a 1’-β-hydroxyl group (Choi et al., 2003). Early studies in Streptomyces 
coelicolor led to the partial elucidation of six γ-butyrolactone compounds (Fig. 2; Anisova et al 
1984) but no biological function was determined in the producing strain. Takano and coworkers 
(2000) characterized the IM-2 type compound SCB1 from S. coelicolor which possesses 
antibiotic stimulatory activity, but does not have same structure as those identified by Anisova 
et al. (1984). In this study, two new γ-butyrolactones, named SCB2 and SCB3, were 
successfully isolated from S. coelicolor and their chemical structures elucidated. Like SCB1, 
they also exhibit antibiotic stimulatory activity in the producing strain. 
 The published and most widely used assays for detecting the γ-butyrolactone signalling 
molecules are bioassays which detect antibiotic production (Hara and Beppu, 1982; Nihira et 






Figure 1.  The types of the γ-butyrolactones and their examples. The three different types of the γ-butyrolactones 
are indicated and their examples from SCB1. Chemical structures of SCB1((-)-SCB1 [2R,3R,1’R]), its isomers 
((+)-SCB1 [2S,3S,1’S], VB type (-)-SCB1 [2R,3R,1’S], VB type (+)-SCB1 [2S,3S,1’R]) and the racemic A-factor 
are shown and the names of chemical structures are indicated below.  
 
 






activity is determined by observing the induced production of the pigmented antibiotics 
actinorhodin and undecylprodigiosin (Takano et al., 2000). These bioassays however can be 
tedious and in some cases difficult to use as the antibiotic production can be effected by 
indicator lawn concentration, medium conditions, and cultivation time. Furthermore, the 
γ-butyrolactones are produced in minute quantities and are difficult to isolate. Therefore to 
study ligand specificity to the receptor and to detect novel γ-butyrolactones, a simple yet 
sensitive and reproducible detection method is necessary.   
 Previous studies revealed that the γ-butyrolactone receptor, ScbR, regulates the antibiotic 
production in S. coelicolor through repressing the transcription of its own gene and that of 
cpkO, a pathway-specific regulatory gene for the CPK antibiotic biosynthesis gene cluster 
(Takano et al., 2005 and Pawlik et al., 2007). The repression is abolished by the presence of the 
γ-butyrolactones resulting in the transcription of the target genes. Based on these findings, we 
have designed and tested a new γ-butyrolactone detection method using ScbR as a sensor and 
the cpkO promoter coupled with a promoterless kanamycin resistance gene as a reporter to 
detect the γ-butyrolactones. 
 Synthetic analogues of A-factor were analyzed for their biological activity in Streptomyces 
griseus, the cognate host for A-factor (Khokhlov, 1991). Similarly, Nihira and coworkers 
chemically synthesized VB analogues, (Nihira et al., 1988). These analogues were tested for 
their ability to induce virginiamycin in the VB cognate host, Streptomyces virginiae. These 
results from both groups indicate the specificity of the VB or A-factor receptor and the 
γ-butyrolactone analogues. However, a systematic analysis of chemically synthesized 
γ-butyrolactone analogues to the receptor protein, ScbR, from S. coelicolor has never been 
carried out.   
 Therefore to elucidate the specificity determinant we have synthesized thirty 
γ-butyrolactone analogues including two newly identified SCBs, SCB2 and SCB3. The 
biological activity of the analogues was measured using the novel kanamycin bioassay and 
analyzed for their affinity to ScbR. Furthermore, we report the possible application of this assay 
to detect γ-butyrolactones produced by actinomycetes. 
 
Experimental Procedures 
Bacterial strains, plasmids and growth conditions 
 Streptomyces strains M145, LW16 (this manuscript) and ΔscbA (M751; Takano et al., 
2001) were manipulated as described (Kieser et al., 2000). E. coli JM101 was manipulated 
according to Sambrook et al. (1989). MS agar (Kieser et al., 2000) was used to prepare spores 
and selection of exconjugants. SMM and SMMS agar (Takano et al., 2001) was used to isolate 





Nutrient Agar (DNAgar) containing 5 μg/ml kanamycin was used for the kanamycin bioassay. 
pGEM-T (Promega) was used for cloning PCR products. pIJ487 (Ward et al., 1986), pIJ6120 
(Takano et al., 2001) and pIJ82 (Hong et al., 2004) was used for constructing the new reporter.  
 
Purification and structural determination of γ-butyrolactones 
 The purification was conducted as reported previously in Takano et al. (2000). The HPLC 
peak samples with precocious antibiotic production from these purification was further 
analyzed by using a C18 reverse column (SHISEIDO C18 capcellpak SG120/5μm, 
4.6mmx250mm) with a UV detector (Nippon Bunko UVIDEC-100V) with elution solvent of 
30% CH3CN/70% H2O/ 0.1% TFA and flow rate of 1.0 ml/min. 
 1HNMR analysis was done on a Nippon Denshi model JNM-GSX-400 spectrometer at 
400 MHz in CDCl3 using CHCl3 δH 7.25 as an internal reference.   
1H-NMR data for 2-(1’-hydroxyoctyl)-3-hydroxymethylbutanolide: δ 4.43 (1H, t, J=8.8 
Hz, H-4a), 4.02 (1H, m, H-1'), 3.99 (1H, t, J=8.8 Hz, H-4b), 3.76 (1H, dd, J=5.6, 10.6 Hz, 
H-5a), 3.70 (1H, dd, J=5.6, 10.6 Hz, H-5b), 2.78 (1H, m, H-3), 2.66 (1H, dd, J=4.8, 9.2 Hz, 
H-2), 1.26∼1.30 (10H, m, H-3'～H-7') and 0.89 (3H, t, J=6.5 Hz, H-8'). One-dimensional 400 
MHz 1H-NMR (Fig. 4) indicated that the purified compound possessed a typical 
2,3-disubstituted γ-butyrolactone skeleton, as evident from the signals at 4.43, 4.02, 3.99, 3.76, 
3.70, 2.78 and 2.66 ppm (see detailed explanation in Fig. 4). 
 
Nano LC-Orbitrap MS analysis of SCB1, SCB2 and SCB3 
 SMMS grown M145 ethyl acetate extracts resuspended in 100% MeOH was analyzed 
using nano-liquid chromatography (LC) on-line coupled to an Orbitrap-MS (Thermo Scientific 
Corporation). Chemically synthesized SCB1, SCB2, SCB3, and IM-2 C9-i (1 ng/μl) were used 
as reference standards and SMMS and ΔscbA ethyl acetate extracts were injected as negative 
control. 
 The system was operated with electrospray ionization source in positive mode. LC 
conditions were as follows: the column was a Dionex C18 column (Acclaim PepMap100, C18, 
3 µm, 75 µm i.d. x 15 cm); the mobile phase consisted of A (H2O/0.1% Formic Acid) and B 
(Acetonitrile/0.1% Formic Acid); the gradient elution started with 20% B at 3 min, 95% B at 45 
min, 95% B at 50 min, 20% B at 55 min and was then kept at 20% B until 60 min, flow rate 
0.200 μl/min, MS mass detection range 150-500 Da. 1 μl of the reference standards and 5 μl of 
the ethyl acetate extracts were injected. Analysis was done by using the Xcalibur software 







Isolation of γ-butyrolactones and the antibiotic bioassay 
 γ-butyrolactones isolation from liquid or solid cultures and the antibiotic bioassay were 
performed as described (Takano et al., 2000).  
 
Construction of scbA and scbR double deletion mutant 
 To construct the scbA scbR double deletion mutant, the disruption cassette, aac(3)IV-oriT, 
from the plasmid pIJ773 (Gust et al., 2003) was amplified by the primers, RB4F and RB4R (Table 
4) and the resulting PCR product was cloned into the cosmid AH10 and then introduced into S. 
coelicolor according to the REDIRECT procedure (Gust et al., 2003). M145 recombinants were 
screened for apramycin resistance and the deletion was confirmed by PCR using the primers 
DDAR2 and scbA sec2 (Table 4), and by Southern analysis (data not shown). The mutant was 
named S. coelicolor LW16.  
 
Construction of the kanamycin assay strain 
 The promoterless-kanamycin gene was PCR amplified from the plasmid pIJ487 by using 
the primers Tnneo1 and neo2 (Table 4). The PCR fragment was cloned into pGEM-T vector 
(Promega) to obtain pTE130. The EcoRI digested fragment from pTE130 was subcloned into 
the EcoRI site of pIJ6120 (which contains an intact scbR and its own promoter region) in the 
orientation so that the start codon of the promoterless-kanamycin gene is flanked by the SacI 
site (Takano et al., 2005), to create pTE131. A 146 bp PCR fragment, corresponding to -25 to 
+34 from the starting site, containing a cpkO promoter and the ScbR binding site region 
(Takano et al., 2005) was amplified by using the primers pkasO1 and pkasO2 (Table 4) which 
contain an SacI restriction site at the 5’ end of each primer, and S. coelicolor M145 genomic 
DNA was used as template. After digestion with SacI, the 137 bp PCR fragment was ligated 
into SacI-digested pTE131 with the promoter orientated to direct transcription towards the 
promoterless-kanamycin gene to obtain pTE133. A 2.22 kb BglII fragment from pTE133 was 
then subcloned into a BamHI site of pIJ82, an integrating vector, to yield pTE134. The relative 
orientation of the scbR and the cpkO promoter with the neo was confirmed by PCR with the 
primers pkasO1, pkasO2, scbRrt2, neo2 (Table 4). pTE134 DNA was sequenced by MWG 
Biotech AG (data not shown).  
pTE134 was introduced into the methylation-deficient E. coli strain ET12567 containing 
the RP4 derivative pUZ8002 (Flett et al., 1997), and transferred to S. coelicolor LW16 by 
conjugation (Flett et al., 1997). Single-crossover exconjugants were selected on MS containing 
hygromycin and nalidixic acid, to obtain transconjugants LW16::pTE134. The genomic DNA 
was isolated and plasmid integration was confirmed by PCR with the primers JGattB1-fwd and 





region (data not shown).  
 
The kanamycin bioassay 
 Chemically synthesized autoregulator analogues or methanol extracted γ-butyrolactones 
from S. coelicolor M145, ΔscbA and various Streptomyces species was spotted onto a confluent 
lawn of S. coelicolor LW16::pTE134 spores plated on DNAgar supplemented with kanamycin 
at a final concentration of 5 μg/ml and then incubated at 30˚C for 3 days. Methanol was used as 
a negative control. For detailed protocol see Hsiao et al. (2009). To determine the detection 
range of the kanamycin bioassay, 62.5 µg to 0.01 µg of autoregulator analogues were tested. 
 
Antibiotic bioassay 
 Antibiotic bioassay was conducted as reported in Takano et al., (2000) 
 
Chemical synthesis of autoregulator analogs 
 Factor type analogues (Fig. 5) containing a C-1' keto group with various alkyl side chains 
at C-2 were synthesized as previously described (Nihira et al., 1988) by reacting 
3-(trimethylsilyoxymethyl)butanolide with a suitable alkyl chloride. 
Virginiae butanolide (VB) type analogues (Fig. 5) and IM-2 type analogues (Fig. 5) with 
various linear alkyl side chains at C-2 were synthesized as described before (Kim et al., 1989) 
by reacting 3-(trimethylsilyoxymethyl)butanolide with a suitable linear aldehyde by Aldol 
condensation . 
 For the synthesis of VB and IM-2 type analogues containing 1'-hydroxy-7'-methyloctyl or 
1'-hydroxy-6'-methyloctyl or 1'-hydroxy-5'-methylheptyl side chain (VB C9-i, IM-2 C9-i, VB 
C9-sec, IM-2 C9-sec, VB C8-sec or IM-2 C8-sec), corresponding branched-chain carboxylic acids 
(7-methyloctanoic acid, and 6-methyoctanoic acid) were first synthesized from 5-bromovaleric 
acid and isobutyl bromide or sec-butyl bromide, respectively, using modified Grignard reaction 
in the presence of dilithium tetrachlorocuprate (Baer et al., 1976). Alkyl chloride was prepared 
from the branched-chain carboxylic acid and was used to synthesize the corresponding A-factor 
type analogues, and reduction with NaBH4 gave corresponding VB type and IM-2 type 
analogues (Fig. 5). 
 SCB1 and its isomers (Fig. 1) which contain 1'-hydroxy-7'-methylheptyl side chain at C-2 
were synthesized as previously described (Takano et al., 2000). 
The synthesized compounds were purified by C18 HPLC and the structure confirmed by 
1HNMR analysis on a Nippon Denshi model JNM-GSX-400 spectrometer at 400 MHz in 






LC-MS and tandem MS  
The extracted ion chromatograms (EIC) of mass range 245.17-245.18 in which SCB1/SCB2 
hydrogen adducts [(M+H)+] should be present show that they eluted late during the run. The 
synthesized SCB1 eluted at RT 40.33 min (Table 1). In the M145 ethyl acetate extract, the m/z 
245.17 eluted at RT 39.30 min and RT 40.20 min (Table 1). In the mass spectra of wild type S. 
coelicolor M145 ethyl acetate extract and the synthesized SCB1 and SCB2 in correspondence 
to the highest peaks detected in the EICs, the following masses were detected: 245.17 (M+H)+, 
227.16 (M+H-H2O)+ and 209.15 (M+H-H2O)+. The best matching chemical formula given by 
the Xcalibur 2.0.5 elemental composition tool software (Thermo Fisher Scientific) for these 
masses are: C13H25O4 (m/z 245.17), C13H23O3 (m/z 227.16) and C13H21O2 (m/z 209.15), which 
confirm the mono- and di-dehydration. 
 In the tandem MS spectrum of m/z 245.17, the most intense peaks correspond to the 
dehydrated structures (m/z 227.16 and m/z 209.15). Fragmentation of mass 227.16 
(M+H-H2O)+ was also performed: major peaks at m/z 169.12, 155.11 and 141.09 were found 
and they represent the mono-dehydrated structures of SCB1 or SCB2 after beta-elimination on 
the acyl chain at different position. Minor peaks at m/z 191.14, 135.12, 133.10, 107.09, 95.09 
and 81.07 were also detected at much lower intensity. Predicted formulas were also given for 
these masses: C10H17O2 (m/z 169.12), C9H15O2 (m/z 155.11), C8H13O2 (m/z 141.09), C10H15 
(m/z 135.12), C10H13 (m/z 133.10), C8H11 (m/z 107.09), C7H14 (m/z 95.09) and C6H9 (m/z 
81.07). 
 MS analysis was also performed to confirm the presence of SCB3 [(M+H)+ 259.19] in the 
M145 ethyl acetate extract. The synthesized SCB3 and IM-2 C9-i were used as reference 
standards. The extracted ion chromatograms (EICs) of mass range 259.18-259.20 in which 
SCB3 hydrogen adduct should be detected show that the synthesized SCB3 eluted at RT 44.21 
min, and the synthesized IM-2 C9-i was eluted at RT 49.35 min and 57.57 min which may 
correspond to a racemic mixture of IM-2 C9-I and with the M145 ethyl acetate extract, the m/z 
259.18 eluted at RT 43.97 min (Table 1).  
 In the MS spectrum of M145 at the highest peak in the mass range 259.18-259.20 at RT 
43.97 min, the following masses are detected: m/z 259.19 (M+H)+, which is SCB3 hydrogen 
adduct, 241.18 (M+H-H2O)+ and 223.17 (M+H-H2O)+ which are the mono- and di-hydrated 
structure of SCB3. The same masses are also found in the reference standards spectra. The best 
matching chemical formula given by the Xcalibur elemental composition tool for these masses 
are: C14H27O4 (m/z 259.19), C14H25O3 (m/z 241.18) and C14H23O2 (m/z 223.17), which are the 
mono- and di-dehydrated structures. 
 In the tandem MS spectrum of mass 259.19 the most intense peaks correspond to the 





(M+H-H2O)+ shows as major peaks with predicted formula m/z 223.17 (C14H23O2), m/z 169.12 
(C10H17O2) and m/z 155.11 (C9H15O2), which represent the mono-dehydrated structures of 
SCB3 after beta-elimination on the acyl chain at different positions and m/z 205.16 (C14H21O1) 
which is a dehydrated form of the ring-opened lactone. Minor peaks of m/z 187.15, m/z 95.09 
and m/z 67.05 are visualised at lower intensity. Predicted formulas for these masses are: C14H19 
(187.15), C7H14 (m/z 95.09) and C5H7 (m/z 67.05). As negative control, SMMS ethyl acetate 
extract and ΔscbA, a mutant which does not produce any γ-butyrolactones, ethyl acetate extract 
were injected. No precursor ions and no fragment ions corresponding to SCB1, SCB2 and 
SCB3 were detected in these MS and MS/MS analysis. 
 
Results 
The isolation and determination of new SCBs from S. coelicolor 
 The structure of SCB1, a γ-butyrolactone in S. coelicolor M145 with antibiotic stimulatory 
activity, has previously been determined (Takano et al., 2000). HPLC analysis indicates the 
presence of two further peaks possessing antibiotic stimulatory activity in S. coelicolor culture 
extracts, in addition to SCB1. These two minor peaks were further analyzed using an antibiotic 
bioassay described previously (Takano et al., 2000). 
 One HPLC peak fraction with a retention time (RT) very soon after SCB1 was applied to a 
C18 reverse phase column and a bioactive peak with a RT of 24-25 min was detected (Fig. 3A). 
This sample was subjected to 400MHz 1H-NMR for structure elucidation and showed that the 
structure may be similar to that of IM-2 C8, especially because a triplet Me signal at 0.89 ppm 
indicated the presence of one terminal Me on a linear side chain, unlike the terminally branched 
side chain of SCB1 showing doublet Me signals (Fig. 4). To further determine the structure, 
chemically synthesized racemic IM-2 C8 (see Experimental procedures) was used for 
comparison of the C18 HPLC retention time, which suggested the structure to be correct (Table 
1). Furthermore, the bioassay of the synthetic IM-2 C8 was active at similar concentrations to 
the natural SCB1 (data not shown). This compound was named SCB2 and the structure was 
determined as 2-(1’-hydroxyoctyl)-3-hydroxymethylbutanolide (Fig. 3B). 
The other minor HPLC peak fraction was also applied onto a C18 reverse phase column and a 
bioactive peak with the RT of 41-45 min was detected (data not shown). Assuming that the 
lactone backbone is retained, the RT of 41-45 min is in between those of IM-2 C8 (linear C8 
side chain, 24-25 min) and IM-2 C9 (linear C9 side chain, 54-56 min). Therefore the structure 





Figure 3. The kanamycin bioassay and the antibiotic bioassay results of the M145 ethyl acetate extract and the 
chemically synthesized SCB1.The M145 ethyl acetate extract and the chemically synthesized SCB1 were spotted 
onto a lawn of LW16::pTE134 on DNAgar plates containing 5 μg/ml kanamycin, or on a confluent lawn of M145. 
The amount of the extract and the SCB1 spotted is indicated above the plates. The plates were incubated at 30 ˚C 
for 72 hours. 
Figure 4. 400MHz 1H-NMR spectrum of SCB2. The predicted structure of SCB2 is shown in the inset. The 
number above each signal indicates the corresponding proton in SCB2. The signals at 4.43 and 3.99 ppm 
corresponded to methylene protons at C-4, and those at 3.76 and 3.70 ppm to hydroxymethylene protons at C-5. 
The signals at 4.02, 2.78 and 2.66 ppm corresponded to three methine protons at C-1’, C-3 and C-2, respectively. 
The remaining signals at 1.26 - 1.30 (10 protons) seemed to come from 5 methylene groups of alkyl side chain at 
C-2. However, the triplet signal at 0.89 ppm corresponded to three protons of one methyl group and indicated the 
presence of unbranched side chain at C-2, which contrasted to the terminal isopropyl containing side chain in 
SCB1. The coupling constant between H-2 and H-3 (J2,3=9.2 Hz) was different from that of VB-A (J2,3=7.4 
Hz)(Yamada et al., 1987), but agreed well with that of IM-2 (J2,3=9.3 Hz) (Sato et al., 1989), suggesting that SCB2 





To further test this hypothesis, the two racemic IM-2 C9-sec and IM-2 C9-i were chemically 
synthesized and the retention time was determined on a reverse phase HPLC. The chemically 
synthesized racemic IM-2 C9-sec eluted at 44-46 min while the racemic IM-2 C9-i eluted at 48-50 
min (Table 1). These results suggest that IM-2 C9-sec maybe the structure of the second peak. 
This compound was named SCB3 and the structure was determined as 
2-(1’-hydroxy-6’-methyloctyl)-3-hydroxymethylbutanolide (Fig. 3C). 
To further confirm the structure of SCB2 and SCB3, MS and tandem MS was conducted 
using the high-accuracy Orbitrap mass spectrometry on the synthesized SCB1, SCB2, SCB3,  
IM-2 C9-i and the ethyl acetate extract of SMMS grown S. coelicolor M145. The RT for the 
synthesized SCB1, SCB2, SCB3 and IM-2 C9-i were 40.33, 41.12, 44.21 and 49.35/57.57, 
respectively (Table 1).  In the M145 ethyl acetate extract, retention times which correspond to 
the mass equivalent to SCB1 [(M+H)+ 245.17], SCB2 [(M+H)+ 245.17] and SCB3 [(M+H)+ 
259.19] were similar but somewhat earlier than the synthetic compounds (Table 1). This maybe 
due to the impurity in the M145 ethyl acetate extracts.  However a mass corresponding to 
SCB3 [(M+H)+ 259.19] was not detected at the same RT as IM-2 C9-i. This strongly confirms 
the previous analysis and that the structure of SCB3 is indeed 
2-(1’-hydroxy-6’-methyloctyl)-3-hydroxymethylbutanolide. The MS and tandem MS spectra of 
the captured molecules in the M145 ethyl acetate extract show high similarity to the 
synthesized SCB1 and SCB2 [both have (M+H)+ 245.17] and also to SCB3 [(M+H)+ 259.19] 
spectra which include the mono- or di-dehydrated structures of SCB1, SCB2 or SCB3 
confirming the production of these three butanolides in M145.   
 
Synthesis of γ-butyrolactone analogues for use in structure-activity studies 
 The newly identified SCBs differ in the nature of the C-2 side chain compared to the 
previously identified compound SCB1. To determine the specificity of these ligands to the 
receptor, further racemic analogues, IM-2 type, VB type, and A-factor type were chemically 
synthesized with different side-chain length and branching. Thirty different analogues which, 
based on the structure, are grouped into 4 types: 1) SCB1 isomers: IM-2 type: (-)-SCB1 
[2R,3R,1’R], (+)-SCB1 [2S,3S,1’S], VB type: (-)-SCB1 [2R,3R,1’S], (+)-SCB1 [2S,3S,1’R]; 2) 
IM-2 type analogues possessing a C-1’-β-hydroxyl group with various linear and branched C-2 
side chains; 3) a VB type series possessing a C-1’-α-hydroxyl group with various linear and 
branched C-2 side chains; 4) A-factor type series possessing a C-1’-keto group. The chemical 
structures are shown in Fig. 1 and 5.   
 
A new γ-butyrolactone detection assay using kanamycin resistance  





antibiotic bioassay based on the precocious production of coloured antibiotics could have been 
utilized (Takano et al., 2000).  However, this method is not always easy to score since the 
production of the coloured antibiotics can vary with time, the density of the inoculum used for 
the indicator lawn, and also the batch of media used. Therefore a new reporter system which is 
both easier to perform and gives a clearer measure of γ-butyrolactone activity was developed. 
 
Figure 5. The chemical structure of the synthesized γ-butyrolactone analogues. The chemical skeletons of 
γ-butyrolactones: (1) A-factor type, a C-1’-keto group; (2) VB type, a C-1’-α-hydroxyl group; and (3) IM-2 type, a 
C-1’-β-hydroxyl group. Linear and branched alkyl side-chain substitutes (R) at C-2 along with their names are 
specified below. 
 
 ScbR, the γ-butyrolactone receptor, which has been shown to be the sole receptor which 
can recognise the γ-butyrolactones to promote antibiotic stimulatory activity, binds to its own 
promoter region and to that of cpkO, a pathway-specific regulatory gene for the CPK cluster, 
and thereby represses the transcription (Takano et al., 2005 and Pawlik et al., 2007). In the 
presence of γ-butyrolactones, ScbR binds to the γ-butyrolactones and relieves DNA binding 
thus allowing the target genes to be transcribed (Takano et al., 2005). Utilizing these properties 





cpkO promoter complete with the ScbR binding site fused to a promoterless-kanamycin 
resistance gene in the conjugative and integrating vector pIJ82 was constructed. This plasmid, 
named pTE134 (Fig. 6), was introduced into S. coelicolor LW16 (a scbA and scbR double 
deletion mutant, see Experimental procedures). LW16 does not produce any γ-butyrolactones 
with antibiotic stimulatory activity as determined by the antibiotic bioassay (data not shown). 
Therefore, in LW16, the ScbR resulting from pTE134 represses the cpkO promoter and the 
strain remains sensitive to kanamycin. In the presence of γ-butyrolactones however, ScbR 
repression is relieved and the strain becomes kanamycin resistant. This method, therefore, was 
named the kanamycin bioassay and can be used to detect γ-butyrolactones which can bind to 
ScbR.   
Figure 6.  The schematic map of pTE134 used for the kanamycin bioassay.  pTE134 is constructed with scbR 
(open arrow) with its own promoter region, scbRp (black arrow) and a cpkO promoter, cpkOp (black arrow) 
coupled with a promoterless kanamycin resistant gene (neo, solid arrow). The light gray arrow indicates hyg 
(omega hygromycin resistance gene), the hatched arrow represents oriT (RP4 origin of single-stranded DNA 
transfer), the deep gray arrow represents int (phiC31 integrase), the shaded arrow indicates a partial coding region 
(204 bp) of scbB and the attP site (phiC31 attP site) is indicated by a vertical black line. The 200 bp length is 
indicated below and the restriction enzymes used for cloning are indicated by vertical black lines (not all SacI and 
EcoRI sites are represented in the map).  
 
 A confluent lawn of S. coelicolor LW16::pTE134 spores was plated onto DNAgar plates 
containing 5 μg/ml kanamycin and spotted with synthesized SCB1 (6.25 to 0.001 μg) and the 
M145 ethyl acetate extract (1 and 0.3 μl) at the time of inoculation. After incubation, the 





(Fig. 7). The same samples, the SCB1 (0.25 and 0.05 μg) and M145 ethyl acetate extract (1 and 
0.3 μl) were used for the antibiotic bioassay and also gave precocious antibiotic production (Fig. 
7). For determining the lowest working concentration detectable by the kanamycin bioassay, 
SCB1 was added into the agar, instead of spotting on top of the agar. This verified the 
minimum concentration to be the same as the antibiotic bioassay reported previously (Takano 
et al., 2000) which was 256 nM of SCB1, suggesting that both bioassays share the same 
detection sensitivity towards SCB1 (data not shown). 
 
Figure 7. The kanamycin bioassay and the antibiotic bioassay results of the M145 ethyl acetate extract and the 
chemically synthesized SCB1. The M145 ethyl acetate extract and the chemically synthesized SCB1 were spotted 
onto a lawn of LW16::pTE134 on DNAgar plates containing 5 μg/ml kanamycin, or on a confluent lawn of M145. 
The amount of the extract and the SCB1 spotted is indicated above the plates. The plates were incubated at 30 ˚C 
for 72 hours. 
 
 The kanamycin bioassay was used to compare the specificity of ScbR towards known 
natural γ-butyrolactones (Table 2). ScbR shows the highest affinity towards the naturally 
produced γ-butyrolactones in its cognate host, SCB1 and the racemic SCB3, with a two-fold 
stronger activity than the racemic SCB2. The SCB1 used here is a pure stereochemical 
compound compared to the racemic mixtures. The (+)- stereochemical compound which is 
present in the racemic mixture showed 250-fold less activity in the case of SCB1 (Table 2) 





almost no activity and can be disregarded. Therefore the activity for the racemic mixtures is 
approximately half for SCB2 (SCB2 possess one chiral carbon) and a quarter for SCB3 (SCB3 
possess two chiral carbons) of what is observed. Taking this into account, the activity can be 
recalculated to: SCB1=0.025, SCB2=0.025, SCB3=0.006 μg. In conclusion, SCB3 has the 
highest affinity towards ScbR followed by SCB1 and SCB2 (Table 2 and Fig. 8). 
 The diameters of the halo detected with 6.25, 1.25, 0.25, 0.05, and 0.025 μg of SCB1 are 
3.5, 3, 2.7, 2 and 1 cm, respectively (Fig. 7). This shows that the size of the growth halo 
increases with increasing amounts of the natural SCB1. However the relationship is not linear 
but shows a sigmoidal curve and therefore it is difficult to determine the concentration of 
samples by analyzing the size of the growth halo.  
Figure 8.  Kanamycin bioassay of the SCB1 isomers, SCB2 and SCB3. SCB1 isomers, SCB2 and SCB3: the 
natural SCB1((-)-SCB1 [2R,3R,1’R]), its isomers: (+)-SCB1 [2S,3S,1’S], VB type (-)-SCB1 [2R,3R,1’S] and VB 
type (+)-SCB1 [2S,3S,1’R], the racemic SCB2 (IM-2 C8) and the racemic SCB3 (IM-2 C9-sec) were spotted onto a 
plate with different amounts. The bold represent the natural SCBs identified from S. coelicolor. The name of the 
compound is indicated above. The amounts of the analogues are indicated at the left. The plates were incubated at 





The IM-2 type γ-butyrolactone analogue with a long C-2 side chain shows the highest 
specificity using the kanamycin bioassay    
 The chemically synthesized structural analogues of SCBs were tested for their binding 
specificity towards ScbR using the kanamycin bioassay. The activity measurement taken was 
the minimum amount of compound required for growth, as determined by finding the lowest 
amount of compound capable of inducing a visible halo of growth in the bioassay (Table 2). 
Racemic A-factor (6.25, 1.25 and 0.25 μg) was tested and the minimum amount required for 
growth was 1.25 μg (Fig. 9). No growth was observed with racemic A-factor with a shorter 
linear C-2 side chain, C4 or C5 (Table 2). 
Twenty-seven chemically synthesized SCB1 isomers, racemic IM-2 type, racemic VB type 
γ-butyrolactone analogues were also tested using a range from 62.5 μg to 0.01 μg (Table 2, Fig. 
5). Consistent with the previous results (Takano et al., 2000) among the four pure SCB1 
isomers ((-)-SCB1, (+)-SCB1, VB type (-)-SCB1, and VB type (+)-SCB1), representing the 4 
different configurations of SCB1, ((-)-SCB1) showed the highest activity, the minimum 0.025 
μg being 250-fold lower than with the other three analogues (Fig. 1 and 8). As also reported 
previously (Takano et al., 2001), ScbR showed a higher specificity towards the IM-2 type 
compounds possessing a 1’-β-hydroxyl group, rather than the VB type which have a 
1’-α-hydroxyl group (Table 2). 
 The activity of the chemically synthesized racemic IM-2 type analogues with varying 
lengths of the linear C-2 side chain was tested and showed that those which possess a length 
from 6-11 carbons had most specificity (Fig. 10). No growth at all was detected with the 
analogues possessing 5 or fewer carbons using up to 31.25 μg of compound. As the maximum 
carbon chain length tested was C11, the activity beyond this length is not known. The most 
active among the IM-2 type analogues was the racemic SCB2 (IM-2 C8, 0.05 μg) which 
possesses an 8 carbon C-2 side-chain length (Table 2).  
 Similarly, the specificity of the chemically synthesized racemic VB type analogues with 
varying lengths of the linear C-2 side chain was tested and showed that 7 to 10 carbons were 
highest (Fig. 11). No growth was detected using 62.5 μg of the racemic VB C6 (racemic VB-C, 
data not shown). 
The different branching positions at the same C-2 side-chain length within the IM-2 and 
VB type analogues were also compared. The pure SCB1 ((-)-SCB1), possessing a C-6’-methyl 
group, is 50-fold more active than the racemic IM-2 C8-sec, possessing a C-5’-methyl group, and 
10-fold more active than the racemic IM-2 C7, possessing a linear C-2 side chain. Furthermore, 
the racemic SCB3 (IM-2 C9-sec), possessing C-6’-methyl group, is 10-fold more active than the 
racemic IM-2 C9-i, possessing a C-7’-methyl group, and 2-fold more active than the racemic 





type analogues with a branched side chain did not show a significant difference (<6-fold) as 
seen in the IM-2 type compounds (Fig.12). 
 The summary of the minimum amount required for growth on kanamycin for the 
chemically synthesized compounds is shown in Table 2.  
Figure 9. Kanamycin bioassay using A-factor. Different concentrations of A-factor were spotted onto a lawn of 
LW16::pTE134 on DNAgar plates containing 5 μg/ml kanamycin, respectively. The plates were incubated at 30 ˚C 
for 72 hours. The concentration where a growth halo is observed indicates the ability for A-factor to bind to ScbR. 
 
Figure 10. Kanamycin bioassay of the IM-2 analogues. IM-2 type series: racemic analogous possessing a 





Figure 11.  Kanamycin bioassay of the VB analogues. VB type series: racemic analogous possessing a 
C-1’-α-hydroxyl group with a different length of linear C-2 side chain were spotted with different concentrations. 
The bold represents the natural γ-butyrolactone VB-D identified from S. virginiae.   
Figure 12.  Kanamycin bioassay of the branched IM-2 and VB analogues. The racemic IM-2 and the racemic VB 
analogues with 1'-hydroxy-7'-methyloctyl or 1'-hydroxy-6'-methyloctyl side chain or 1'-hydroxy-5'-methylheptyl 






Identification of two new possible γ-butyrolactone producing actinomycetes using the 
kanamycin bioassay 
 The kanamycin bioassay was exploited to identify possible γ-butyrolactone producers 
from among nine actinomycetes species obtained from the Tübingen strain collection (Table 3). 
These nine species were grown on SMMS for 3 days (Fig. 13), and γ-butyrolactones were 
isolated by ethyl acetate extraction (see Experimental procedures). Some species, (Streptomyces 
antibioticus ETH 6143, Streptomyces griseus ETH4289, Streptomyces tendae and Nocardia 
brasiliensis) did not grow well on SMMS or on SMMS supplemented with 5% yeast extract. 
Nevertheless, all strains were isolated and tested. Extracts from two out of nine species, 
Streptomyces olivaceus ssp. atratus and Streptomyces mediteranei, which are producers of 
narbomycin and rifomycin, respectively, had an ability to induce a growth halo in the bioassay 
(Fig. 13) suggesting that these two species produce compounds, most likely to be 
γ-butyrolactones, which have affinity towards ScbR.  
 
Figure 13. Kanamycin bioassay of three antibiotic producers from the Tübingen collection. S. antibioticus, S. 
olivaceus ssp. Atratu and S. mediteranei were grown on SMMS for 3 days at 30 ˚C (upper pictures) and extracted 
by ethyl acetate (see Experimental procedures) and spotted onto lawns of LW16::pTE134 on DNAgar plates 
containing 5 μg/ml kanamycin which were incubated at 30 ˚C for 6 days. Only the example for S. antibioticusis 











Multiple γ-butyrolactones produced in S. coelicolor 
 Two additional signalling molecules, SCB2 and SCB3, from S. coelicolor were identified 
and both exhibit a similar lactone structure to the previously identified compound SCB1, as 
well as the same IM-2 type stereo-specificity. The difference in structure was the C-2 
side-chain length with a linear C8 for SCB2 and a branched C9 for SCB3. SCB2 did not 
correspond to any of the six γ-butyrolactones identified previously, however as the chirality of 
SCB3 was not assigned, there is a possibility that it has the same structure as Acl1a (Fig. 2; 
Anisova et al., 1984). Both newly identified compounds induce precocious antibiotic 
production in an S. coelicolor bioassay, and the highest affinity towards ScbR was shown by 
SCB3 followed by SCB1 and SCB2 as determined by the kanamycin bioassay.  
 The γ-butyrolactones from S. coelicolor have shown to be synthesized by ScbA which is a 
protein also conserved in the A-factor and VB producing Streptomyces (Hsiao et al., 2007 and 
Kato et al., 2007). The S. coelicolor scbA deletion mutant does not produce any 
γ-butyrolactones with antibiotic stimulatory activity (Takano et al., 2001) indicating that SCB1, 
SCB2 and SCB3 all are synthesized by ScbA. One possible explanation for the different side 
chain structures of the three signalling molecule maybe due to the precusors used in the 
biosynthesis, and suggests a somewhat relaxed substrate specificity for ScbA. From the 
proposed biosynthesis pathway of A-factor in Streptomyces griseus, a dihydroxyacetone 
phosphate (DHAP) and a β-keto acid derivative is condensed by the ScbA homologue and 
further reduction and dephosphorylation result in A-factor (Kato et al., 2007). The β-keto acid 
derivatives may be provided either by a dedicated biosynthesis pathway or by scavenging an 
intermediate from fatty acid metabolism. We have extensively analyzed the S. coelicolor 
genome and have been unable to identify a dedicated biosynthesis pathway capable of 
providing the β-keto acid derivatives. It is therefore seems likely that the fatty acid metabolism 
intermediates may be the precusors for SCB biosynthesis. Streptomyces produce both linear and 
branched fatty acids (Han et al., 1998) which correlate to the C-2 side chain differences 
observed in this manuscript. The same hypothesis has been suggested by Kato and coworkers 
(2007). 
 Interestingly, S. coelicolor is not the only multiple γ-butyrolactone producing strain to 
have been reported. Five different virginiae butanolides (VB-A to VB-E) were identified from 
Streptomyces virginiae (Yamada et al., 1987 and Kondo et al., 1989), and two active factors 
were isolated from Streptomyces bikiniensis (Gräfe et al., 1983). In addition, γ-butyrolactones 
from 11 Streptomyces species were analyzed by HPLC (Hashimoto et al., 1992) and only 3 
species produced a single γ-butyrolactone while the others produced 2-4 different compounds. 





their producing strains. 
 
The new γ-butyrolactone detection reporter system 
 The kanamycin bioassay was successfully applied as a sensitive γ-butyrolactone detection 
tool in S. coelicolor. It utilizes the cpkO promoter which is tightly controlled by ScbR and is 
fused to a kanamycin resistance cassette along with the γ-butyrolactone receptor, ScbR, as a 
sensor. The high kanamycin sensitivity in the absence of γ-butyrolactone is due to the specific 
and high affinity of ScbR to the cpkO promoter resulting in the tight repression of the gene. 
Some spontaneous resistant mutants do arise, especially with low concentrations of kanamycin 
(Fig. 8). To obtain optimal sensitivity of the assay, kanamycin concentrations should be 
systematically varied to be able to monitor the resistant growth without any background 
 The kanamycin bioassay has the same minimum active concentration for SCB1 as with the 
antibiotic bioassay (256 nM, data not shown) which is reasonable considering that both 
methods use ScbR as the sensor. However when recognising the non-cognate γ-butyrolactones, 
the kanamycin bioassay was much more sensitive than the antibiotic bioassay. Only 50- fold 
higher concentration of A-factor, compared to SCB1 were required to give activity with the 
kanamycin bioassay while the antibiotic bioassay required 100 -fold higher concentration 
(Takano et al., 2000).  
 The kanamycin bioassay is also more sensitive compared to the other Streptomyces 
γ-butyrolactone assays when detecting the non-cognate signalling molecules. The A-factor 
bioassay required 3 x 103-fold higher concentration of VB (non-cognate signal) than A-factor 
by the streptomycin cosynthesis method using a streptomycin non-producing mutant, S. griseus 
HH1 (Miyake et al., 1989). While a 1.7 x 104-fold higher concentration of A-factor or IM-2 
(non-cognate signals) was required than VB to trigger virginiamycin production in a liquid 
culture of S. virginiae (Hashimoto et al., 1992 and Nihira et al., 1988) and a 8.3 x 104-fold 
higher concentration of VB-A (non-cognate signal) was required than IM-2 to induce the blue 
pigment production in liquid cultures of Streptomyces lavendulae FRI-5 (Hashimoto et al., 
1992). This may reflect the higher sensitivity of the kanamycin bioassay as it is directly 
measuring the binding affinity of the ligand to the receptor and not detecting antibiotic 
production which is the end product of the signalling cascade and may have other unknown 
influences. However the higher sensitivity can also lead to background kanamycin resistance 
observed in some cases which can be pertubations and noise. In conclusion, this new assay is 
much clearer than the antibiotic bioassay, is also simple to use and directly exhibits the 
relationship between ScbR and the ligands. 
 Similar repressor-inducer reporter systems are available. Tahlan and coworkers have 





tetR-like regulators from S. coelicolor using Escherichia coli as a host (Tahalan et al., 2008). 
Also the tetracycline (Tc)-inducible repressor (tetR)-operator (tetO) regulation system from E. 
coli transposon Tn10 has been widely used as a tool in many organisms including Streptomyces 
(Stebbins et al., 2001 and Rodríguez-García et al., 2005). However this is the first reporter 
system using a γ-butyrolactone receptor to detect the signalling molecules in Streptomyces.  
 
ScbR ligand specificity  
 From our data, the chemical analogues with a shorter C-2 side-chain length than 8 (for the 
IM-2 type) or 9 carbons (for the VB type) resulted in a lower binding affinity than the SCBs 
and must have at least 6 (for the IM-2 type) or 7 (for the VB type) carbons and no more than 10 
(for the VB type) carbons for the C-2 side-chain length to bind to ScbR. We do not have ligands 
with more than 11 carbons at the C-2 side chain to conclude the limit of the longest C-2 
side-chain length for the IM-2 type. The IM-2 type analogue with 9 carbons for the C-2 
side-chain length with branching at C-6’ position showed the best affinity than the branching at 
C-7’ position and no branching, in this order. We have therefore shown for the first time, that 
the branching at the C-6’ position is the preferred ligand to bind to ScbR. In conclusion, the 
γ-butyrolactone structure with the highest affinity to ScbR is as follows: 1) IM-2 type 
configuration 2) C-2 side-chain length to be C7-C8 3) branching at the C-6’ group. 
 21 synthetic analogues of A-factor with varying lengths of either linear or branched C-2 
side chains or different substitutes at C-3 position were analyzed for their biological activity in 
S. griseus, the cognate host for A-factor (Khokhlov, 1991). None of these analogues gave 
significant activity compared to A-factor except when the C-3 position was substituted for 
acylated products. The A-factor type analogues with one carbon longer or shorter than C8 all 
with a methyl residue at the end of the chain resulted in a 10-fold lower activity compared to 
A-factor (Khokhlov, 1991). Similarly, Nihira and coworkers chemically synthesized 41 VB 
analogues, varying the C-2 and C-3 stereochemistry to include the A-factor and cis and trans 
VB type of γ-butyrolactones as described above, and also varying the C-2 linear side-chain 
length up to C10, and different substitutes for the C-3 position (Nihira et al., 1988). These 
analogues were tested for their ability to induce virginiamycin in the VB cognate host, S. 
virginiae. The cis VB type compounds with C7 and C8 linear side chain was most active while 
the trans VB type compounds with the equivalent side-chain length gave 12.5-fold less activity. 
The C9 A-factor type compound was the only A-factor analogue to give the highest activity 
which was 1250-fold less compared to the cis VB type C7 compound, thus demonstrating the 
importance of the C-1’ free hydroxy group.  
 For all three Streptomyces γ-butyrolactone receptors that has been tested using synthetic 





exceeded in their binding specificity towards the receptor than the naturally produced 
γ-butyrolactones. To obtain chemical ligands which have better binding properties than the 
natural compounds, other structural substitutes than that of the C-2 side-chain length or 
branching will be interesting to test. 3D crystallization analysis of the receptor with the various 
γ-butyrolactones may give valuable information on further binding specificities and possible 
new structural substitutions.  
 
Potential application for the kanamycin bioassay  
 In the screening for possible new γ-butyrolactone producers (Table 3 and Fig. 13), two of 
the nine tested strains from the Tübingen strain collection were able to produce compounds 
which could be recognized by ScbR. These strains have not been shown previously to produce 
any γ-butyrolactones. The extracts from the other strains did not show γ-butyrolactone induced 
kanamycin resistant growth but this maybe due to the unsuitable growth conditions used for the 
preparation of the extracts as in some cases the strains did not grow efficiently. It is also 
possible that the extraction of the γ-butyrolactone was not at the appropriate timing of growth 
as these compounds are known to be produced in a growth-dependent manner (Takano, 2006). 
Therefore by optimising the suitable medium for growth and altering the timing for the extract 
preparation may assist in the detection of further γ-butyrolactones from different strains. This 
result together with the higher sensitivity towards the γ-butyrolactones than the commonly used 
bioassay proves the feasibility of the kanamycin bioassay as a powerful tool for large scale 
screening of γ-butyrolactone producers.  
 
Significance 
The significant conclusion from this work is the characterization of two further 
γ-butyrolactones from S. coelicolor and the identification of the γ-butyrolactone receptor (ScbR) 
specificity determinant by use of a novel small signalling molecule reporter system analyzing 
both natural and synthetic ligands. This is the first report where many synthetic γ-butyrolactone 
analogues were tested systematically to compare their binding specificity to ScbR. The 
favoured ligand consists of an IM-2 type, β-hydroxyl group on the C-1’ position, with a long 
(7–10 carbons, C8 the best) C-2 side chain. Surprisingly, we have been able to show for the 
first time the importance of a methyl branch at the C-6’ position of the C-2 side chain. This 
preference was confirmed also as the newly characterised γ-butyrolactone, SCB3, follows the 
ScbR ligand preference and also has the highest affinity compared to the two other cognate 
signalling molecules. Understanding the ligand specificity determinant will allow further 
potential design of new compounds to either inhibit or to promote antibiotic production by 





system can be applied to detect γ-butyrolactones which are only produced in small quantities 
and can be difficult to detect. We have demonstrated this use by identification of two new 
commercial antibiotic producing Streptomyces strains which most likely can synthesize 
γ-butyrolactones with affinity towards ScbR.   
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Table 1. Retention time of SCB1, SCB2 and SCB3 chemically synthesized or extracted from  
M145 analyzed by HPLC or by Nano LC-Orbitrap MS 
               Retention time (min)               
Compound        HPLC (C18 RP column)    NanoLC-Orbitrap MS  
Chemically synthesised                                                          
 SCB1 23-24 40.33 
 SCB2 (IM-2 C8) 25-27 41.12 
 SCB3 (IM-2 C9-sec) 44-46 44.21  
 IM-2 C9-i 48-50 49.35/57.57      
M145 ethyl acetate extract                          
 SCB1 22-23 39.30   
 SCB2 (IM-2 C8) 24-25 40.20    




























Table 2. Minimum concentration of γ-butyrolactone analogues which show kanamycin 
resistance                                                                                
Analogues        IM-2 type(μg)   VB type(μg)  A-factor type(μg)  SCB1 isomers (μg)         
 C2 ━ NA  NA NA 
 C3 ━ NA NA NA 
 C4 ━a NA ━ NA 
 C5 ━ ━ ━ NA 
 C6 12.5 ━b NA NA 
 C7 0.25 6.25c NA NA 
 C8 0.05d 1.25 NA NA 
 C9 0.25 0.25 NA NA 
 C10 1.25 1.25 NA NA 
 C11 6.25 ━ NA NA 
 C8-sec 1.25 12.5 NA  NA 
 C9-i 0.25 0.25 NA NA 
 C9-sec 0.025e 1.25 NA NA     
 A-factor NA NA 1.25f NA 
 (-)-SCB1 NA NA NA 0.025g 
 (+)-SCB1 NA NA NA 6.25* 
 VB-type (-)-SCB1 NA NA NA 6.25* 
 VB-type (+)-SCB1 NA NA NA 6.25             
All compounds are a racemic mixture apart from the four SCB1 isomers. 
━: No growth halo on the plate (the highest used amount is 31.25 μg, except for VB C6 where 
62.5μg was used). 
*: The growth halo was not clear. 
NA: not applicable (this analogue is unavailable). 
The bold superscript letters indicate the natural γ-butyrolactones: a. IM-2, b. VB-C, c. VB-D, 












Table 3. The Streptomyces species from the Tübingen collection which was tested for 
γ-butyrolactone production                                                                 
      Strain                          Antibiotic  Growth on plates  Growth halo  
Streptomyces antibioticus ETH 6143 (Tü 2) cinerubin X − 
Streptomyces antibioticus ETH 6677 (Tü 4) angolamycin O − 
Streptomyces olivaceus ssp. Atratus (Tü 5) narbomycin O + 
Streptomyces griseus ETH4289 (Tü 19) streptomycin X − 
Streptomyces tendae ETH11313 (Tü 21) carbomycin X − 
Nocardia brasiliensis ETH27413 (Tü 69) ferrioxamin E X − 
Streptosporangium roseum ETH28349 (Tü 74) unknown O − 
Streptomyces mediteranei (Tü 75) rifomycin O + 
Microellobosporia cinerae ETH28583 (Tü 76) unknown O −      
Tü 2 - Tü 76: strain number of the Tübingen strain collection 
X: Strains which grew well on the SMMS and SMMS supplemented with yeast extract. 
O: Strains which barely grew on the SMMS and SMMS supplemented with yeast extract. 
−: No growth halo on the plate 























Table 4. Primers used in this work                                          




scbA sec 2 ctaggatcctgtccaccggaccagggtgcagg 
Tnneo1 tcgaattcatgattgaacaagatg* 
neo2 agcttaagtcagaagaactcgtca* 




JGattPint-rev gtaagcacccgcgtacgtgt                                            
* The EcoRI site is underline. 


































ScbA from Streptomyces coelicolor A3(2) has homology to fatty acid 
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γ-butyrolactones play an important role in the regulation of antibiotic production and 
differentiation in Streptomyces. However the biosynthetic pathway for these small molecules 
has not been determined and in vitro synthesis has not been reported so far.  The function of 
the AfsA family of proteins, originally proposed to catalyse γ-butyrolactone synthesis, has been 
in debate. To clarify the function of the AfsA family and to understand the synthesis of the 
γ-butyrolactones, we have performed in silico analysis of this protein family. AfsA consist of 
two divergent domains each of which has similarity to the fatty acid synthesis enzymes FabA 
and FabZ. The two predicted active sites in ScbA, the AfsA orthologue found in Streptomyces 
coelicolor, were mutated and γ-butyrolactone biosynthesis was abolished in all four constructed 
mutants, strongly suggesting that ScbA has enzymatic activity. 
 
Introduction 
Bacterial signalling molecules have been shown to be key regulators of differentiation, 
antibiotic production, plasmid conjugation, biofilm formation, and pathogenicity (see reviews, 
Chamilli et al., 2006, Vendeville et al., 2005 and Venturi et al., 2006). γ-butyrolactones which 
are produced by the Gram-positive soil-dwelling bacteria Streptomyces, were among the first 
signaling molecules to be identified (Khokhlov et al., 1967). The first and the most well 
characterized γ-butyrolactone is A-factor from Streptomyces griseus, which is required in 
nanomolar concentrations for antibiotic (streptomycin) production and sporulation. Today, 
several γ-butyrolactones are known including the Streptomyces coelicolor butyrolactones 
(SCBs) which regulate actinorhodin, undecylprodigiosin and the recently identified PKS 
biosynthesis cluster, Cpk in S. coelicolor (see review Takano, 2006, for a review; Yamada, 
1999).                                                                                  
The first γ-butyrolactone biosynthesis analysis was of virginiae butanolides (VB) isolated 
from Streptomyces virginiae which is thought to involve a condensation of the glycerol 
derivative, dihydroxyacetone and 7-methyl-3-oxo-octanoyl CoA to form a 
7-methyl-3-oxo-octanoic acid. In the presence of NADH this is then converted into 
6-dehydroVB A, and further to VB A in the presence of NADPH (Sakuda et al., 1990, 1992, 
1993). However in vitro synthesis proving this biosynthesis pathway has never been reported. 
Recently, Shikura et al. (2002) identified a stereospecific reductase essential for the last step in 
VB production.  
A putative A-factor biosynthetic gene, afsA, was cloned from S. griseus (Horinouchi et al., 
1985) and a number of homologues of AfsA have subsequently been identified from several 
streptomycetes (see Takano, 2006, for a review). However, in vitro A-factor synthesis has not 





afsA on a multi-copy plasmid leads to precocious production of streptomycin in S. griseus, and 
synthesis of A-factor in several Streptomyces species that normally do not produce it 
(Horinouchi et al., 1985).  Expression of afsA in E. coli also results in production of 
biologically active γ-butyrolactones which is reduced in the presence of cerulenin, a fatty acid 
synthesis inhibitor (Ando et al., 1997).  From these results and those from Sakuda et al. (1990, 
1992) outlined above, it was concluded that AfsA alone can produce A-factor from a glycerol 
derivative and an α-keto acid derived from fatty acid biosynthesis. 
A contrary view arose from studies of the gene barX, an afsA homologue from S. virginiae, 
which is located adjacent to barA, encoding the VB binding protein. A barX deletion mutant 
produces less virginiamycin (VM) and VBs, but the addition of VBs to the mutant did not 
restore VM production (Kawachi et al., 2000) in contrast to the situation reported for the afsA 
mutant in S. griseus (Hara & Beppu, 1982). Furthermore, BarX enhances the stability of the 
interaction between BarA and its cognate barB (barA homologue) promoter by a 
protein-protein interaction that leads to repression of barB expression. Thus the authors 
conclude that BarX does not possess enzymatic activity analogous to AfsA, but may be 
involved in the regulation of VB synthesis. ScbA is the afsA homologue in S. coelicolor, 
genetically the most well characterized streptomycete with a completely sequenced genome. 
scbA is located divergently from the γ-butyrolactone binding protein determinant, scbR (Takano 
et al., 2001) thus exhibiting the same gene organization as in S. virginiae (see Takano, 2006, for 
a review). A deletion mutant of scbA does not produce any γ-butyrolactones with antibiotic 
stimulatory activity and expression of scbA is absent in both the scbA and scbR deletion 
mutants. While the expression of scbR is induced by addition of SCB1, a γ-butyrolactone, to 
the scbA mutant, scbA transcription is not inducible under the same conditions (Takano et al., 
2001). Thus some direct role for ScbA in transcriptional activation of its own gene appears 
likely, suggesting a possible regulatory function for ScbA. Production of SCBs is detected at 
transition to stationary phase which also coincides with the transcription of scbA (Takano et al., 
2001).  
To clarify these conflicting results, and to understand the function of ScbA and the other 
members of the AfsA family, we have undertaken an in silico analysis of the protein sequences. 
From these analyses, a number of conserved residues that are likely to participate in an 
enzymatic function of ScbA were identified. Point mutations in these positions were created 
and the resulting S. coelicolor strains were tested for the ability to produce γ-butyrolactones 
with antibiotic stimulatory activity. All tested point mutations resulted in the loss of antibiotic 
stimulatory function, indicating that ScbA is indeed an enzyme involved in γ-butyrolactone 






Material and methods 
Bacterial strains, plasmids and growth conditions 
 Strains and plasmids used in this study are listed in Table 1. Streptomyces strains were 
manipulated as described previously (Kieser et al., 2000). Escherichia coli was grown and 
transformed according to Sambrook et al. (1989). SMM (Takano et al., 2001) was used for 
RNA isolation, isolation of γ-butyrolactones and antibiotic production determination. SMMS 
agar (Takano et al., 2001) was used for γ-butyrolactone bioassays. MS agar (Kieser et al., 2000) 
was used to make spore suspensions and for plating out conjugations with E.coli ET12567 
containing the RP4 derivative pUZ8002 (Flett et al., 1997). R2 (Kieser et al., 2000) and R2YE 
(Kieser et al., 2000) was used to observe morphological differentiation and antibiotic 
production of mutants.  
 
Primers, PCR and DNA sequencing 
All primers used in this work are listed in Table 2. Amplification of DNA by PCR was 
done with Taq polymerase or ProofStart polymerase (Qiagen). E. coli colony PCR was carried 
out by mixing a small amount of cells picked from a single colony directly into the PCR 
reaction pre-mixture. DNA sequences were done by MWG. 
 
DNA and RNA manipulations  
Plasmid DNA isolation, restrictions and cloning experiments were carried out as described 
in Sambrook et al. (1989). Streptomyces genomic DNA was isolated according to Leblond et al. 
(1996). RNA was isolated as described in Strauch et al. (1991).  
 
Construction of ScbA mutants 
The conserved glutamates Glu78 and Glu240 of ScbA were mutated to alanine, and the 
conserved arginine Arg243 to lysine by site-directed mutagenesis using SLIM (Chiu et al., 
2004).  
Glu to Ala replacement  To mutate Glu to Ala in ScbA, at amino acid position 78 (DNA 
position 232 - 234) and 240 (718-720), the GAG triplet was changed to GCC using the primers 
E78A and E240A (Table 2). pIJ6147 was used as template to amplify a 562 bp product with (1) 
96°C 5 min (2) 96°C 45 s 65°C 35 s 70°C 45 s repeated for 25 cycles (3) 70°C 7 min. This 
fragment was gel purified and cloned into pGEM-T Easy vector (Promega), yielding pTE101. 
Both PCR primers, E78A and E240A, includes one mutation site, Glu78Ala and Glu240Ala 
respectively, and one AgeI site at the 5’ end of the primer allowed subsequent cloning of the 
556 bp DNA fragment from pTE101 into the AgeI site of pIJ6143. pIJ6143 has four AgeI sites, 





(III) region in scbA (Fig. 3). pIJ6143 was incubated with 2.5 fold ethidium bromide for 10 min 
at 37°C and 1 unit of AgeI (New England Biolabs) was added and incubated at 37°C for 30 min 
and Calf intestine alkaline phosphatase (CIAP) treated for 30 min at 37°C to obtain partial 
digested DNA fragments. DNA fragments around 3.7 kb was gel eluted. The eluted fragment 
was ligated with a 556 bp AgeI segment from pTE101 and the mixture used to transform E. coli 
JM101 (Chung et al., 1989). Plasmids were isolated from the transformants and then digested 
with BtgI and PvuII to determine the integrity of scbA and the orientation of the insert. The 
obtained candidate plasmid, pTE102, has 49 bp deleted in between two AgeI sites [from AgeI (I) 
to (II), Fig. 3]. The missing 49bp was replaced by using a modified version of the site-directed 
ligase-independent PCR-mediated mutagenesis (SLIM) method of Chiu et al. (2004). The 
primers 49nt F1, 49nt R1, F1 and R1 (see Table 2) was used for SLIM PCR using pTE102 as 
template. Primer 49nt F1 and R1 was used to amplify coding strand, and primer 49nt R1 and F1 
was used to amplify the corresponding strand of pTE102 using a mixture of Taq DNA 
polymerase (5 units, Qiagen) and ProofStart DNA polymerase (0·2 unit, Qiagen) with (1) 95°C 
2 min (2) 94°C 15 s 53°C 25 s 68°C 5 min repeated 25 cycles (3) 68°C 7 min. PCR products 
were purified with the Qiagen PCR purification kit and pTE102 was removed by treatment 
with 10 units of DpnI (New England Biolabs). The conditions for SLIM heteroduplex 
formation were performed as described in Chiu et al. (2004). An aliquot of 20 µl reaction was 
used to transform competent E. coli JM101 (Chung et al., 1989). Clones were screened by 
colony PCR using PCR primer Scbart1 and Scbart2 (Table 2) to identify a 484 bp PCR product 
(instead of the 435 bp present in the pTE102) using PCR condition: (1) 96°C 5 min (2) 96°C 30 
s 58°C 30 s 70°C 30 s repeated for 25 cycle (3) 70°C 7 min and the candidate was confirmed 
by DNA sequencing within scbA gene (MWG) using scba414 and 628-re-c primers, and named 
pTE103. The EcoRI 1.28 kb fragment from pTE103 was subcloned into the EcoRI site of the 
conjugative vector pSET152, to yield pTE104.  
To obtain the single mutation at amino acid position 78 (Glu to Ala), the primers E78A20 
and E78A20anti (Table 2) were used in the SLIM PCR as indicated above to amplify DNA 
from pIJ6143. Primer E78A20c (Table 2), which contains at the 3’ end, the GCC triplet (instead 
of GAG present in the wild type of scbA) and primer 628-re-c (Table 2) was used to screen for 
the modified scbA at PCR condition: (1) 96°C 5 min (2) 96°C 30 s, 65°C 30 s, 70°C 30 s, at 25 
cycles (3) 70°C 7 min. The resulting plasmid, designated pTE105, was checked for the 
presence of the correct point mutations and the absence of further mutations in the 945 bp scbA 
by DNA sequencing (MWG). The EcoRI 1.28 kb fragment from pTE105 was subcloned into 
the EcoRI site of pSET152, to yield pTE106. The single mutation at the amino acid position 
E240A (Glu to Ala) was constructed by the NdeI/BbpI DNA fragment from pTE103 and 





subcloned into the EcoRI site of pSET152 which resulted in pTE108. 
Arg to Lys replacement To mutate Arg to Lys in ScbA at amino acid position 243, the CGG 
triplet was changed to AAG (DNA position 727-729) using SLIM-PCR as indicated above. 
Except that the primer R243K and R243K-anti (Table 2) were used in the SLIM PCR to 
amplify DNA from pIJ6143, and R243K-c (Table 2), which contains at the 3’ end, the CTT 
triplet (instead of CGG present in the wild type of scbA) and primer scba414 (Table 2) was 
used to screen for the modified scbA with (1) 96°C 5 min (2) 96°C 30 s, 57°C 30 s, 70°C 35 s, 
25 cycles (3) 70°C 7 min. The resulting plasmid, designated pTE109 was analysed for the 
presence of the correct point mutations and the absence of further mutations in the 945 bp scbA 
by DNA sequencing. The EcoRI 1.28 kb fragment from pTE109 was subcloned into the EcoRI 
site of the conjugative vector pSET152, to yield pTE110. 
 
Introduction of the mutation into Streptomyces  
pTE104, pTE106, pTE108 and pTE110 were introduced into the methylation-deficient E. 
coli strain ET12567 containing the RP4 derivative pUZ8002 (Paget et al., 1999), and 
transferred to S. coelicolor M751 by conjugation (Flett et al., 1997). Single-crossover 
exconjugants were selected on MS containing apramycin and nalidixic acid, to obtain 
transconjugants M751::pTE104, M751::pTE106, M751::pTE108 and M751::pTE110, 
respectively. The genomic DNA of each strain was isolated and plasmid integration was 
confirmed by PCR with primer JGatt B1-fwd and JGatt Pint-rev (Table 2) which gave an 
amplified product of 0.8 kb corresponding to the inserted region (data not shown). 
 
Reverse Transcriptase (RT)-PCR  
RT-PCR was conducted using RNA isolated from M751::pSET152 (negative control: 
mutant complemented with vector), M751::pIJ6147(positive control: mutant complemented 
with wt scbA), M751::pTE104, M751::pTE106, M751::pTE108 and M751::pTE110 grown in 
SMM liquid medium after 24h (Fig. 3A). 2 μg of RNA were used to synthesize the cDNA and 
27 ng of this cDNA were used as template for a PCR reaction as previously reported using 
primers for scbA, hrdB, redQ, cpkE, and actIII except the PCR conditions were 96°C 5 min, 
then 30 cycles of 96°C 40 s, 58°C 40 s, 72°C 40 s and extension at 72°C for 7 min (Takano et 
al., 2005).  
 
HPLC-MS monitoring of γ-butyrolactone formation 
Extracts from SMMS grown M751::pSET152, M751::pIJ6147, M751::pTE104, 
M751::pTE106, M751::pTE108, M751::pTE110, SMMS (media only) and the standard (SCB1) 





ion trap system. The system was operated with the electrospray ionisation (ESI) source in the 
positive mode. HPLC conditions: Agilent Zorbax Eclipse XDB C8 column, 5µm, 150 x 4.6 mm, 
mobile phase:  A = water, B = methanol,  gradient elution: starting with 10 % at 1 min to 100 
% at 17 min, kept at 100 % for 5 min, flow rate 1.0 ml min-1. MS conditions: dry temperature 
350 °C, nebulizer 60 psi, dry gas 11 l/min, ion mode positive (MS and MS²). 
 
Other methods  
γ-butyrolactones were isolated and the bioassay was conducted as described previously in 
Takano et al. (2001). M751::pSET152, M751::pIJ6147, M751::pTE104, M751::pTE106, 
M751::pTE108 and M751::pTE110 were grown on SMM liquid or SMMS solid medium, and 
ethylacetate extracts were made from stationary phase culture supernatants at OD450nm 1.2 (the 
last time point, Fig. 3A). Equal amounts of the supernatant extracts were spotted onto confluent 
lawns of M145, the indicator lawn. After 48 h of incubation, the antibiotic stimulatory activity 
was determined (Fig. 3B). Antibiotic production assay was conducted using 1 ml sample of 
cells grown in 50 ml SMM as described in Strauch et al. (1991). 
 
Results  
ScbA has active sites that are similar to FabA and FabZ 
  ScbA contains two AfsA repeats according to Pfam (Pfam03756) (Sonnhammer et al., 
1998). These repeats show no similarity to any other proteins in the databases using standard 
BLAST or PSI-BLAST searches (Altschul et al., 1997). A sequence search of all proteins with 
known structure using the advanced remote homology detection tool HHpred, which is based 
on pairwise comparision of hidden Markov models (Söding et al., 2005) revealed that ScbA 
consists of two domains homologous to the superfamily of thioesterase/thiol ester 
dehydrase-isomerases defined in the SCOP database (Murzin et al., 1995). Each of these 
domains contains the previously described AfsA repeat as their most conserved part. Two 
members of the thioesterase/thiol ester dehydrase-isomerase superfamily, namely FabA 
(beta-hydroxydecanol thiol ester dehydrase) and FabZ ((3R)-hydroxymyristoyl ACP 
dehydrase), have several conserved active site positions that also appear in both domains of 
ScbA (see below). Moreover, FabA and FabZ are functional as homodimers whose two active 
sites are located at the dimer interface (Leesong et al., 1996 and Kostrewa et al., 2005). This 
strongly suggests a similar spatial arrangement of the two domains in ScbA. Although the 
overall sequence similarity of ScbA to FabA or FabZ is weak (15% and 13% amino acid 
identity respectively), the similarity in the region around the FabA/FabZ active site is 
pronounced, and in particular the hydrophobicity pattern is well conserved (Fig. 1). 
The active site in FabA and FabZ is formed between the long α-helix of one subunit and a loop




































































































































































































































































































































































































































N-terminal to the equivalent helix of the other subunit. The residues involved in catalysis are a  
conserved aspartate/glutamate located in the helix and a conserved histidine present in the loop 
region that form the catalytic diad. A conserved glutamine forms a hydrogen bond with the 
carboxyl side chain of the conserved glutamate/aspartate residue and stabilizes its position 
(Leesong et al.,1996, Kimber et al., 2004 and Kostrewa et al., 2005). In ScbA, the glutamates 
(E78, E240) and glutamines (Q82, Q244) are perfectly conserved in both domains, while the 
histidine residue is only present in the C-terminal domain. In other homologues the C-terminal 
histidine is replaced by an arginine (H226R) (Fig. 1). The arginine residue may be related with, 
or the functional difference between ScbA and FabA/FabZ may be due to the arginine residue 
that is well conserved in both domains of ScbA (R81, R243) is situated just before the 
conserved glutamine but is not present in FabA or FabZ.  
 
Mutagenesis of the predicted active site residues in ScbA: glutamate 78, glutamate 240 
and arginine 243 
 To test the prediction that these homologous amino acids are involved in forming the 
active site of ScbA, the conserved glutamates E78 and E240 were mutated to alanine, and the 
conserved arginine R243 to lysine in the AfsA repeat domain. E78 and E240 were mutated to 
alanine separately to yield pTE106 (E78A) and pTE108 (E240A), respectively, and together to 
yield pTE104 (EA). The conserved arginine R243 was mutated to yield pTE110 (R243K) 
(Materials and Methods, Fig. 1 and 2).  These constructs were then introduced into the scbA 
deletion mutant M751 by conjugation to give strains M751::pTE104, M751::pTE106, 
M751::pTE108 and M751::pTE110. The original promoter was retained in all constructs.   
Figure 2. Schematic map of amino acid exchanges made in ScbA. scbA, represented as an open arrow, has two 
AfsA repeat domains (solid box) and three AgeI site (line). Mutated sites DNA position 232-234 (E78A), 718-720 
(E240A) and 727-729 (R243K) are indicated by lines. The primers used for mutagenesis are shown by arrows and 





All mutated ScbA strains lost the ability to produce γ-butyrolactones even though the 
mutated genes were expressed   
 The ability of the constructed mutants to produce SCB1 γ-butyrolactone was tested by 
bioassay,  looking for the ability of ethyl acetate extracts isolated from stationary phase 
cultures of the strains to induce pigmented antibiotic production in the indicator strain M145 
(as detailed in the Materials and Methods). The results are presented in Fig. 3B.  As 
previously reported, an extract from the positive control strain M751::pIJ6147 stimulated 
pigmentation; however, it needed extracts that were twofold more concentrated than that of 
M145::pSET152. Extracts from M751::pTE104, M751::pTE106, M751::pTE108 and 
M751::pTE110 showed no antibiotic stimulatory activity, even when using a twofold excess of 
supernatant extract compared with the positive control (Fig. 3B). This result indicates that the 
amino acid replacements (E78A, E240A and R243K) in these two putative active sites leads to 
an inability to produce active γ-butyrolactones. 
 These results were corroborated by analyses of the metabolic profiles by HPLC-MS using 
a synthetic reference of SCB1. As shown in Fig. 3C, only M751::pSET152 and M751::pIJ6147 
were capable to produce SCB1, while no related γ-butyrolactones were detectable in the 
mutants. MS reveals the characteristic fragmentation that is initiated with the loss of two 







Figure 3. Amino acid exchange 
mutants do not produce bioactive 
γ-butyrolactones. (A) growth 




and M751::pTE110 strains were 
grown in SMM liquid media at 30°C. 
At time point 18 h, 20 h, 22 h, 24 h 
and 34 h, samples were collected to 
measure OD450nm.  The strains were 
indicated as ■ : M145::pSET152, ●: 
M751::pSET152, ▲: M751::pIJ6147, 
▼: M751::pTE104, ♦: M751::pTE106, 
◄ : M751::pTE108 and ►: 
M751::pTE110. (B) γ-butyrolactone 
bioassays. Ethyl acetate extracts from 
M751::pSET152, M751::pIJ6147, 
M751::pTE104, M751::pTE106, 
M751::pTE108 and M751::pTE110 
culture supernatants were spotted onto 
confluent lawns of M145 on SMMS 
and incubated at 30°C for 48 h. 
Antibiotic stimulatory activity (purple 
halo) indicates that the strain produces 
active γ-butyrolactones. 0.25ng of 
chemically synthesized SCB1 was used as positive control and methanol and ethyl acetate were spotted as a 
negative control. (C) HPLC-MS profiles of extracts from wild type and mutants. Displayed is single ion 
monitoring (SIM) for m/z = 245. Ethyl acetate extracts from SMMS grown M145::pSET152, M751::pSET152, 
M751::pIJ6147, M751::pTE104, M751::pTE106, M751::pTE108, M751::pTE110, SMMS (media only) and 
chemically synthesised SCB1 were analysed by HPLC. The peak corresponding to SCB1 is seen in samples 









Figure 4. Mass spectrometry data of M145::pSET152 where SCB1 production was observed. (A) (a) Base peak 
chromatogram of M145::pSET152. (b) Extracted ion chromatogram (SIM) for m/z 245 ([244 + H]+) of sample 
M145::pSET152. (c) Base peak chromatogram of SCB1 standard. (B) (a) Mass spectrum of the peak at retention 
time 14.5 min of sample M145::pSET152. (b) Mass spectrum of SCB1 standard. (c) MS/MS spectrum of the m/z 
245 hydrogen adduct, peak at 14.5 min of sample M145::pSET152. (d) MS/MS spectrum of the m/z 245 











Figure 5. Mass spectrometry data of M751::pIJ6147. (A)(a) Base peak chromatogram of sample M751::pIJ6147. 
(b) Extracted ion chromatogram (SIM) for m/z 245 ([244 + H]+) of sample M751::pIJ6147. (c) Base peak 
chromatogram of SCB1 standard. (B) (a) Mass spectrum of the peak at retention time 14.5 min of sample 
M751::pIJ6147. (b) Mass spectrum of SCB1 standard. 
 
 To exclude any possibility that the mutated scbA constructs were not being correctly 
expressed, RT-PCR was conducted as described in Material and Methods. The expression of 
hrdB encoding the major sigma factor for S. coelicolor was readily detected in all samples (Fig. 
6), while the scbA transcript was detected in all the samples except for M751::pSET152, 
which is the scbA deletion mutant with an integrated vector only (Fig. 6). No amplified 





contamination of the RNA samples (data not shown). This suggests that scbA was expressed in 
the mutants and that the mutations, and not the loss of transcription, led to the loss of bioactive 
γ-butyrolactone production. 
 To assess the effect of the mutations on growth and antibiotic production, M751::pTE104, 
M751::pTE106, M751::pTE108 and M751::pTE110 were grown on several solid media (R2, 
SMMS, R2YE and MS) in triplicate, but they showed only slights differences compared to 
wt::pSET152 or M751::pSET152 (data not shown; see discussion). The mutants were also 
grown on SMM liquid media at 30°C in triplicates and after 18 h samples were taken at four 
time points (every 2 h) and after 34 h at OD450nm. The antibiotic production of 
undecylprodigiosin and actinorhodin was varied with each growth, and no conclusion could be 
made from these results (data not shown). RT-PCR using the undecylprodigiosin 
pathway-specific activator, redD, and a representative biosynthesis gene, redQ, the 
actinorhodin pathway-specific activator, actII-ORF4 and a representative biosynthesis gene, 
actIII, the Cpk pathway-specific activator, cpkO and a representative biosynthesis gene, cpkE, 
was conducted in triplicate to determine the effect of the mutation on the expression of these 
genes. The expression levels of the three biosynthesis genes were similar in all the strains 
tested (Fig. 6). The three activators showed varied expression levels (data not shown) which 
may correspond to the growth phase in which the RNA was isolated (see discussion).  
 
Figure 6. Gene expressions in the constructed mutants of scbA. RT-PCR using cDNA synthesized from RNA 
isolated from M145::pSET152, M751::pSET152, M751::pIJ6147, M751::pTE104, M751::pTE106, 
M751::pTE108 and M751::pTE110 was conducted. Amplified products were run on an agarose gel and the 
amplified gene products are indicated on the left side of the gel. The expected sizes of the amplified products are: 
hrdB: 550 bp; scbA: 480 bp; redQ: 80 bp; cpkE 95 bp, and actIII 97 bp. All PCR was performed at 30 cycles. The 






 The precise mechanism of ScbA/AfsA homologues in γ-butyrolactones synthesis has 
been under considerable debate for the last decade. Moreover the exact biosynthetic pathway 
for the γ-butyrolactones is unknown despite their importance in the regulation of antibiotic 
production. Our results point strongly to a role for ScbA in the biosynthesis of SCB1. 
Standard BLAST analysis of the AfsA family of proteins has not revealed any similarity to 
other proteins in the database since the sequencing of AfsA in 1985. By using a novel software, 
HHpred (Söding et al., 2005), we were able to determine for the first time, that ScbA has 
active sites similar to fatty acid synthesis genes. The synthesis of fatty acids is performed by 
the type II fatty acid biosynthesis pathway in eubacteria. There are four steps in the elongation 
cycle which extends two carbons per cycle. In E. coli the dehydration of the β-hydroxyl-ACP 
is performed by FabA or FabZ. Unsaturated fatty acids are produced by the isomerase, FabM, 
utilizing the fatty acid intermediate produced by FabZ, or directly by FabA that has been 
shown to have an additional from trans-2- to cis-3-decenoyl-ACP isomerase activity (Heath et 
al., 1996 and Brock et al., 1967). FabZ on the other hand does not exhibit an isomerase 
activity and is involved in both saturated and unsaturated fatty acid elongation. FabA is mainly 
found in Gram-negative bacteria that produce unsaturated fatty acids while FabZ is found in 
most bacteria (Kimber et al., 2004). The 3D structures and the active sites have been 
determined for both FabA and for FabZ. The active site residues determined from mutational 
studies are H70 and D84 for E. coli FabA (Leesong et al., 1996) and H133 and E147 for 
Plasmodium falciparum FabZ (Kostrewa et al., 2005).  
We chose to mutate the conserved glutamates in the two AfsA repeat domains of ScbA. 
The other active site residue, histidine, in the fatty acid synthases was not conserved in the 
N-terminal domain of ScbA but only in the C-terminal region so this histidine was not mutated. 
The mutated C-terminal arginine R243 on the other hand was not conserved in the fatty acid 
synthase but only in the AfsA repeat domains. The mutagenesis of either one or both 
conserved glutamates or the arginine abolished the production of γ-butyrolactones with 
antibiotic stimulatory activity. This strongly suggests that these amino acids are important for 
ScbA activity indicating the HHpred prediction was indeed correct and that ScbA is indeed an 
enzyme homologous to FabA and FabZ. The exact enzymatic role of ScbA will need further 
biochemical analysis, but from the similarity of the active sites to FabA and FabZ, a 
dehydratase activity is likely, which is consistent with the previously proposed biosynthesis 
model of butyrolactones by Sakuda et al. (1992).  
Using the 3D structures determined for FabA and FabZ, a structure of ScbA is proposed 
(Fig. 7). FabA and FabZ are homodimers (Leesong et al., 1996). Their two identical active 





arrange in a similar fashion to form functional active sites. As the two domains have diverged 
considerably (pair wise sequence identity of 20%), whereas the key residues remain 
unchanged (Fig. 1), it is likely that they catalyze similar reactions but use different substrates.  
Figure 7. Proposed structural model of ScbA. Modelled structure of ScbA deduced from the homology to FabA 
and FabZ with their duplicated "hot dog" fold, showing the two active catalytic sites which presumably bind fatty 
acid derivatives. The classic inhibitor of FabZ, 3-decanoyl-N-acetylcysteamine (DAC), which is modelled into 
the structure (green spacefill) gives the approximate arrangement for the bound substrates of ScbA. The 
conserved parts of the N- and C-terminal domains (the central alpha helices and the preceding loops) are depicted 
in blue and red, respectively. In cyan are the side-chains of the conserved E78 and E240, in magenta the 
conserved Q82 and Q244, in red the conserved R81 and R243. Further residues with potential functional 
importance are R228 (yellow) and D72 (orange). 
 
 As ScbA has similarity to the active sites of fatty acid synthetases, could ScbA also effect 
synthesis of fatty acids? Streptomyces produces unsaturated fatty acids (Gesheva et al., 1997) 
but so far from the S. coelicolor genome sequence, no obvious type II FabZ homologue has 
been identified (Bentley et al., 2002) while a distant orthologue was found in S. avermitillis 
(Ikeda et al., 2003). Preliminary data suggest that S. coelicolor wild-type (wt) and the scbA 
mutant both produce C14, C16, C17 unsaturated fatty acids in SMMS (data not shown). This 
result may exclude the possibility of ScbAs involvement in unsaturated fatty acids. However 
the enzymes responsible for the synthesis of these fatty acids, i.e. the FabA or FabZ equivalent 





was found to have a weak similarity to FabZ. From the genome sequence of S. avermitillis, a 
similar multi-domain gene (SAV7361) which also has a FabA homologous domain was found 
as well as an individual FabA (SAV3654, 31% amino acid identity to E. coli FabA) and FabZ 
(SAV3655, 31% amino acid identity) homologue. However, there are no other homologues of 
FabA or FabZ in S. coelicolor. Instead, we have identified a FabM homologue (SCO5144) 
which is also highly conserved in S. avermitilis (SAV3120, 86% amino acid identity to 
SCO5144). In Streptococcus pneumoniae a FabA homologue has not been identified, but a 
FabM homologue which encodes for a trans-2, cis-3 decenoyl-ACP isomerase was found 
along with a FabZ homologue (Marrakchi et al., 2002).  It is likely that SCO5144 is involved 
in the isomerase activity but what gene in S. coelicolor is responsible for the dehydration of 
β-hydroxyacl-ACP to produce branched fatty acid is not clear.   
scbA is divergent to the γ-butyrolactone receptor scbR. SCO6264 located adjacent to scbR, 
also affects γ-butyrolactone synthesis in S. coelicolor (T. Nihira and E. Takano, unpublished). 
This gene is homologous to barS1 which is responsible for the reduction of the C6 position of 
VBs in S. virginiae (Shikura et al., 2002). barS1 is also positioned close to barX on the 
chromosome, the scbA homologue in S. virginiae.  There are ten scbA homologues, including 
scbA and barX, found in the NCBI database. Out of these genes nine have surrounding 
sequences available for analysis. Six out of these possess homologous genes that probably 
encode a short-chain dehydrogenases family of proteins which include SCO6264 and barS1. 
The genes adjacent to the afsA/scbA like gene mmfL in S. coelicolor plasmid SCP1 and avaA 
in S. avermitilis, mmfH and SAV2267, respectively, are classified as medium chain acyl-CoA 
dehydrogenases and are somewhat distant from the others but still have homology to 
dehydrogenases. The only exception to the “rule” of having a dehydrogenase homologue in 
the cluster was S. griseus. This species is atypical, as the γ-butyrolactone receptor is at least 
100 kb away from afsA, the scbA homologue (Ando et al., 1997). Considering the 
conservation of the position of these dehydrogenase homologues, it is possible that these genes 
are also involved in γ-butyrolactone synthesis as in the case of barS1 and SCO6264. The 
differences in the dehydrogenase family may also be related to differences in the 
γ-butyrolactone precursor and end-product structures. 
We have previously shown that the scbA deletion mutant overproduces antibiotics 
(Takano et al., 2001). In this presented experiment, we were only able to detect a slight 
difference in antibiotic production for all the strains using the integrative plasmid. This may be 
due to the integration of pSET152 which effects the production of the pigmented antibiotics, 
both positively and negatively, which we observe repeatedly even in the wt with the vector 
alone and also the instability of the vector integration without selection (data not shown). To 





However, no difference was observed in the expression of the biosynthesis genes in all the 
strains and the expression of the regulators was variable. This is possibly due to the RNA 
isolated at a relatively late time point which was too late to see a clear difference in the 
expression levels of the biosynthesis genes as well as the effect of the integrated vector. To 
clearly determine the effect of the mutation on antibiotic production, we are currently 
introducing these mutations in ScbA into the chromosome.  
We have also previously reported a possible regulatory function for ScbA (Takano et al., 
2001) based on the observation that the expression of scbA was not detected in the scbA 
mutant and was not complemented by addition of SCB1. In the present work, the mutated 
ScbAs did not produce bioactive SCBs, but their expression under their own promoter, albeit 
in the ΦC31 attachment site, was restored to the same level as the wt. This suggests that we 
have now uncoupled the regulatory function and the enzymatic functions of ScbA, 
strengthening the possibility that ScbA has dual function.  
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Table1. Strains and plasmids used in this study                            
Strains or plasmids   Description                            Source or reference         
S. coelicolor A3(2)   strains 
M145 Wild-type(genome sequenced) Kieser et al., 2000 
M751 In-frame deletion of scbA Takano et al., 2001 
M751::pSET152 pSET152 integrated in M751 This work 
M751::pIJ6147 pIJ6147 (full length scbA) integrated in M751 This work 
M751::pTE104 pTE104 (Glu-Ala scbA mutant) integrated in M751 This work 
M751::pTE106 pTE106 (E78A scbA mutant) integrated in M751 This work 
M751::pTE108 pTE108 (E240A scbA mutant) integrated in M751 This work 
M751::pTE110 pTE110 (Arg-Lys scbA mutant) integrated in M751 This work 
E. coli strains 
JM101 General-purposes cloning strain Sambrook et al., 1989 
ET12567 Strain used for conjugated between E.coli MacNeil et al., 1992 
and Streptomyces 
Plasmids 
pSET152 Non replicative conjugative cloning plasmid Bierman et al., 1992 
pUZ8002 Non transmissible transfer plasmid Flett et al., 1997 
pGEM-T Easy PCR product cloning vector Promega 
pIJ6143 scbA within pGEM-T-easy vector Takano et al., 2001 
pIJ6147 scbA within pSET152 vector Takano et al., 2001 
pTE101 562 bp mutated scbA PCR product cloned into This work 
 pGEM-T-Easy 
pTE102 AgeI scbA fragment of pTE101 cloned into pIJ6143 This work 
 (lost 49nt) 
pTE103 pTE102 derivate containing full length of scbA This work 
 (with 49nt) 
pTE104 EcoR I scbA fragment of pTE103 cloned into pSET152 This work 
pTE105 pIJ6143 derivate containing E78A mutated scbA This work 
pTE106 EcoR I DNA fragment of pTE105 subcloned into This work 
 pSET152 
pTE107 NdeI/BbpI DNA fragment from pTE103 subcloned This work 
 into pIJ6143 
pTE108 EcoR I scbA fragment of pTE107 cloned into pSET152 This work 
pTE109 pIJ6143 derivate containing Arg-Lys mutated scbA This work 





Table 2. Primers used in this work                                       




































redQrtrv gcgtcgtcgctgatcttca                                                         
* The AgeI site is indicated by underline and nucleotide changes are in capital 
^ The insertion sequence is bold capital. 















Evidence for additional roles of ScbA in regulation of antibiotic 














 Small signalling molecules called γ-butyrolactones regulate the production of secondary 
metabolites and/or morphological differentiation in Streptomyces. ScbA from Streptomyces 
coelicolor A3(2) has been previously reported to synthesize γ-butyrolactones (SCBs). To 
assess whether ScbA has any additional metabolic and physiological functions, various scbA 
point mutant genes were used to replace the deleted scbA gene at its native locus on the S. 
coelicolor chromosome. All the scbA point mutant strains lost the ability to produce active 
SCBs; this phenotype resembles that of a scbA gene deletion mutant strain. Interestingly, 
strains expressing the mutant ScbA Glu78Ala/Glu240Ala and ScbA Arg243Lys proteins, both 
had different antibiotic production profiles in liquid and solid media compared to the scbA 
deletion mutant. The glutamate double mutant strain developed aerial mycelia and spores on 
DNAgar, a phenotype that was not observed for the wild type, the scbA gene deletion mutant 
and the other scbA point mutant strains. These results suggest that ScbA has additional roles 
other than the synthesis of the SCBs in the regulation of antibiotic production and 
morphological differentiation in S. coelicolor A3(2). 
 
Introduction 
The Gram-positive, soil-dwelling bacteria of the genus Streptomyces are well known by 
their complex morphological differentiation and the ability to produce valuable secondary 
metabolites including more than 70% of commercially important antibiotics (Hopwood, 2007). 
γ-Butyrolactones, extracellular low-molecular weight compounds, have been identified and 
studied for their ability to regulate antibiotic production and/or morphological differentiation 
(Takano, 2006). The γ-butyrolactones induce antibiotic production at nanomolar 
concentrations and diffuse freely in and out of the cell. These characteristics strongly suggest 
that the γ-butyrolactones can be regarded as microbial hormones, or signalling molecules 
(Takano, 2006). The structure of thirteen γ-butyrolactones, which all have a 2,3-di-substituted 
γ-butyrolactone skeleton in common, have been elucidated (Takano, 2006 and Hsiao et al., 
2009). The first γ-butyrolactone to be identified is A-factor which triggers streptomycin 
production and aerial mycelium formation in Streptomyces griseus (Mori, 1983 and 
Horinouchi and Beppu, 1994). Other well known γ-butyrolactones include virginiae 
butanolides (VBs) which control virginiamycin production in Streptomyces virginiae (Yamada 
et al., 1987 and Kondo et al., 1989), IM-2 which elicits production of showdomycin and 
minimycin in Streptomyces lavendulae FRI-5 (Sato et al., 1989) and Streptomyces coelicolor 
butanolides (SCBs) which stimulate the production of the pigmented antibiotics actinorhodin 
(Act) and undecylprodigiosin (Red) in S. coelicolor A3(2) (Takano et al., 2000 and Hsiao et 





AfsA is the key enzyme to synthesize A-factor in S. griseus (Kato et al., 2007). An 
A-factor-deficient mutant of S. griseus which produced neither streptomycin nor formed aerial 
mycelia, was restored to wild type by exogenous addition of A-factor (Hara et al., 1982 and 
Mori et al., 1983). Introduction of afsA into an A-factor-deficient mutant and A-factor 
nonproducing Streptomyces caused A-factor production with a gene dosage effect (Horinouchi 
et al., 1985). AfsA contains two AfsA repeat domains (Pfam03756) and was proven to catalyze 
the condensation of dihydroxyacetone phosphate (DHAP) with 8-methyl-3-oxononanoyl-acyl 
carrier protein. The resulting product was reduced by BprA (butenolide phosphate reductase) 
or another unknown reductase and dephosphorylated by an undefined phosphatase to generate 
A-factor (Kato et al., 2007). Expression of AfsA in E. coli caused this host to produce two 
A-factor analogues with bioactivity, suggesting that the reductase(s) and phosphatase(s) can be 
provided by E. coli (Kato et al., 2007 and Ando et al., 1997).      
Deletion of barX, the homologue of afsA in S. virginiae, yielded a mutant strain that 
produced less VBs and virginiamycin. However, exogenous addition of VB did not restore 
production of virginiamycin in this mutant, indicating that BarX acts as a regulator rather than 
an enzyme (Kawachi et al., 2000). On the other hand, a barS1 mutant, deficient in 
6-dehydro-VB-A reductase activity, lost ability to produce VBs and virginiamycin; its 
virginiamycin production level was completely restored to that of wild type by addition of 
VB-C. The BarS1 enzyme is essential for catalysis of the stereospecific reduction of the 
A-factor type precursor into a VB-type compound, which corresponds to the last VB 
biosynthetic step (Shikura et al., 2002). The barS2 gene, flanking barS1 and barX, encodes a 
putative dehydrogenase. A barS2 mutant showed a delay and reduction of both VBs and 
virginiamycin production. The barS2 mutant was complemented by addition of VB or by an 
intact barS2 gene, suggesting that BarS2 is also involved in VB biosynthesis in S. virginiae 
(Lee et al., 2008).    
The afsA homologue in S. coelicolor A3(2), the model organism of Streptomyces, is scbA, 
which lies adjacent to scbC (SCO6267, 76% identity in amino acid sequence to BprA in S. 
griseus) and scbB (SCO6264, 32% identity in amino acid sequence to BarS1 in S. virginiae). A 
scbA gene deletion mutant strain (without deletion of its transcriptional start site) 
overproduced Act and Red, but lost the ability to produce the γ-butyrolactones with antibiotic 
stimulatory activity plus its promoter activity, suggesting that ScbA may have both an 
enzymatic and regulatory function (Takano et al., 2001). Recently, we reported that ScbA has 
similarity to the fatty acid synthase enzymes FabA and FabZ (Hsiao et al., 2007). Mutagenesis 
of potential active site amino acid residues in ScbA, glutamate 78, glutamate 240 (which are 
also conserved and are shown to be active sites in FabA and FabZ), and arginine 243 (which is 





loss of γ-butyrolactone production with antibiotic stimulatory activity when introducing these 
mutant genes into a S. coelicolor scbA gene deletion mutant via integration into an attachment 
site. Again, this strongly suggested that ScbA is an enzyme involved in synthesis of SCBs 
(Hsiao et al., 2007). However, these strains with mutated scbA genes displayed inconclusive 
antibiotic production phenotypes (Hsiao et al., 2007). 
To clarify the effect of these mutated ScbA proteins on antibiotic production and 
morphological development in S. coelicolor A3(2) and to further investigate the role of ScbA 
in this organism, four mutated scbA genes, created in the previous work (Hsiao et al., 2007), 
were introduced into the native scbA locus on the S. coelicolor chromosome through gene 
replacement in the scbA deletion mutant. These scbA mutant strains were tested for their 
ability to produce SCBs, antibiotics, and to differentiate using various growth media. None of 
the scbA point mutant genes complemented the ability to produce SCBs in the scbA deletion 
mutant while the wild type scbA gene did, which confirmed our previous observations (Hsiao 
et al., 2007), thus resembling a scbA gene deletion mutant (Takano et al., 2001). However, the 
Glu78Ala/Glu240Ala double mutant and the Arg243Lys point mutant showed different 
antibiotic production profiles in R2 solid medium and R2 liquid medium. Furthermore, only 
the Glu78Ala/Glu240Ala double mutant was able to form aerial mycelium and spores on 
DNAgar. Therefore, ScbA may have additional roles in the regulation of antibiotic production 
and morphological development in S. coelicolor A3(2).  
 
Materials and Methods 
Bacterial strains, plasmids and growth conditions 
Strains and plasmids used in this study are listed in Table 1. Streptomyces strains were 
manipulated according to Kieser et al. (2000). E. coli was grown and transformed as described 
by Sambrook et al. (1989). MS agar (Kieser et al., 2000) was used to make spore suspensions, 
for plating out conjugations with E. coli ET12567 containing the RP4-derivative pUZ8002 
(Flett et al., 1997) and to observe morphological differentiation of mutants. The following 
media, SMMS (Takano et al., 2001), R2 (Kieser et al., 2000), R2YE (Kieser et al., 2000), the 
nitrogen-, phosphate-, carbon-limited minimal medium EVANS (Fink et al., 2002), Difco 
Nutrient Agar (BD; abbreviated as “DNAgar” in text and “DNA” in the figure) and GluDNA 
(DNAgar with addition of 235 mM glutamic acid) were used to observe morphological 
differentiation and antibiotic production of mutants. R2 solid medium was used for the 
isolation of γ-butyrolactone, Act and Red. R2 liquid medium (Kieser et al., 2000) was used for 
RNA and γ-butyrolactone isolation, and antibiotic production determination. For promoting 
sporulation, DNAgar was supplemented with phosphate containing 0.05 M NaH2PO4 and 0.05 





MnCl2 and NaCl, and 0.07g/L of CaCl2 (0.1% v/v), different sugars (1% v/v; i.e. glucose, 
mannitol, glycerol, arabinose and sucrose), different nitrates (final concentration 30 mM; i.e. 
sodium nitrate and calcium nitrate), ammonium sulphate (final concentration 30 mM). 
 
DNA and RNA manipulations 
Plasmid DNA isolation, restrictions and cloning experiments were as described by 
Sambrook et al. (1989). Streptomyces chromosomal DNA was isolated according to Leblond 
et al. (1996). Total RNA of Streptomyces was isolated according to Strauch et al. (1991). 
 
Construction of the scbA point mutant strains LW29-LW32  
Non-replicating plasmids containing the mutated scbA genes were constructed as follows: 
A 989 bp NdeI/BclI DNA fragment of pTE105, pTE108, pTE103 or pTE110 (Hsiao et al., 
2007), containing the mutant scbA genes encoding E78AScbA, E240AScbA, EAScbA (double 
mutant) or R243KScbA, respectively, was cloned into the non-replicating plasmid pIJ6140 
(Takano et al., 2001) to obtain pTE111, pTE112, pTE113 or pTE114, respectively (Fig. 1 and 
Table 1). The correct construction of these plasmids was confirmed by PCR using primers 
scbArt1 and 628-rt-c (Table 2). These plasmids were subsequently used to place the mutated 
scbA genes at the native locus of scbA on the chromosome. 
Plasmids pTE111, pTE112, pTE113 and pTE114 were introduced into the 
methylation-deficient E. coli strain ET12567 containing the RP4-derivative pUZ8002 (Paget 
et al., 1999), and transferred to S. coelicolor M751 (a scbA gene deletion mutant strain) by 
conjugation (Flett et al., 1997). Single-crossover exconjugants were selected on MS agar 
containing apramycin and nalidixic acid. Representative exconjugants were grown on MS agar 
without apramycin for four rounds of sporulation. Subsequently, the resulting spores were 
selected for apramycin-sensitivity indicating that a double-crossover recombination event had 
occurred. The genomic DNA of each apramycin-sensitive strain was isolated, and the proper 
placement of the mutated scbA was confirmed by PCR with primers RCseq59 and scbArt1, 
which gave an amplified product of 1.1 kb with the mutated scbA genes and of 385 bp for the 
deleted scbA gene fragment from M751 (Fig. 2). Southern blots were conducted to confirm the 
proper orientation of the mutated scbA genes (Fig. 3). For Glu78Ala mutant strains, five 
apramycin-sensitive colonies were obtained from a total of 5000 screened. PCR (data not 
shown) and Southern analysis (Fig. 3) confirmed that the full length scbA had become 
replaced in four of these strains. These independently obtained Glu78Ala mutant strains 
showed identical phenotypes in antibiotic production and morphology. The promoter and 
coding sequence of this scbA point mutation (Glu78 to Ala78) were confirmed by DNA 





Glu240Ala mutant strains, PCR analysis confirmed that 12 out of 33 candidates had a full 
length scbA (Fig. 2). Two were chosen to be confirmed by Southern analysis (Fig. 3) and these 
gave identical phenotypes. The promoter and coding sequence of this scbA point mutation 
(Glu240 to Ala240) were confirmed by DNA sequencing (AGOWA) and this strain was named 
LW30 (Glu240Ala mutant strain). For Glu78Ala/Glu240Ala double mutant strains, three 
correct strains were obtained from more than 10000 screened. All three were confirmed by 
PCR (data not shown) and Southern analysis to have the full length scbA (Fig. 3) and showed 
identical phenotypes. One strain was reconfirmed by sequencing of the scbA coding and 
promoter region and named LW31 (Glu78Ala/Glu240Ala double mutant strain). For 
Arg243Lys mutant strains, five correct strains, confirmed by PCR (data not shown) and 
Southern analysis (Fig. 3), were obtained from 4000 colonies screened (Fig. 3). All five 
showed identical phenotypes. The promoter and coding sequence of this scbA point mutation 
(Arg243 to Lys243) were confirmed by DNA sequencing and this strain was named LW32 
(Arg243Lys mutant strain). 
 
Growth of strains M145, M751, LW29-LW32 
The various strains (M145, M751, LW29-LW32) were inoculated (2.25 x 108 spores) in 
60 ml R2 liquid medium and incubated at 30°C and 220 rpm. The optical density at 450 nm 
(OD450) was recorded every two hours from 16-24 h and at 42 h after inoculation (Fig. 5A). 
Samples for γ-butyrolactones, RNA and antibiotic isolation were taken at 17 h (exponential 
phase), 21 h (transition phase) and 42 h (stationary phase) after inoculation (the three time 
points indicated in Fig. 5A). Experiments were done in duplicate to ensure reproducibility of 
results. 
 
γ-butyrolactones isolation and quantification 
The γ-butyrolactones were isolated from liquid cultures of M145, M751, LW29-LW32 
according to Takano et al. (2001). Ethyl acetate extracts were made from culture supernatants 
at 17 h, 21 h and 42 h after inoculation (the three time points indicated in Fig. 5A). The 
kanamycin bioassay for quantification of γ-butyrolactones was conducted as described (Hsiao 
et al., 2009). Equal amounts of the supernatant extracts were spotted onto lawns of the 
indicator strain LW16::pTE134. After 3 days, the growth of the indicator strain was 
determined.  
 
Antibiotic production assay 
Antibiotic production assay was performed using 1 ml of cells from liquid cultures of M145, 





LC/MS-TOF measurement of γ-butyrolactones 
Strains were grown on R2 solid medium for 3 days and γ-butyrolactones were extracted 
by ethyl acetate as described previously (Takano et al., 2001). For each sample, the extracts 
from a single plate were used for analysis. SCB1 (40 ng) and SCB3 (1 ng) were used as 
standards. All experiments were done using an Agilent 1100 Series LC/MS-TOF system. 
HPLC conditions were as follows: the column was an Agilent Zorbax Eclipse XDB C8 
column (5 µm, 150 x 4.6 mm); the mobile phase consisted of A (water, 0.2 % (v/v) acetic acid) 
and B (methanol, 0.2 % (v/v) acetic acid); the gradient elution started with 0 % B at 2 min to 
100 % at 11 min, and was then kept at 100 % for 5 min, flow rate 0.8 ml/min. The system was 
operated with the atmospheric pressure chemical ionization (APCI) source in positive mode. 
MS-TOF conditions were: capillary voltage 3500 V, nebulizer pressure 50 psi, drying gas 
5 l/min, gas temperature 325°C, vaporizer temperature 350°C, fragmentor voltage 120 V, 
skimmer voltage 60 V, octapole RF 250 V, mass range (m/z) 50-3200. Reference masses 
obtained from the APCI-TOF tuning mix (Agilent) including compounds at 121.050873 m/z 
and 922.009798 m/z were added to the sheath flow liquid at 0.02 ml/min and were 
continuously monitored to maintain the calibration of the instrument. 
 
RT-PCR 
RT-PCR was conducted (Hsiao et al., 2007) using RNA isolated from liquid cultures of 
strains M145, M751, LW29-LW32 grown (Fig. 5A) in liquid R2 medium as described above.  
 
Results 
Construction of S. coelicolor strains with mutant scbA genes placed in the native scbA 
chromosomal location 
To assess possible additional functions of ScbA, we previously complemented S. 
coelicolor M751 (a scbA gene deletion mutant) with various scbA genes carrying point 
mutations using vector pSET152, which integrates at the phage attachment site, followed by 
determination of the antibiotic phenotypes of these strains (Hsiao et al., 2007). However, 
control experiments showed that the integrative vector pSET152 itself altered the production 
of antibiotics (Hsiao et al., 2007). We therefore decided to place these mutant scbA genes at 
the native scbA locus in the S. coelicolor M751 chromosome by gene replacement. The 
in-frame deleted scbA gene (244 bp) in the non-replicating plasmid pIJ6140, also containing 1 
kb upstream region (including the scbR gene [646 bp]) and 1.1 kb downstream region 
(including the scbC gene [855 bp]) of scbA, was replaced by a 989 bp NdeI/BalI DNA 
fragment from pTE105 containing a mutation at coding position Glu78 in the scbA gene which 





concept, 989 bp NdeI/BalI DNA fragments from pTE108 containing a mutation at coding 
position Glu240 in the scbA gene encoding E240AScbA, from pTE103 containing two 
mutations at coding position Glu78 and Glu240 in the scbA gene encoding EAScbA, or from 
pTE110 containing a mutation at coding position Arg243 in the scbA gene encoding 
R243KScbA, was placed into pIJ6140 to obtain pTE112, pTE113 or pTE114, respectively (Fig. 
1). These plasmids were introduced into S. coelicolor M751 via conjugation resulting in 
apramycin-resistant exconjugants. After three rounds of sporulation on nonselective MS agar, 
PCR with primers (RCseq59 and scbArt1) that amplify the scbA coding region was performed 
on total DNA isolated from apramycin-sensitive strains. Those strains which have the mutated 
scbA alleles replaced at the scbA deleted region on the chromosome through homologous 
recombination were selected by the difference in size of the PCR amplified product (Fig. 2, 
only PCR of E240AScbA is shown). The correct integration was further verified by Southern 
analysis (Fig. 3) and each point mutation was confirmed by DNA sequencing (data not shown). 
The confirmed strains were designated LW29 (a Glu78Ala mutant), LW30 (a Glu240Ala 
mutant), LW31 (a Glu78Ala/Glu240Ala double mutant) and LW32 (an Arg243Lys mutant). 
 
Phenotypic differences between S. coelicolor wild type and various scbA mutant strains  
To determine the phenotypes of the various S. coelicolor strains carrying mutated scbA 
genes with respect to antibiotic production and morphological differentiation, S. coelicolor 
M145 (wt), M751 and mutant strains LW29-LW32 were grown on the solid media SMMS, R2, 
R2YE, MS, DNAgar and GluDNAgar. In three independent experiments, all the scbA point 
mutants conferred a reproducible phenotype in antibiotic production and morphological 
differentiation (Fig. 4). When grown on GluDNAgar for 41 h, M145 produced a yellow pigment 
while all other strains did not. On DNAgar, only LW31 generated aerial mycelia and spores 
which were visible under the microscope, and produced blue pigmented antibiotics, Act, at 90 h. 
This phenotype was also observed in a separate experiment after prolonged incubation (8 days; 
data not shown). Interestingly, on MS agar, strain LW31 showed a delay in aerial mycelia and 
spore formation compared to the other strains (at 48 and 65 h; Fig. 4). Moreover, LW31 required 
7 days to generate spores on MS agar while all other mutant scbA strains, M145 and M751, 
required 5 days to sporulate and produced, on average, one order of magnitude more viable 
spores than LW31 (data not shown). When grown on SMMS, all the scbA point mutant strains 
precociously overproduced Act and Red similar to strain M751, while on R2YE no obvious 
differences compared to M145 or M751 were observed. Act production on R2 by LW32 was less 
while the other scbA point mutants showed similar antibiotic production as strain M751 (48 h; 
Fig. 4). Therefore, to determine antibiotic production, γ-butyrolactone production and scbA gene 






Figure 1. Schematic representation of the various scbA mutant constructs and the homologous recombination 
event. The deleted scbA gene in S. coelicolor M751 was replaced with the four mutated scbA genes via 
homologous recombination. The gray arrow indicates the location and orientation of scbR, the open arrow 
represents scbA (the deep gray segment indicates the remaining scbA in M751), the deep gray arrow represents 
the deleted scbA and the solid arrow represents scbC. The light gray box indicates oriT and the hatched arrow 
represents the apramycin resistance gene (Apra). The scbA gene was mutated at position 232-234 (corresponding 
to Glu78 in ScbA to Ala), 718-720 (Glu240 to Ala) and 727-729 (Arg243 to Lys) and are indicated by vertical 
black lines. The plasmids pTE111-pTE114, with corresponding mutated sites (labelled by asterisks) used for gene 
replacement are shown.  
 
Figure 2. PCR analysis of the potential LW30 mutants. PCR products were amplified from genomic DNA 
isolated from apramycin-sensitive exconjugants with primers RCseq59 and scbArt1 which contained either the 
mutated scbA gene encoding E240AScbA or the deleted scbA gene (lane 2-10). The positions of the full length 
scbA gene (1.1 kb) product and the deleted scbA (385 bp) fragment are indicated by arrows. M: 100 bp ladder 





Figure 3. Southern blot analysis of the S. coelicolor scbA point mutant strains. (A) The NcoI restriction map and 
gene organization in the 3.7 kb NcoI fragment. The gray arrow indicates scbR, the open arrow represents the full 
length scbA: either mutated scbA (mscbA) or wild type scbA (scbA), the deep gray arrow represents the deleted 
scbA (ΔscbA) and the solid arrow represents scbC. The corresponding strain name is indicated on the right. (B) 
Genomic DNA was isolated from M145, M751 and the scbA point mutant strains (LW29-LW32) and digested 
with NcoI and hybridized with 493 bp DIG labelled PCR fragment of scbR (indicated as DNA probe in (A)). 
M145 and the point mutant strains showed two hybridizing DNA fragments of 1.3 and 2.4 kb (indicated as 
two-headed arrows in (A) and arrows in (B)) and M751 revealed two fragments of 1.3 and 1.7 kb (indicated as 
two-headed arrows in (A) and arrows in (B)). Strain names are indicated above the picture. 
 
Comparison of antibiotic production levels by strains with mutant scbA genes and strain 
M751 during growth in R2 liquid medium  
Strains M145, M751 and all the scbA point mutant strains, showed a similar growth pattern 
in R2 liquid medium, suggesting that the scbA mutations did not affect growth (Fig. 5A). Strain 
LW31 was markedly reduced in Red production (0.44-fold of M751, Fig. 5B), whereas other 
scbA point mutant strains produced Red slightly more than M145 and at equal levels with M751 
after 42 h incubation. In contrast, LW31 produced a relatively higher amount of Act compared to 
the other point mutants and M751, and about 2-fold more than M145 (Fig. 5B). The experiment 
was repeated and growth curves and antibiotic production ratios were reproduced. Although the 
overall antibiotic production levels were somewhat lower in the second experiment (data not 





In R2 liquid medium, LW32 produced Act at the same level as M751, differing from the 
reduced Act production observed during growth on solid R2 medium. In an attempt to analyze 
this in more detail, 1.85×106 spores of strains M145 and M751, and the scbA point mutant 
strains (LW29-LW32) were spread on R2 solid media and incubated for 48 h (Fig. 6A). Act 
and Red were extracted from the medium and their production levels were determined in 
comparison to that of M751 (Fig. 6B). In strain LW32, Act (0.22-fold compared to M751) and 
Red (0.5-fold compared to M751) production was less than in M751. The other strains with 
scbA point mutations produced similar levels of both antibiotics as M751, and slightly higher 
amounts than those of M145 (Fig. 6B). 
 
Figure 4. Growth and antibiotic production phenotype comparison of S. coelicolor strains M145, M751, and 
LW29-LW32. 106 spores of M145, M751, LW29-LW32 were spread on GluDNAgar [GluDNA], DNAgar [DNA], 
MS, SMMS, R2YE and R2 agar, respectively, and then incubated at 30˚C for 41 h, 48 h, 65 h, 90 h. Strain names 
are indicated on the left. The reverse side of the plate is shown except for MS (at 48 h and 65 h) and DNAgar (at 






Figure 5. Growth and production of antibiotics by S. coelicolor strains M145, M751, and LW29-LW32 in R2 
liquid medium. (A) Growth curve of M145 (■), M751 (●), LW29 (▼), LW30 (∆), LW31(◊) and LW32(⌂) are 
indicated, respectively. Strains were grown in R2 liquid medium at 30˚C. At time points 16, 18, 20, 22, 24 and 42 
h, samples were collected to measure OD450nm. X axis indicates the incubation time in hour and Y axis represents 
the optical density at 450 nm (OD450). At 42 h antibiotic production was assessed. Timepoints where RNA and 
butyrolactones were isolated are indicated as tp1 (17 h), tp2 (21 h), and tp3 (42 h). (B) Actinorhodin (Act) and 
undecylprodigiosin (Red) production of M145, M751, LW29, LW30, LW31 and LW32. 1 ml of each strain was 
collected at 42 h. The deep gray bar represents Act production and the light gray bar Red production, respectively. 
The strain names and amount of antibiotic production are listed below in a table. Results are presented as 
microgram of antibiotic per milligram (dry weight) of mycelium (μg/mg dry weight). (C) The averaged ratio of 
Act and Red production in M145, M751, LW29, LW30, LW31 and LW32 from two growth curves. The 
production level of Act (deep grey) and Red (light grey) of tested strains were compared to M751 and are shown 
in ratios where the M751 production value was taken as 1.0. All productions are the average of two independent 
experiments with standard deviation marked with error bars. The values of the ratio and standard deviation of 
antibiotic production are also indicated below in a table. X axis indicates the strain names and Y axis represents 






Figure 6. Act and Red production of S. coelicolor strains M145, M751, and LW29-LW32 on R2 solid medium. 
(A) 1.85×106 spores of strains were spread as a confluent lawn on R2 solid medium and incubated at 30˚C for 41 
h and 48 h (indicated above). Strain names are indicated on the left. Pictures are taken from the bottom of the 
plates. (B) The production of Act (deep grey) and Red (light grey) of each strain after 48 h incubation were 
compared to that of M751, respectively, and shown as ratios which are presented as a bar chart with M751 as 1.0 
and the ratio numbers indicated below in the table. The real number of antibiotic amount are indicated in the 
bracket and presented as microgram of antibiotic per gram of agar (μg/g). The X axis indicates the strain names 
and the Y axis represents the ratio of antibiotic production. 
 
Comparison of γ-butyrolactone synthesis and confirmation of scbA expression in the 
scbA point mutant strains  
To determine whether the scbA point mutant strains are able to produce γ-butyrolactones, 
ethyl acetate extracts were prepared from liquid R2 medium cultures in the exponential phase 
(tp1, at 17 h), transition phase (tp2, at 21 h) and stationary phase (tp3, at 42 h, Fig. 5A) and 
analyzed by the kanamycin bioassay. Extracts containing SCBs allow growth of the indicator 
strain (LW16::pTE134) on DNAgar containing kanamycin by restoring the transcription of the 
kanamycin resistance gene (Hsiao et al., 2009). Incubation with the extracted samples isolated 





that SCBs were produced at exponential phase to transition phase but not at stationary phase in 
the R2 liquid medium. Neither extracts from the scbA point mutant strains nor from M751 
induced growth of the indicator strain on the kanamycin plates (Fig. 7A). Even when using 
2-fold larger samples compared to that of M145, no growth was observed with samples of 
scbA mutant strains (data not shown), indicating that these strains do not produce SCBs. These 
results were reproducible, and a same dataset for γ-butyrolactones was obtained in a second 
experiment (data not shown).  
Extracts were also prepared from cells grown on R2 solid media and analyzed for 
γ-butyrolactones by HPLC-MS (Fig. 7B and C). In view of the growth differences in liquid 
and solid cultures, and the fact that SCBs apparently are rapidly degraded in R2 liquid medium 
(Fig. 7A), the extracts were prepared from agar plates incubated for only 3 days when colonies 
had formed aerial mycelia. In M145, two masses were detected by HPLC-MS, namely 258, 
corresponding to SCB3, and 244, corresponding to SCB1 and/or SCB2. However, in M751 
and the scbA point mutant strains, none of these masses were detected, although there were 
some weak signals at the same retention time as SCB3, which may be background signals 
from the R2 medium (Fig. 7C). From these results, we conclude that the scbA point mutant 
strains did not produce SCB1, SCB2 and SCB3.  
 To rule out the possibility that the inability to synthesize SCBs was due to the failure to 
transcribe the mutated scbA genes, RNA was isolated from the same culture samples used to 
extract γ-butyrolactones, tp1, tp2, and tp3 (Fig. 5A). Reverse transcriptase PCR (RT-PCR) was 
conducted to analyze the gene expression level of scbA (Fig. 8). The expression of hrdB, the 
major vegetative sigma factor, was used as a control and was detected in all samples. A scbA 
PCR product was successfully amplified from all strains at either tps, except from M751, the 
scbA gene deletion strain, and from the samples using RNA or water as a template, confirming 
that there was no genomic DNA contamination in the RNA. A positive control was performed 
with M145 genomic DNA. In a separate experiment, RT-PCR was also conducted on the RNA 
samples isolated from a second culture to check reproducibility. PCR products of both hrdB 
and scbA were successfully amplified from M145 (tp3), LW29 (tp2 and tp3), LW30 (tp1 and 
tp3), LW31 (tp1 and tp3) and LW32 (tp3), indicating that all the point mutant strains and 
M145 were able to transcribe scbA (data not shown). The inability to produce γ-butyrolactones 






Figure 7. Determination of γ-butyrolactone production in S. coelicolor strains M145, M751, and LW29-LW32 
using the kanamycin bioassay and HPLC-MS analysis. (A) Ethyl acetate extract from culture supernatant of each 
strain at three time points (at 17 h, 21 h and 42 h, respectively) were spotted onto confluent lawns of 
LW16::pTE134 on DNAgar containing 5 μg/ml kanamycin, and incubated at 30˚C for 3 days. Induced growth on 
the agar plate was scored as indicating that the strain produced γ-butyrolactones. The three time points indicated 
on the left correspond to the arrows shown in Fig. 5A (17 h, 21 h and 42 h, respectively). Sample names are 
indicated above the agar plates. (B) and (C) The HPLC-MS profile of extracts from S. coelicolor strains M145, 
M751, and LW29-LW32. Measurements of peaks at m/z 245 and 259 which correspond to the masses for 
SCB1/SCB2 (both possess the same mass) and SCB3 respectively, are shown. Ethyl acetate extracts from R2 
grown M145, M751, LW29, LW30, LW31 and LW32, R2 (medium only), and chemically synthesized SCB1 and 
SCB3 were analyzed by HPLC-MS. The peak of chemically synthesized SCB1 is indicated by an arrow and the 
peak containing SCB1 and/or SCB2 in sample M145 is indicated by an open arrow in (B). The peak 
corresponding to SCB3 was seen in samples SCB3 and M145 and is shown by a hatched arrow in (C). Sample 
names are indicated next to the trace. X axis indicates the retention time in minutes and Y axis represents the 





Figure 8. RT-PCR analysis of scbA transcription in S. coelicolor strains M145, M751, and LW29-LW32. RT-PCR 
was performed with cDNA synthesized from RNA isolated from M145, M751, and strains LW29-LW32 grown in 
R2 liquid medium for 17 h (tp 1), 21 h (tp 2) and 42 h (tp 3; strain names and time points are indicated above the 
picture), respectively. PCR performed directly with RNA, M145 genomic DNA and water are indicated as RNA, 
gDNA and -. M: 100 bp ladder DNA molecular weight marker. The expected sizes of the amplified products were: 
hrdB, 550 bp and scbA, 480bp.    
 
Glucose with sodium nitrate stimulates aerial mycelium formation of the scbA point 
mutant strains, M751 and M145, on DNAgar 
On DNAgar, only LW31 generated aerial mycelia and spores. To further investigate this, 
DNAgar was supplemented with several medium components and the growth phenotypes of 
strains M145, M751 and LW31 were analyzed by incubating the plates for 5 days. When 
adding phosphate, sodium nitrate, or trace elements to DNAgar, LW31 still generated aerial 
mycelia earlier than M145 and M751 (Fig. 9A). However, when adding glucose, strains M145 
and LW31 both were able to form aerial mycelia, while M751 barely generated aerial mycelia 
(Fig. 9B). Replacement of glucose with the same molar ratio of mannitol, glycerol or 
arabinose resulted in poor growth with copious antibiotic production by M145, M751 and 
LW31. However, there was no difference in sporulation among these three strains (Fig. 9B). 
Furthermore, replacement of glucose with sucrose did not cause M145 nor M751 to produce 
any aerial mycelia while a slight aerial mycelial growth was observed for LW31 (Fig. 9B). 
With the combination of glucose and sodium nitrate, all three strains were able to form aerial 
mycelia and produce antibiotics (Fig. 9C). But addition of both glucose and ammonium sulfate 
resulted in poor growth with copious antibiotic production by M145 and LW31 (Fig. 9C). 
Addition of ammonium sulfate alone, or the combination of glucose together with calcium 
nitrate to DNAgar resulted in the same phenotype as that observed on DNAgar (Fig. 9A and 
C). Among these medium components, glucose together with sodium nitrate successfully 
promoted the aerial mycelium formation of all three strains, whereas glucose alone only 
boosted that of M145 and LW31, and the rest tested components failed to promote the growth.    
To further assess the effect of glucose and sodium nitrate, all the scbA point mutant 
strains, M145 and M751 were grown and compared on DNAgar with glucose alone or with 





generated by M145, LW30 and LW31 were visible on the agar, whereas the other strains were 
barely able to form aerial mycelia. With the combination of glucose and sodium nitrate, all the 
scbA point mutants, M145 and M751 were able to form aerial mycelia. 
  On the other hand, when M145, M751 and LW31 were grown on the nitrogen-, carbon- 
and phosphate-limited EVANS minimal media, no obvious difference of morphological 
phenotype among these three strains was observed and all formed aerial mycelia and also 
produced antibiotics (Fig. 9E).  
 
All M751 strains complemented with mutated scbA genes (via integration) failed to 
produce yellow pigment and failed to sporulate on DNAgar   
Following the observations that LW31 was able to sporulate on DNAgar, and that the 
ScbA point mutant strains did not produce yellow pigment, we assessed whether the same 
phenotypes could be observed in strain M751 complemented with the mutated scbA genes 
using the integrative plasmid pSET152 (Hsiao et al., 2007). M145::pSET152 (wt strain 
complemented with empty vector), M751::pSET152 (scbA gene deletion mutant strain 
complemented with empty vector), M751::pIJ6147 (scbA gene deletion mutant complemented 
with wt scbA), M751::pTE104 (complemented with mutant EAScbA), M751::pTE106 
(complemented with mutant E78AScbA), M751::pTE108 (complemented with mutant 
E240AScbA) and M751::pTE110 (complemented with mutant R243KScbA) (Hsiao et al., 
2007) were grown and compared for the production of yellow pigment on DNAgar and 
GluDNAgar (Fig. 10). On GluDNAgar, only M145::pSET152 produced yellow pigment (after 
48 h incubation) whereas the other strains started to produce Red (Fig. 10). Neither the 
complemented strains (LW31 equivalent strain M751::pTE104 as well) nor the parental strains 
sporulated on DNAgar after 8 days incubation (Fig. 10). 
 
Discussion 
 Aim of this study was to investigate functions of ScbA in S. coelicolor that had remained 
unclear till now. The phenotype of M751 (a scbA gene deletion mutant strain) suggested that 
ScbA was an enzyme able to synthesize SCBs and might also regulate its own transcription 
(Takano et al., 2001). Moreover, AfsA, the ScbA homologue in S. griseus, was shown to be 
the key enzyme to synthesize A-factor (Kato et al., 2007). In the previous study, mutagenesis 
of predicted active site residues of ScbA (Hsiao et al., 2007) supported the enzymatic function 
of ScbA in the biosynthesis of SCBs but left a possible regulatory role of ScbA undetermined. 
In the present study, our results indicate that ScbA may have the suggested regulatory role in 





Figure 9. Growth phenotype comparison of S. coelicolor strains M145, M751, and LW29-LW32. M145, M751 
and LW31 were grown on DNAgar [indicated as DNA] and DNAgar supplemented (A) with final concentration 
0.5 mM phosphate [DNA+Pi], final concentration 30 mM sodium nitrate [DNA+NaNO3] and 0.1% trace 
elements [DNA+TE]; (B) with 1% of glucose [DNA+Glucose], mannitol [DNA+Mannitol], arabinose 
[DNA+Arabinose], glycerol [DNA+Glycerol] or sucrose [DNA+Sucrose]; (C) with 1% glucose combined with 
final concentration 30 mM sodium nitrate [DNA+Glucose+NaNO3] or with final concentration 30 mM 
ammonium sulfate [DNA+(NH4)2SO4] or with 30 mM ammonium sulfate [DNA+Glucose+(NH4)2SO4] or with 
30 mM calcium nitrate [DNA+Glucose+CaNO3], respectively. All agar plates were incubated for 5 days at 30˚C. 
(D) The scbA point mutant strains, M751 and M145 were grown on DNAgar supplemented with 1% glucose 
[DNA+Glucose] or with 1% glucose combined with final concentration 30 mM sodium nitrate 
[DNA+Glucose+NaNO3]. All agar plates were incubated for 5 days at 30˚C. (E) Strains M145, M751 and LW31 
were grown on the minimal EVANS media with nitrogen-, carbon- or phosphate limitation, respectively. All the 
agar plates were incubated at 30˚C for 5 days. Media and strain names are indicated next to the plates. The agar 





Figure 10. Growth and yellow pigment production phenotype comparison of S. coelicolor strains M145::pSET152, 
M751::pSET152, M751::pIJ6147, M751::pTE104, M751::pTE106, M751::pTE108 and M751::pTE110. 106 viable 
spores of test strains were spread on DNAgar and GluDNAgar and incubated at 30˚C for 48 h  to show yellow 
pigment production (shown as reverse side of the agar plates) and 8 days to show morphology (shown as the top 
side of the agar plates). The media and incubation time are indicated above and strain names are indicated on the 
left 
 
 In R2 liquid medium, strain LW31, the Glu78Ala/Glu240Ala double mutant, produced 
1.5-fold more Act while Red was produced much less compared to M751, the scbA gene 
deletion mutant strain. The production of Red was even less than that of wild type. On R2 solid 
medium, the trend in pigmented antibiotic production was similar and Act production was 
higher in LW31 compared to M751, while Red production was less in LW31 than in M751 but 
comparable to that of M145. On the other hand, strain LW32, the Arg243Lys point mutant, 
showed the biggest difference in antibiotic production and produced much less Act and Red on 
solid R2 medium compared to M751 and even M145. In liquid R2, LW32 produced Act similar 





similar variation in antibiotic production on solid and liquid medium has been observed 
previously. S. coelicolor with 5-6 additional copies of afsR, a pleiotropic regulatory gene for 
antibiotic production, produced Act and Red 200-fold and 20-fold higher amounts on SMMS 
solid medium, respectively, compared to the wild type. In SMM (a liquid version of SMMS), it 
only produced 10-fold higher Act and 2.5-fold higher Red in SMM, a liquid version of SMMS 
(Floriano and Bibb, 1996). In this case, the antibiotic production by the mutant strain, although 
being reduced in liquid, was still higher than that in M145. However, in case of LW31 and 
LW32, there was a reversal in the amount of antibiotic produced when compared to M752 in 
liquid and solid medium. The reason for this discrepancy in the two scbA point mutant strains is 
not clear. We have seen that changing agar supplier has an effect on antibiotic production levels 
(Takano, personal communication) and therefore the component in the agar may be the cause 
for the difference in antibiotic production seen between liquid and solid R2 medium as this is 
the only component that is different in these media. 
 Despite these variations in antibiotic production in liquid and solid media, two strains with 
point mutants of ScbA, namely strains LW31 and LW32, clearly showed a different antibiotic 
production phenotype compared to the scbA gene deletion mutant strain M751. None of the 
mutants produce γ-butyrolactones. Therefore we expected that the various ScbA mutant strains 
would produce antibiotics at a similar level. This was not the case however and differences in 
antibiotic production were observed in some scbA point mutant strains which suggested a 
possible antibiotic production regulatory role of ScbA. Further detailed analysis of this 
phenomenon in both liquid and solid media is required to fully understand these effects. 
LW31 was different from the other scbA point mutant strains, and from M145 and M751, 
in that sporulation was observed on DNAgar and delayed growth on MS (Fig. 4). The aerial 
mycelium formation of other strains was promoted on DNAgar by supplementing with glucose 
and sodium nitrate (Fig. 9). Strain LW31, with the ScbA Glu78Ala/Glu240Ala double mutation, 
apparently did not require these factors, suggesting variations between the scbA mutant strains 
in an unknown function of ScbA to regulate morphological development which was not 
observed previously (Takano et al., 2001), and which may be related with glucose and/or 
nitrate as main carbon and nitrogen source. However, in most cases glucose was reported to 
repress sporulation (Pope et al., 1996 and Chouayekh et al., 2007). This is the first report where 
a reverse effect has been observed, namely that addition of glucose to the DNAgar medium 
stimulates sporulation of all strains. Further study will be needed to understand the effect of 
glucose in DNAgar medium. The antibiotic and differentiation differences observed with LW31 
indicate that the Glu78Ala/Glu240Ala double mutation has a more severe effect than the scbA 
single point mutations in the other strains. It is interesting to note that LW31 was very difficult 





screened; see Materials and Methods). As it was so difficult to obtain, there is a possibility that 
a second site mutation not in scbA had been selected. Moreover, M751 complemented with the 
same point mutation, the gene encoding EAScbA provided on pSET152 (M751::pTE104), did 
not form aerial mycelia as LW31 did on DNAgar (Fig. 10). To assess whether the 
morphological phenotype of LW31 was caused by the point mutations in scbA or by a second 
mutation may be investigated by complementing LW31 with the wild type scbA. This remains 
to be done in future work. 
 In agreement with the previous report (Hsiao et al., 2007), all the scbA point mutant 
strains failed to produce SCBs although all mutated scbA genes were transcribed (Fig. 7 and 
10). This suggests that the mutated active site amino acid residues are important for the 
enzymatic function of ScbA to synthesize SCBs, but did not affect the function to regulate its 
own transcription. This was not the case in the scbA gene deletion mutant strain since very little 
transcript of scbA was observed in strain M751. This observation, and the antibiotic production 
phenotype differences, clearly suggest that ScbA has a regulatory function. On the other hand, 
ScbR, the γ-butyrolactone receptor in S. coelicolor, is able to bind to the promoter region of 
scbA shown by gel retardation experiments (Takano et al., 2001) Transcription analysis of all 
the scbA point mutant strains to determine the expression profiles of the genes encoding ScbA, 
ScbR, and key proteins for Act and Red synthesis (i.e. activator) will be crucial to further 
elucidate the possible regulatory function of ScbA. 
 The LW29-LW32 scbA point mutant strains and M751 as well as the integrated scbA point 
mutants all failed to produce the yellow pigment, which is thought to be the end product of the 
S. coelicolor polyketide (CPK) gene cluster lay next to the scbA gene (Takano et al., 2005 and 
Pawlik et al., 2007), while M145 produced the yellow pigment on GluDNAgar (Fig. 4, Fig. 10). 
This correlation between the yellow pigment and the SCB production observed in all the scbA 
mutant strains confirmed the results from Takano et al., (2005) in that ScbA activates the 
yellow pigment production through the γ-butyrolactones by inhibiting the repression exerted by 
ScbR at the CPK activator.  
 SCBs produced by M145 were only detected at the exponential and transition phases but 
not at the stationary phase in the R2 liquid medium (Fig. 7) as reported previously (Takano, 
2006) and may imply a R2 medium-dependent degradation process of SCBs. The SCB 
degradation mechanism is unclear and needs further study.  
 In this study, we successfully constructed the scbA point mutant strains, involving gene 
replacement at the native scbA locus on the chromosome of strain M751. These strains 
displayed a stable antibiotic phenotype, suggesting that the inconclusive antibiotic phenotype 
stated in the previous report (Hsiao et al., 2007) was due to the use of vector pSET152, 





also were observed when studying scbR complemented strains which were obtained either via 
pSET152 or gene replacement (Takano and Gottelt, unpublished data). Lee and coworkers 
(2008) also reported that the initiation of the virginiamycin production of a barS2 
complemented strain was delayed 1-2 h compared to that of S. virginiae which may be due to 
the integration of pSET152 in the attB site of the chromosome.  
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Table 1. Strains and plasmids used in this study                                    
Strains or plasmid  Description                     Source or reference    
S. coelicolor A3(2) strains 
M145 Wild-type (genome sequenced) Kieser et al., 2000 
M751 In-frame deletion of scbA in M145 Takano et al., 2001 
LW29 E78A mutated scbA in M751 This work 
LW30 E240A mutated scbA in M751 This work 
LW31 EA mutated scbA (E78A and E240A) in M751 This work 
LW32 R243K mutated scbA in M751 This work 
M751::pSET152 pSET152 integrated in M751 Hsiao et al., 2007 
M751::pIJ6147 pIJ6147 (full length scbA) integrated in M751 Hsiao et al., 2007 
M751::pTE104 pTE104 (E78A/E240A scbA mutant) integrated Hsiao et al., 2007 
 in M751  
M751::pTE106 pTE106 (E78A scbA mutant) integrated in M751 Hsiao et al., 2007 
M751::pTE108 pTE108 (E240A scbA mutant) integrated in M751 Hsiao et al., 2007 
M751::pTE110 pTE110 (R243K scbA mutant) integrated in M751 Hsiao et al., 2007 
 
E. coli strains 
JM101 General-purposes cloning strain Sambrook et al., 1989 
ET12567 Strain used for conjugation between E. coli MacNeil et al., 1992 
 and Streptomyces 
Plasmids 
pGEM-T Easy PCR product cloning vector Promega 
pUZ8002 Non transmissible transfer plasmid Flett et al., 1997  
pTE103 E78A/E240A mutated scbA within pGEM-T Easy Hsiao et al., 2007 
pTE105 E78A mutated scbA within pGEM-T Easy Hsiao et al., 2007 
pTE108 E240A mutated scbA within pSET152 Hsiao et al., 2007 
pTE110 R243K mutated scbA within pSET152  Hsiao et al., 2007 
pTE111 989 bp NdeI/BclI E78A mutated scbA fragment  This work 
 of pTE105 cloned into pIJ6140  
pTE112 989 bp NdeI/BclI E240A mutated scbA fragment This work 
 of pTE108 cloned into pIJ6140 
pTE113 989 bp NdeI/BclI E78A/E240A mutated scbA This work 
 fragment of pTE103 cloned into pIJ6140 
pTE114 989 bp NdeI/BclI R243K mutated scbA fragment This work 





Table 2. Primers used in this work         






hrdBrt2 TCGTCCTCGTAGCACG                                                   
* The NdeI site is indicated by underline. 








































Overexpression of ScbA, a key protein for γ-butyrolactone 












ScbA is involved in biosynthesis of γ-butyrolactones and directly or indirectly plays a role 
in the regulation of antibiotic production and morphological differentiation in Streptomyces 
coelicolor. To clarify the various functions of ScbA, it is important to obtain soluble and active 
ScbA protein. In this study, six different vectors were tested for the expression of ScbA protein. 
When using the pQE80 vector, the soluble form of ScbA was detected in Escherichia coli by an 
anti-ScbA antibody which was produced in this study.  
 
Introduction 
The Gram-positive bacterial genus Streptomyces employs γ-butyrolactone, a signalling 
molecule, as an autoregulator to control antibiotic production and/or morphological 
differentiation (Takano, 2006). Streptomyces coelicolor, the model organism of Streptomyces, 
produces at least three γ-butyrolactones, collectively termed SCBs (Takano et al., 2000). These 
SCBs appear to regulate, indirectly or directly, the production of the pigmented antibiotics 
actinorhodin (Act), undecylprodigiosin (Red), and the yellow pigment which may be the end 
product of the CPK cluster (Takano et al., 2001, Takano et al., 2005 and Pawlik et al., 2007). 
In vitro synthesis of A-factor, the first γ-butyrolactone identified from Streptomyces 
griseus, has finally been successful (Ando et al., 1997) three decades after it was identified 
(Khoklov et al., 1967). The A-factor synthase AfsA (313 amino acids) was expressed in E. coli 
using the expression vector pQE80 (Qiagen), involving a fusion of the recombinant AfsA 
(H-AfsA) protein with 12 amino acids and 6 histidine residues at the N-terminal end and four 
amino acids at the C-terminal end (Kato et al., 2007). The purified H-AfsA protein was 
incubated with cell lysates of the ΔafsA mutant strain plus the chemically synthesized 
γ-butyrolactone precursor, 8-methyl-3-oxononanoyl-N-acetylcysteamine. The product of the 
AfsA activity, 8-methyl-3-oxononanoyl-DHAP ester, was reduced and dephosphorylated by 
BprA (butenolide phosphate reductase) or another unknown reductase and by an undefined 
phosphatase, respectively, in the cell lysate to generate A-factor which was confirmed by 
LC-ESIMS (Kato et al., 2007). This result clearly showed that AfsA has an enzymatic function 
and catalyzes the essential and initial condensation step in the A-factor biosynthesis in S. 
griseus (Kato et al., 2007). Previously, this group also reported that an afsA gene deletion 
mutant of S. griseus lost the ability to produce A-factor, and that the introduction of afsA into E. 
coli stimulated this host to produce compounds with A-factor activity (Ando et al., 1997) 
MmfL, the homologue of AfsA encoded by the linear plasmid SCP1 in S. coelicolor, also 
has enzymatic activity. It synthesizes a newly identified signalling molecule 
2-alkyl-4-hydroxymethylfuran-3-carboxylic acid (AHFCA) also called methylenomycin furan 





high-copy number expression vector, in E. coli BL21star(DE3) caused the host to produce 
MMFs (Corre et al., 2008), which were not produced in the control strain.   
In Streptomyces virginiae, BarX, the homologue of AfsA, was reported to have a 
regulatory function instead of an enzymatic function (Kawachi et al., 2000). The BarX protein 
(32 kDa) was fused with an N-terminal maltose-binding protein (MBP, 42 kDa) which was 
expressed by pMAL-c (New England Biolabs), a multiple-copy plasmid (20/cell), and purified 
from E. coli JM105. This recombinant BarX-MBP protein was able to stabilize the 
DNA-binding activity of BarA, the γ-butyrolactone receptor in S. virginiae, as shown by gel 
retardation analysis. BarX-MBP itself did not show any DNA-binding ability (Kawachi et al., 
2000). 
In the previous study (Hsiao et al., 2007), we have reported that ScbA, the homologue of 
AfsA in the S. coelicolor chromosome, also has enzymatic activity as proven by active site 
mutagenesis: Mutations in predicted active site residues of ScbA (glutamate 78 and/or 240 to 
alanine; arginine 243 to lysine) yielded ScbA mutant strains that did not produce 
γ-butyrolactones with antibiotic stimulatory activity, a phenotype which resembles that of a 
scbA gene deletion mutant. To further study the enzymatic function of ScbA and to further 
analyze the role of the active site residues in ScbA, it is necessary to produce and purify wild 
type and mutant ScbA proteins in sufficient quantities to conduct for instance activity assays 
and substrate binding experiments.  
Numerous vectors for expression of native and heterologous genes in Streptomyces are 
available (Kieser et al., 2000). The most commonly used promoters for these vectors are the 
ermE* promoter (Bibb et al., 1985), frequently deployed as a strong constitutive promoter, and 
the tipA promoter, a thiostrepton-inducible strong promoter (Murakami et al., 1989). The 
recombinant protein can be expressed with an expression-tag, such as His-tag, for purification, 
(Takano et al., 1995) and enhanced green fluorescent protein (EGFP), as a reporter for spatial 
and temporal gene expression (Sun et al., 1999). High copy number, low copy number, or 
integrative plasmids are also available (Kieser et al., 2000).   
In this study, ScbA was overexpressed in both E. coli and Streptomyces using six different 
expression vectors. ScbA expression under the control of tipA promoter was not observed in 
Streptomyces. ScbA expression, however, was successful in E. coli, and was detected with 
antibodies generated in this study against denatured insoluble His-ScbA protein isolated from E. 
coli. 
 
Materials and Methods 
Bacterial strains, plasmids and growth conditions 





manipulated according to Kieser et al. (2000). E. coli was grown and transformed as described 
by Sambrook et al. (1989). MS agar (Kieser et al., 2000) was used to make spore suspensions. 
LB (Sambrook et al., 1989), TSB (Tryptic soy broth, DB), YEME liquid medium (Kieser et al., 
2000), S-medium (Tiffert et al., 2007) were used as growth media.  
 
Construction of pTE86  
 A 1 kb DNA fragment, containing the whole coding region of scbA and newly created 
restriction sites for NdeI and EcoRI at its 5’-end and 3’-end, respectively, was amplified from 
the genomic DNA of S. coelicolor M145 by PCR with primers ScbAex1 and ScbAex2 (Table 
2) and was cloned into pGEM-T (Promega) to generate pIJ6153. A NdeI/EcoRI DNA fragment 
of pIJ6153 was cloned into the expression vector pET-26b(+) (Novagen), which attaches the 
His-tag at the C-terminal end of ScbA to give pTE86. pTE86 was introduced into E. coli 
BL21(DE3)pLysS (Novagen; Fig. 1).  
 
Construction of pTE89 and overexpression of MBP-tagged ScbA in E. coli  
The scbA gene was amplified from M145 genomic DNA by PCR with primers 
pTST-scbA-f and pTST-scbA-r to generate a BglII site and a HindIII site at the 5’- and 3’-end, 
respectively, of the scbA coding sequence (945 bp). The resulting PCR product was digested by 
BglII and HindIII and then cloned into BamHI/HindIII digested pTST101 to obtain pTE89 
which encodes a ScbA with a maltose binding protein (MBP) at the N-terminal end. The coding 
sequence of scbA was confirmed by sequencing (MWG). A single colony of E. coli JM101 or 
Tuner/pOFX-JK2 harbouring pTE89 was grown overnight at 37˚C in LB containing ampicillin 
and kanamycin (50 μg/ml). Subsequently, 50 ml of fresh LB with antibiotics was inoculated 
with 0.5 ml of the overnight culture and incubated at 37˚C until OD600 reached 0.6. After 
induction with isopropyl-ß-D-thiogalactoside (IPTG; 0.1 mM) and L-rhamnose (0.2 %), the 
culture was further incubated for 4 h at 30˚C.  
  
Construction of pTE115 and overexpression of the N-terminal His-tagged ScbA in S. 
coelicolor M145 
The NdeI/EcoRI digested fragment of pIJ6153, containing the complete coding sequence 
of scbA (945 bp), was ligated with NdeI/EcoRI digested pIJ4123 (Takano et al., 1995) and then 
transformed into M145. Transformants were selected with kanamycin, and various plasmids 
were isolated and their proper construction confirmed by XhoI, BamHI, NdeI and EcoRI 
digestion (data not shown). The resulting plasmid was named pTE115.  
M145/pTE115 was grown overnight (12 or 24 h) at 30˚C in 50 ml TSB-YEME liquid medium 





μg/ml (or 20 μg/ml) for 8 h (5, 6, 10 or 12 h; data not shown).   
Also, M145/pTE115 was precultured at 30˚C in 50 ml S-medium with kamamycin (50 μg/ml) 
for 65 h. Subsequently, 15 ml of the preculture was inoculated into 150 ml fresh S-medium 
containing kamamycin with or without 10 μg/ml thiostrepton for 24 h, grown for a further 24 h 
(Fig. 3).  
 
Construction of pTE116 and pTE117 and overexpression of the C-terminal His-tagged 
ScbA in Streptomyces lividans TK23 and S. coelicolor M145 
The scbA gene was amplified from M145 genomic DNA by PCR with primers scbAex1 
and scbA-bg (Table 2) to generate NdeI and BglII sites at the 5’- and 3’-end of the scbA coding 
sequence (945 bp), respectively. The resulting PCR fragment was cloned into pGEM-T easy 
vector (Promega) and the resulting insertion was selected by AgeI digestion (which was created 
by the insertion of scbA) and confirmed by sequencing (MWG). The resulting plasmid was 
named pTE116. The NdeI/BglII fragment of pTE116 was subcloned into the NdeI/BamHI 
fragment of pGM202, an E. coli-Streptomyces shuttle expression vector, to generate pTE117 
which encodes a ScbA with a C-terminal His-tag under the control of the tipA promoter. 
pTE117 was transformed into S. lividans TK23 and then into S. coelicolor M145 to obtain 
M145/pTE117. The proper construction of pTE117 was confirmed by PCR with primers seq2 
and seq3 (Table 2).   
M145/pTE117 was grown for two days at 30˚C in 50 ml S-medium with 50 μg/ml 
kamamycin. Subsequently, 30 ml 48 h-old culture was transferred into 300 ml S-medium with 
kanamycin, grown for 6 h, and then induced with thiostrepton at a final concentration of 25 
μg/ml for 18 h. Cells were harvested from cultures and were washed and sonicated in Buffer C 
(20 mM Tris pH8.0, 100 mM KCl, 1 mM dTT and 1% protease inhibitor). The insoluble 
material was removed by centrifugation at 12,000 g for 15 min. The soluble fraction was 
incubated with 1 ml Ni-NTA resins (Sigma, P6611), which had been preequilibrated with buffer 
C, for overnight at 4˚C with shaking. The gel was washed with 3 volume of buffer C containing 
40 mM imidazole. The recombinant protein was eluted with buffer C containing 200 mM 
imidazole and analyzed by 12% SDS-PAGE (Fig. 4) and MALDI-TOF (Matrix assisted laser 
desorption/ionization time-of-flight mass spectrometry). 
 
Construction of pTE118 and pTE119 and overexpression of the N-terminal Strep-tagged 
ScbA in S. lividans TK23 and S. coelicolor M145 
The scbA gene was amplified from M145 genomic DNA by PCR with primers scba-bgl2 
and RCseq59 (Table 2) to generate a BglII site at the 5’-end of the scbA coding sequence. The 





selected by AgeI digestion and confirmed by sequencing (AGOWA). This plasmid was named 
pTE118. The BgIII/EcoRI fragment of pTE118 was subcloned into the BamHI/EcoRI fragment 
of pGM191.1Nfg, an E. coli-Streptomyces shuttle expression vector, to generate pTE119 which 
encoded ScbA with an N-terminal Strep-tag under the control of the tipA promoter. This 
plasmid was confirmed by MluI and NdeI digestion. M145/pTE119 was obtained by 
transforming the pTE119 isolated from S. lividans TK23 which has become non-methylated.  
M145/pTE119 or M145 (as a negative control) was precultured at 30˚C in 50 ml S-medium 
with or without kanamycin (50 μg/ml) for 65 h. Subsequently, 15 ml of the preculture was 
inoculated into 150 ml fresh S-medium containing kanamycin and 10 μg/ml thiostrepton from 
the beginning of the cultivation and grown for 24 h (24 h incubation in total) or in S-medium 
with kanamycin but without thiostrepton for 24 h and then induced with thiostrepton for 
another 24 h (48 h incubation in total) (Fig. 5).  
   
Construction of pTE120-129 and overexpression of the N-terminal His-tagged ScbA and 
mutated ScbA in E. coli   
The whole coding sequence of the scbA gene was amplified from pIJ6147 by PCR with 
primers scbA 80F and scbA 80R (Table 2) to generate EcoRI and KpnI restriction sites at the 
5’-end and a PstI site at the 3’-end of the scbA coding sequence. The resulting PCR fragment 
was cloned into the pGEM-T easy vector and the resulting plasmid was selected by PstI 
digestion and confirmed by sequencing (AGOWA). The resulting plasmid was named pTE120. 
Based on the same concept, a PCR fragment amplified from pTE105, pTE108, pTE104 or 
pTE110 (Hsiao et al., 2007), containing E78AscbA, E240AscbA, EAscbA or R243KscbA, 
respectively, was cloned into the pGEM-T easy vector to obtain pTE121, pTE122, pTE123 or 
pTE124. Their proper construction was confirmed by sequencing (AGOWA), respectively. A 
KpnI/PstI DNA fragment of pTE120, pTE121, pTE122, pTE123 or pTE124 was subcloned into 
an E. coli expression vector pQE80 (Qiagen) containing six histidine residues contiguous to the 
5’-end of the multiple cloning sites to generate pTE125, pTE126, pTE127, pTE128 or pTE129, 
respectively. These plasmids were transformed into several E. coli hosts, BL21(DE3) 
(Novagen), Tuner (BL21 ΔlacYZ, Novagen), Tuner/POFX-JK2 (Castanie et al., 1997) and C41 
(Miroux and Walker, 1996). A single colony of E. coli host harboring an expression plasmid 
was grown overnight at 37˚C in LB containing ampicillin (50 μg/ml). Subsequently, 50 ml of 
fresh LB with ampicillin was inoculated with 0.5 ml of the overnight culture and incubated at 
37˚C until OD600 reached 0.6. After induction with IPTG (0.1 or 0.05 mM), the culture was 







Overexpression and purification of recombinant His-ScbA protein, and preparation of 
ScbA polyclonal antiserum from rabbit 
A single colony of BL21(DE3)pLysS/pTE86 was grown overnight and inoculated in 2.5 L 
of LB containing kanamycin (50 μg/ml) and chloramphenicol (25 µg/ml), followed by 
incubation at 37˚C. When the OD600 had reached 0.5, 1 mM IPTG was added and the culture 
was incubated for another 2 h at 27˚C. Then, the cells were collected, washed in ice-cold PBS 
buffer (Sambrook et al., 1989), and disrupted by French press. Inclusion bodies were recovered 
from bacterial lysates by centrifugation (4°C, 2675 g, 30 min) and washed with cold PBS 
containing 2 % Triton X-100. The pellet corresponding to the inclusion body fraction was 
obtained by centrifugation and washed three times with PBS to remove Triton X-100. Protein 
in the obtained pellet was solubilized and purified in Buffer D (20 mM Tris pH 8.0, 100 mM 
KCl, 1 mM DTT, 6 M guanidinium chloride (GdCl) and 1% protease inhibitor) on a 30 ml 
Ni-NTA resin column using an imidazole gradient on a Pharmacia FPLC system. To refold 
His-ScbA, pure protein fractions were dialyzed against refolding buffer [20 mM Tris pH 8, 1 
mM EDTA, 1 mM DTT and 100 mM KCl] overnight using Spectrapor3 tubing with 6-8 kDa 
cutoff. Misfolded and aggregated proteins were removed by centrifugation. The soluble protein 
fraction corresponding to the refolded His-ScbA was used to raise polyclonal antibodies in 
rabbit.  
 
Overexpression and purification of recombinant His-ScbA protein, and preparation of  
ScbA polyclonal antiserum from chicken 
A single colony of E. coli BL21(DE3)/pTE86 was grown overnight at 37°C in LB 
containing kanamycin (50 µg/ml). Subsequently, 1 L of LB with antibiotics was inoculated with 
35 ml of the overnight culture and incubated at 27°C until OD600 reached 0.8. Then, 1 mM 
IPTG was added and the culture was incubated for another 3 h at 27˚C. The cells were washed 
with and sonicated in buffer A [20 mM Tris pH 8.0, 200 mM NaCl] and centrifuged at 14,000 g 
for 40 min. The recombinant His-ScbA protein was in inclusion bodies, therefore the obtained 
pellet was dissolved in buffer B [20 mM Tris pH 8.0, 6 M Urea pH 8.0]. For purification of 
His-ScbA, the dissolved pellet fraction was applied to a Ni-NTA resin column, which had been 
pre-equilibrated with buffer B. After the overnight binding reaction, unbound protein was 
removed by washing three times with the same buffer containing 40 mM imidazole. His-ScbA 
protein was eluted from the column with 250 mM imidazole buffer. Recombinant His-ScbA 
protein was analyzed by SDS-PAGE, and extracted from these gels for MALDI-TOF analysis 







SDS-PAGE and Western blot analysis 
Cells were harvested by centrifugation, washed and sonicated in Buffer C (see above). The 
cell lysates were analyzed by SDS-PAGE and Western blot analysis. SDS-PAGE was done in 
12% gels as described by Laemmli (1970). The prestained protein ladder markers of Fermentas 
(SM0671) were used. After separation, proteins were stained with Coomassie Blue G250 or 
blotted on to a polyvinylidene difluoride (PVDF) membrane using a wet blotter (BioRad) 
(overnight, 10V). PVDF membranes were treated with diluted anti-His antibodies (1:3000, 
Santa Cruz Biotechnology), anti-Strep antibodies (1:3000, IBA), and anti-ScbA antibodies 
raised in chicken (1: 12,000) as described previously (Tiffert et al., 2007). 
 
MALDI-TOF analysis 
MALDI-TOF was used to determine the tryptic peptide mass fingerprint of overexpressed 
proteins which were isolated from SDS-PAGE. Gel pieces were transferred to 1.5 ml 
Eppendorf tubes. The Coomassie Blue strain was removed by washing the gel pieces with 25 
mM ammonium bicarbonate and acetonitrile. Gel pieces were completely dried and then the 
proteins in the gel pieces were reduced with 10 mM DTT in 0.1 M ammonium bicarbonate for 
30 min at 56 ˚C. Excess liquid was removed and proteins were further alkylated by 55 mM 
iodoacetamide (IAA) in 0.1 M ammonium bicarbonate for 30 min at RT in the dark. Excess 
liquid was removed and gel pieces were washed with 25 mM ammonium bicarbonate and 
acetonitrile. For tryptic digestion, 10 ng/µl cold bovine trypsin (Promega) was added and the 
tubes were kept at 37 ˚C overnight. The digested peptides were eluted in 50:50 acetonitrile/ 
0.1% formic acid (in water). Subsequently, 1 μl of the extract was mixed with 1 μl of a matrix 
(20 mg/ml α-cyano-4-hydroxycinnamic acid in 50% acetonitrile), transferred onto a stainless 
steel sample holder, and dried before being introduced into the mass spectrometer. Mass spectra 
were obtained by averaging the signals from 100 laser shots, and by using a Voyager DE Pro 
instrument (Applied Biosystems, Famingham). 
 
Results and Discussion 
Overexpression of the His-tagged ScbA and the MBP-tagged ScbA in E. coli 
To study the ScbA protein in more detail, and to analyze its enzymatic function (e.g. in 
substrate binding experiments), an attempt was made to purify active ScbA protein from E. 
coli.   
The E. coli construct with the scbA coding sequence cloned into pET-26b(+) and fused to 
a C-terminal His-tag (pTE86) failed to express soluble recombinant His-ScbA proteins (34 kDa; 
Fig. 1). Although it was possible to purify the insoluble ScbA protein and to refold it (Fig. 1, 





rabbit showed the same signals observed in the crude extract from the scbA deletion mutant as 
wild type, suggesting that this antibody was not specific to ScbA (data not shown). Therefore, 
this antibody was not used in subsequent experiments. 
In an attempt to produce soluble protein, ScbA (33.7 kDa) was fused with a maltose 
binding protein (MBP; 42 kDa) (pTE89) and expressed in E. coli JM101. This resulted in 
successful expression of the MBP-ScbA protein (75.7 kDa) which was purified as a soluble 
protein. A faint band with a protein of a smaller size and unknown identity was visible as well 
(Fig. 2). Upon removal of MBP by Factor Xa, multiple faint bands around 31 kDa were 
detected, instead of one intense band at ~34 kDa (ScbA), suggesting that ScbA had been 
degraded (Fig. 2). One possible explanation is that ScbA was misfolded already when purified 
as a MBP-ScbA fusion protein.  
As the MBP-bound ScbA was soluble, this fusion protein could be used in further 
experiments. However, considering that MBP is 42 kDa, which is even larger than ScbA itself 
(33.7 kDa), MBP may influence the activity and overall properties of ScbA. Therefore, ScbA 
was overexpressed in Streptomyces expecting that expression in the original host supported 
proper folding of the protein, and to avoid precipitation.  
 
Overexpression of the His-tagged ScbA in S. coelicolor and S. lividans  
The scbA gene was amplified by PCR and cloned into the high-copy expression vector 
pIJ4123 (Takano et al., 1995) under control of the thiostrepton-inducible tipA promoter (PtipA) 
to generate pTE115. The recombinant ScbA protein was expressed with an N-terminal His-tag 
which can be purified by Ni(2+)-affinity chromatography and removed by digestion with 
thrombin, if necessary. The S. coelicolor M145/pTE115 was grown overnight in TSB-YEME 
liquid medium with kanamycin under noninduced conditions, and then induced by thiostrepton 
(5 μg/ml). SDS-PAGE analysis of the crude cell lysates failed to reveal the induced His-ScbA 
fusion protein around 34 kDa (data not shown). Different culture conditions were tested: a 
higher amount of thiostrepton (20 μg/ml), different induction initiation time points (after 12 or 
24 h preculture) and different induction period lengths (incubation for 5, 6, 10 or 12 h after 
induction), but none was successful (data not shown). To obtain expression of ScbA, S. 
coelicolor M145 harbouring pTE115 was preincubated in S-medium with kanamycin for 65 h 
and then induced by thiostrepton (10 μg/ml) for 24 h at the time of inoculation, or after an 
additional 24 h of incubation. Again, SDS-PAGE analysis of the soluble and insoluble fractions 
did not show any induced His-ScbA protein (data not shown). Therefore, Western blot analysis 
using an anti-His antibody was performed. Bands were visible only in the insoluble fraction, 








Figure 1. SDS-PAGE analysis of crude cell lysates of E. coli BL21(DE3)pLysS/pTE86. The His-ScbA protein was 
purified from BL21(DE3)pLysS/pTE86 cell lysates and analyzed by 12 % SDS-PAGE. The abbreviations denote: 
WC: whole cell extract (400 μg of protein per lane); S: soluble fraction (200 μg of protein per lane); P: insoluble 
fraction; RF: the refolded recombinant His-ScbA protein (5 μg of protein per lane). M: prestained protein ladder. 
The molecular weights of the marker proteins are indicated on the left of the ladder. The arrow indicates the 
purified and refolded recombinant His-ScbA (34 kDa) protein. 
 
 
Figure 2. SDS-PAGE analysis of the purified MBP-ScbA protein. The MBP-ScbA protein was purified from 
BL21(DE3)/pTE89 cell lysates and digested by Factor Xa which removed the MBP tag from ScbA. Samples (10 
μg of protein per lane) were analyzed by 12% SDS-PAGE. The abbreviations denote: M: prestained protein ladder, 
Lane 1: Purified MBP-ScbA protein; Lane 2: MBP-ScbA protein after digestion by Factor Xa. The MBP-ScbA 
(75.7 kDa) and MBP (42 kDa) proteins are indicated by arrows. Several proteins which may correspond to ScbA 
(33.7 kDa) or degraded ScbA are also indicated. A faint band of an unknown protein in the MBP-ScbA fraction is 








Figure 3. Western blot analysis of crude cell lysates of S. coelicolor M145/pTE115. The cell lysates (200 μg of 
protein per lane) prepared from M145/pTE115 were resolved in 12% SDS-PAGE and analyzed with anti-His 
antibodies. The abbreviations denote: S: soluble fraction; P: insoluble fraction; ‡: induced with thiostrepton for 24 
h at the time of inoculation; +: induced at 24 h after inoculation; -: without induction. The arrow indicates an 
approximately 34 kDa protein band which corresponds to the size of ScbA. 
 
The insoluble His-ScbA protein in M145/pTE115 may result from the location of the tag 
(N-terminal end). Therefore, the scbA was cloned into an E. coli-Streptomyces shuttle 
expression vector, pGM202, to obtain pTE117, with the His-tag at the C-terminal end of ScbA, 
also under the control of the tipA promoter (see Materials and Methods). Due to the fact that S. 
coelicolor, but not S. lividans, carries a methyl-sensing restriction system, it was necessary to 
pass pTE117 through the non-methylating E. coli ET12567 strain. Unfortunately, the selection 
marker of pTE117 and ET12567 both were kanamycin resistancy and therefore the plasmid 
could not be selected in E. coli ET12567. Plasmid pTE117 was first transferred into S. lividans 
TK23 and the non-methylated pTE117 isolated from TK23 was then transferred into M145 to 
obtain M145/pTE117. M145/pTE117 was grown in S-medium containing kanamycin and 
induced by thiostrepton (25 μg/ml; see materials and methods) and Western blot analysis using 
the anti-His antibody revealed that at least one protein with the expected size of ScbA (~34 kDa) 
was induced in the soluble fraction (data not shown). 
The thiostrepton induced soluble protein from M145/pTE117 with the expected size of 
ScbA was purified by Ni-NTA resin chromatography and analyzed by SDS-PAGE. This 
showed that at least four proteins around 34 kDa, the expected size for His-ScbA, had been 
purified (Fig. 4A). Two proteins, most likely to be the same upper two proteins as observed in 
the SDS-PAGE (Fig. 4A and 4B), were also detected by the Western blot analysis using the 





further identify these proteins, the four protein bands were extracted from the gel and analyzed 
by MALDI-TOF. The results showed that those proteins were not ScbA but hypothetical 
proteins encoded by SCO6549, SCO1858, SCO2771 and SCO0200, respectively (Fig. 4C). 
These proteins may have been purified because SCO6549 and SCO1858 possess highly 
His-rich regions in the N- and C-terminus, respectively, while SCO0200 has a number of His 
residues at the C-terminus. SCO2771 does not have any His-rich region. Also S. lividans 
TK23/pTE117 extracts were subjected to Ni-NTA chromatography and two His-rich 
hypothetical proteins identified as homologues of SCO6549 and SCO1858 in S. coelicolor, 
were also purified and identified by MALDI-TOF analysis (Fig. 4D). Although the annotation 
of these isolated proteins does not indicate a direct link to thiostrepton (StrepDB: the S. 
coelicolor annotation server), these proteins appeared to be induced by thiostrepton, which is 
known to induce proteins of unknown function in Streptomyces (Ali et al., 2002). In summary, 
His-ScbA protein was not detected in these Streptomyces strains with the various constructs in 
SDS-PAGE analysis nor in Western analysis using His antibodies.  
 
Overexpression of the N-terminal Strep-tagged ScbA by pTE119 in S. coelicolor M145  
To avoid these thiostrepton-induced His-rich proteins with a similar size to ScbA which 
gave false-positive signals, the scbA was fused with an N-terminal Strep-tag under control of 
the tipA promoter in an E. coli-Streptomyces shuttle expression vector, pGM191.1Nfg, to 
generate pTE119. Because pTE119 also carried a kanamycin selection marker, M145/pTE119 
was obtained via the same procedure as M145/pTE117, namely via S. lividans. M145/pTE119 
or M145 was grown for 65 h in S-medium with or without kanamycin. These precultures were 
inoculated into fresh S-medium with thiostrepton (25 μg/ml) for 24 h or incubated in uninduced 
conditions for 24 h and then induced with thiostrepton and grown for another 24 h. Multiple 
proteins were recognized by Western blot analysis using anti-Strep antibodies and proteins 
around 34 kDa, the expected size for Strep-ScbA, were visible in fractions from both induced 
and uninduced cells of M145 and M145/pTE119 (Fig. 5) implying that many biotinylated 
proteins possessing the same sequence as Strep-tag were produced by Streptomyces. With the 
overexpression construct, there was no extra band that was induced compared to the uninduced 
cultures; no overexpression of the Strep-ScbA thus was observed using this expression plasmid. 
When attempting to overexpress ScbA in Streptomyces, growth was reduced when the 
cells were induced. Therefore, growth of S. coelicolor harboring the overexpression plasmid 
pTE119 was assessed. M145/pTE119 cultures grown for 65 h in S-medium without kanamycin 
reached a wet weight of 0.74 g while cultures with kanamycin had a wet weight of 0.35 g. 
When selecting for the plasmid, the cultures lost their mass by 2.1-fold compared to that 





Figure 4. SDS-PAGE, Western blot and MALDI-TOF analysis of crude cell free lysates of S. coelicolor 
M145/pTE117 and S. lividans TK23/pTE117. The soluble protein fraction prepared from S. coelicolor 
M145/pTE117 was applied to a Ni-NTA resin column. Elution fractions were resolved in 12% SDS-PAGE (A) and 
analyzed with anti-His antibodies (B). The abbreviations denote: CE: the cell free extract (200 μg of protein per 
lane); AF: the fraction after binding to Ni-NTA resins (200 μg of protein per lane); W1 and W4: the first and the 
final wash fractions (50 μg of protein per lane); E1, E2 and E3: the elution fractions (~5 μg of protein per lane). M: 
prestained protein ladder. The molecular weights of the marker proteins are indicated on the left of the ladder. The 
samples isolated for MALDI-TOF analysis are indicated by the arrows and number. Protein bands No.1 and 2 
correspond to the proteins detected by the anti-His antibodies in (B). (C) MALDI-TOF analysis of the purified 
proteins. Four protein samples (indicated in A) were digested by trypsin and analyzed by MALDI-TOF. The genes 
dentified from the analysis are indicated above the corresponding amino acid sequence, which is shown in black 
and the identified peptides are indicated in bold and by underline. (D) SDS-PAGE analysis of the soluble protein 
fraction of S. lividans TK23/pTE117. The soluble protein fractions of S. lividans TK23/pTE117 were used for 
protein purification by Ni-NTA column chromatography. Samples obtained were loaded onto a 12% SDS-PAGE. 
The abbreviations denote: M: prestained protein ladder, Lane 1: the purified fraction made from TK23/pTE117 (10 







growing cells, suggesting that M145 preferred to grow without pTE119. The tipA promoter can 
be expressed to a basal level without thiostrepton induction (Murakami et al., 1989) causing 
expression of ScbA without induction in pTE119. This may cause reduced growth which 
indirectly suggests that expression of the ScbA protein maybe somewhat toxic to the cells. 
Whether this toxicity is connected to the function of ScbA in Streptomyces will need further 
study.   
 
Overexpression of N-terminal His-tagged ScbA protein using the expression vector pQE80 
in E. coli  
During this work, Kato and coworkers successfully expressed the ScbA homologue, AfsA 
from S. griseus, in E. coli using the expression vector pQE80, providing polylinkers at both the 






Figure 5. Western blot analysis of crude cell lysates of S. coelicolor M145/pTE119. The soluble fraction (A) and 
insoluble fraction (B) (~200 μg of protein per lane) prepared from S. coelicolor M145 and M145/pTE119 (above 
the pictures) were resolved in 12% SDS-PAGE and analyzed with anti-Strep antibodies. The abbreviations denote: 
M: prestained protein ladder; ‡: induced with thiostrepton for 24 h at the time of inoculation; +: induced at 24 h 
after inoculation; -: without induction. The proteins around 34 kDa are indicated. 
 
Therefore, pQE80 was employed to express the native scbA gene and four active-site scbA 
point mutants which had lost the ability to synthesize SCBs (Hsiao et al., 2007). The coding 
sequences of these scbA genes were cloned into pQE80 to generate pTE125, pTE126, pTE127, 
pTE128 or pTE129 (see Materials and Methods) and these constructs encoded the native 
H-ScbA or mutated H-ScbA (37.18 kDa; “H” stands for His-tag) with 12 amino acids and 6 
histidine residues at the N-terminal end and 7 amino acids at the C-terminal end: 
Met-Arg-Gly-Ser-His(6)-Gly-Ser-Ala-Cys-Glu-Leu-Gly-Thr- {ScbA or mutated ScbA} 
-Leu-Gln-Pro-Ser-Leu-Ile-Ser. E. coli BL21(DE3) strains harboring the respective 
overexpression plasmids were grown to 0.6 at OD600, then induced by 0.1 mM IPTG and grown 
for 3 h at 27°C. The cell lysates were analyzed by SDS-PAGE and no obvious protein was 
induced in either the soluble or insoluble fractions (data not shown). To optimize expression 
conditions, BL21(DE3) harboring pQE80, pTE125 (with the native scbA gene) or pTE128 
(with the EAscbA gene) was induced with different concentrations of IPTG (0.05 and 0.1 mM) 
at different incubation temperatures (37°C or 18°C, Fig. 6). In these conditions the insoluble 
fractions revealed several induced proteins around 37 and 70 kDa by SDS-PAGE analysis (Fig. 
6A) and no proteins were induced in the soluble fraction (data not shown). Only the protein of 
approximately 37 kDa, the predicted size of H-ScbA, was detected by Western blot analysis 





host strain BL21(DE3) was replaced by E. coli Tuner strain (BL21 ΔlacYZ). This strain enables 
adjustable levels of protein expression. The strain was used with or without additional plasmid 
pOFX-JK2 which carries dnaJ and dnaK (encoding chaperones which facilitate correct protein 
folding) or C41 (tolerant to the expression of toxic recombinant proteins or membrane proteins). 
In cell lysates of these cultures only a few proteins were detectable in the insoluble fractions 
(Fig. 6B) but not in the soluble fractions (data not shown) when using the anti-His antibody for 
Western analysis, suggesting that these hosts did not improve the solubilization of the fusion 
proteins.  
One possibility why ScbA was not detected after induction is that the His-tag was folded 
into a position where the anti-His antibody could not detect it. Therefore, a polyclonal 
anti-ScbA antibody was made from chicken using the urea denatured His-ScbA protein which 
was used previously to generate anti-ScbA antibody using rabbit. The inclusion bodies of the 
His-ScbA protein were isolated from the E. coli BL21(DE3)/pTE86 strain, dissolved in urea 
and purified by Ni-NTA resin column chromatography (see Materials and Methods). In the 
concentrated elution fraction, multiple bands around 34 kDa, the size of the His-ScbA, were 
visible in SDS-PAGE. Three of these bands were isolated and analyzed by MALDI-TOF 
analysis (Fig. 7A). In all three samples the same five peptides were identified, corresponding to 
fragments located in the middle of the ScbA protein sequence, suggesting that all three proteins 
are in fact ScbA (Fig. 7B). This may suggest that ScbA is modified or degraded to produce 
these three proteins in E. coli (Fig. 7A) The three proteins corresponding to the purified 
denatured recombinant His-ScbA (drHis-ScbA), were isolated and used to generate anti-ScbA 
antibodies from chicken (Agrisera) (see Materials and Methods).  
To test the sensitivity of the new anti-ScbA antibody, the purified drHis-ScbA protein, 
which was used to raise the antibody, and the cell free lysates of some constructs made in this 
study were used for Western blot analysis (Fig. 8). The anti-ScbA antibody recognized three 
proteins in the purified drHis-ScbA protein which was previously proven by MALDI-TOF 
analysis (Fig. 7 and 8). ScbA expressed in Streptomyces (TK23/pTE117 and M145/pTE119) 
was also analyzed. The Western analysis gave positive signals in the induced fractions and a 
weak signal corresponding to a slightly smaller size was detected in the non-induced fractions. 
Though the signals from the induced Streptomyces fractions show a similar size to that 
observed with drHis-ScbA that was used to raise the antibodies, there is a possibility that these 
proteins are not ScbA. When overexpressing ScbA using pTE117 in Streptomyces, only 
His-rich proteins were induced and purified when using the anti-His antibody and Ni-NTA 
resin chromatography (Fig. 4 A, B, C, D). The antibodies raised against drHis-ScbA also may 
detect any proteins with His-rich motifs. Therefore these signals seen in the Streptomyces 





Figure 6. SDS-PAGE analysis and Western blot analysis of the cell lysates of E. coli BL21(DE3) harboring 
pQE80, pTE125 and pTE128. The insoluble fraction (~200 μg of protein per lane) prepared from E. coli 
BL21(DE3) harboring pQE80, pTE125 and pTE128 (above the pictures) cultures incubated for 3 h at 37°C or 
18°C after induction were resolved in SDS-PAGE (A) and in Western blot (B; using the anti-His antibody). The 
abbreviations denote: M: prestained protein ladder; 0.1 or 0.05: amount of IPTG (mM); -: without induction. The 
proteins around 34 kDa are indicated. The induced proteins at 37 kDa (which correspond to His-ScbA) and 70 kDa 
are represented by arrows. 
 
whether these signals in the cell free lysates of Streptomyces TK23/pTE117 (His-ScbA) and 
Streptomyces M145/pTE119 (Strep-ScbA) correspond to ScbA, these proteins will be further 
tested by MALDI-TOF analysis. 
Protein bands in the induced soluble fractions of E. coli BL21(DE3)/pTE86 (300 μg), 
BL21(DE3)/pTE128 (300 μg) and C41/pTE125 (300 μg) were detected using the drHis-ScbA 
antibodies. A very faint band was also observed in the E. coli lysate with only the vector 
introduced [BL21(DE3)/pQE80] but only when using three-fold more (1 mg) protein compared 
to the other E. coli soluble fractions. Because E. coli does not encode a single protein with a 
significant similarity to ScbA (NCBI Blast result), this weak signal cannot be a homologue of 
ScbA. Alternatively, it may be a His-rich protein produced by the E. coli host which also was 
recognized by the drHis-ScbA antibodies. This suggests that those strong signals seen in the 
other E. coli soluble fractions may indeed be induced ScbA proteins. MALDI-TOF analysis of 
these protein bands will be used to further test this.  
Based on the above results, the following procedure will be adapted to overexpress and 
purify soluble native ScbA and point mutant ScbA proteins. BL21(DE3) with the pQE80 vector 
will be used as an expression host, with low IPTG concentrations (0.1 or 0.05 mM) for 








Figure 7. SDS-PAGE and MALDI-TOF analysis of cell free lysates of E. coli BL21(DE3)/pTE86. (A) The urea 
denatured fraction prepared from BL21(DE3)/pTE86 was applied to a Ni-NTA resin column. Elution fractions 
were analyzed by 12% SDS-PAGE. The abbreviations denote: AF: the fraction after binding to Ni-NTA resins (20 
μg of protein per lane); W1 and W4: the first and the final wash fractions using buffer B (~20 μg of protein per 
lane); W2-1 and W2-3: the first and the final wash fractions obtained by using buffer B containing 40 mM 
imidazole (~20 μg of protein per lane); E1 to E5: the elution fractions (5-20 μg of protein per lane); CS: 
concentrated elution fraction (10 μg of protein per lane). M: prestained protein ladder. The samples around 34 kDa 
(the size of the His-ScbA) isolated for MALDI-TOF analysis are indicated by arrows and numbers. (B) 
MALDI-TOF analysis of the overexpressed recombinant His-ScbA protein. The coding sequence of ScbA is 







Figure 8. Western blot analysis of the cell lysates prepared from cultures with the vector constructs made in this 
study. The soluble fractions prepared from TK23/pTE117 (400 μg of protein), M145/pTE119 (400 μg of protein), 
BL21(DE3)/pTE86, pTE128 (300 μg of protein) and pQE80 (1 mg of protein) and C41/pTE125 (300 μg of protein) 
were analyzed by Western blot analysis using the anti-ScbA antibody generated from chicken. The abbreviations 
denote: +: with thiostrepton induction; -: without induction. The drHis-ScbA was used as a positive control. Strain 
names are indicated above the pictures. The arrows indicate drHis-ScbA corresponding to Fig. 7A. The faint bands 
in the non-induced fractions and the vector only fraction are indicated by stars. The bands that may represent 
degraded recombinant ScbA proteins are indicated by a question mark. 
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Table1. Strains and plasmids used in this study                                    
Strains or plasmid    Description                 Source or reference       
S. coelicolor A3(2) strains 
M145 Wild-type (genome sequenced) Kieser et al., 2000 
M751 In-frame deletion of scbA in M145 Takano et al., 2001 
 
S. lividans strains 
1326 Wild-type Kieser et al., 2000 
TK23 S. lividans 66 derivative (spc-1)(Spcr) Kieser et al., 2000 
 
E. coli strains 
JM101 General-purpose cloning strain Sambrook et al., 1989 
ET12567 Strain used for conjugation between E.coli MacNeil et al., 1992 
 and Streptomyces 
BL21(DE3) F-, ompT, hsdSB(rB-mB-), (λ+),  Novagene 
 T7 RNA polymerase gene on chromosome, 
Tuner F-, ompT, hsdSB(rB-mB-), gal, dcm, lacY1  Novagen 
C41 BL21 derivative Miroux et al., 1996 
 
Plasmids 
pGEM-T cloning vector Promega 
pGEM-T Easy cloning vector Promega 
pUZ8002 Non transmissible transfer plasmid Flett et al., 1997 
pET-26 (+) Expression vector Novagen 
pQE80 cis-repressed, IPTG-inducible, N-terminal  Qiagen 
 His6-tagged recombinant protein expression 
 vector; Ampr  
pOFX-JK2 dnaK-danJ cloned into pET17Xb Castanie et al., 1997 
pGM191.Nfg Streptomyces–E. coli shuttle vector, tsr aphII, G. Muth (unpublished) 
 PtipA promoter, N-terminal Strep tag 
pGM202 Streptomyces–E. coli shuttle vector, tsr aphII, G. Muth (unpublished) 
 PtipA promoter, C-terminal His-tag 
pTST101 expression vector malE-eGFP, rrnB, Ampr  Altenbuchner et al. 2000 
pIJ4123 Streptomyces His-tag expression vector; Takano et al., 1995 
 tsr kan PtipA redD 
pIJ6147 scbA cloned into pSET152  Takano et al., 2001 
pIJ6153 1 kb scbA PCR product cloned into pGEM-T Easy This study 






pTE89 BamHI/HindIII digested scbA PCR product cloned This study  
 into pTST101 
pTE104 EcoR I scbA fragment of pTE103 cloned into  Hsiao et al., 2007 
 pSET152  
pTE105 pIJ6143 derivate containing G78A mutated scbA Hsiao et al., 2007 
pTE108 EcoR I scbA fragment of pTE107 cloned into  Hsiao et al., 2007 
 pSET152  
pTE110 EcoR I DNA fragment of pTE109 subcloned into  Hsiao et al., 2007 
 pSET152 
pTE115 NdeI/EcoRI scbA fragment of pIJ6153 cloned into This study 
 pIJ4123 
pTE116 1 kb scbA PCR product cloned into pGEM-T Easy This study 
pTE117 NdeI/BglII scbA fragment of pTE116 cloned into This study 
 pGM202  
pTE118 1 kb scbA PCR product cloned into pGEM-T Easy  This study 
pTE119 EcoRI/BglII scbA fragment of pTE118 cloned into  This study 
 pGM191.1Nfg  
pTE120 1 kb scbA PCR product cloned into pGEM-T Easy This study 
pTE121 1 kb E78AscbA PCR product cloned into    
 pGEM-T Easy 
pTE122 1 kb E240AscbA PCR product cloned into  This study 
 pGEM-T Easy 
pTE123 1 kb EAscbA PCR product cloned into  This study 
 pGEM-T Easy 
pTE124 1 kb RKscbA PCR product cloned into  This study 
 pGEM-T Easy 
pTE125 KpnI/PstI scbA fragment of pTE120 cloned into  This study 
 pQE80 
pTE126 KpnI/PstI scbA fragment of pTE121 cloned into This study 
 pQE80 
pTE127 KpnI/PstI scbA fragment of pTE122 cloned into  This study 
 pQE80 
pTE128 KpnI/PstI scbA fragment of pTE123 cloned into  This study 
 pQE80 
pTE129 KpnI/PstI scbA fragment of pTE124 cloned into  This study 






Table 2. Primers used in this work                                       









pTST-scbA-r CGAAGCTTCAGCCGGAGAACG   
scbA 80F GGAATTCGGTACCCCCGAAGCAGTAGTTTTGATC& 
scbA 80R AAAACTGCAGGCCGGAGAACGCGGGGCCGGACAG#                    
*  The NdeI site is underlined. 
**  The BglII site is underlined. 
*** The EcoRI site is underlined. 
   The HindIII site is underlined. 
& The EcoRI site is underlined and the KpnI site is shown in bold. 





























Small signalling molecules, γ-butyrolactones, mainly produced by Streptomyces species, 
have an important role in cellular physiology as they regulate the production of valuable 
secondary metabolites (i.e. antibiotics) and, in some cases, morphological development. 
γ-Butyrolactones are produced at nanomolar concentrations, which is sufficient to trigger the 
signal transduction events needed for secondary metabolism (Takano, 2006). Generally, these 
γ-butyrolactones diffuse freely across the cell membrane and through the cell wall and bind to 
their cognate receptor. This blocks the DNA-binding activity of the receptor protein, resulting 
in transcription of a target gene, eventually leading to the production of antibiotics and/or 
morphological development (Takano, 2006). 
 
Streptomyces coelicolor produces multiple signalling molecules 
In the model organism Streptomyces coelicolor, at least three small diffusible factors with 
ability to induce antibiotic production were detected by C18 reverse phase HPLC. The most 
abundant of these factors was isolated and its structure was elucidated as a γ-butyrolactone. 
This factor, possessing a lactone ring and a branched C-2 side chain with eight carbon atoms in 
length, was designated S. coelicolor butanolide 1, SCB1 (Takano et al., 2000). In the work 
reported in this thesis, two other signalling molecules, named SCB2 and SCB3, were isolated 
and characterized. These factors also possessed lactone rings but with a different C-2 side chain, 
a linear side chain with eight carbon atoms for SCB2 and a branched side chain with nine 
carbon atoms for SCB3 (Chapter 2). Each of these three SCBs is able to elicit the production of 
the pigmented antibiotics actinorhodin (Act) and undecylprodigiosin (Red), and to bind ScbR, 
the γ-butyrolactone receptor in S. coelicolor, but with different binding affinities: SCB1 and 
SCB2 show the same binding affinity toward ScbR while SCB3 has a slightly higher binding 
affinity (~2-fold) (Chapter 2).  
Recently, S. coelicolor was also found to produce small diffusible factors with a furan ring, 
named methylenomycin furans (MMF1 to MMF5), which induce methylenomycin production 
and have no effect on Act and Red production (O’Rourke et al., 2008 and Corre et al., 2008). S. 
coelicolor thus has at least two independent signalling systems, both producing multiple 
signalling molecules.   
 
The ligand preference of the γ-butyrolactone receptor, ScbR  
The signalling system in Streptomyces is based on the specificity of the receptor protein 
for its cognate signals (Takano, 2006; see Chapter 2 for details). The chemical structure 
differences among γ-butyrolactones are mainly in the length of the C-2 side chain and the group 
present at the C-1’ position (See Figure 3 in Chapter 1). These features are important for their 





2001), S. virginiae (a virginiae butanolide bioassay experiment; Nihira et al., 1988) and S. 
griseus (a streptomycin induction experiment; Khokhlov, 1980). 
ScbR has γ-butyrolactone binding activity (Takano et al., 2001) with a different binding 
affinity for each SCBs (Chapter 2). ScbR also binds to the promoter regions and represses the 
expression of some of its target genes (See Chapter 1 for details, Takano et al., 2001 and 2005). 
Based on these findings, a γ-butyrolactone detection method which uses ScbR as a sensor and 
one of its targets, the promoter of cpkO, coupled to the promoterless kanamycin resistance gene 
as a reporter was established (See Chapter 2 for details). In the absence of γ-butyrolactones, 
ScbR binds to the cpkO promoter and represses the expression of the kanamycin resistance 
gene. This repression is abolished when the γ-butyrolactones bind to ScbR which leads to 
kanamycin resistance. As this reporter system, the kanamycin bioassay, reflects the binding 
affinity of ScbR to its ligands (the degree of ligand binding is reflected by the kanamycin 
resistancy in a sigmoidal curve), it was used to investigate the ligand preference of ScbR. 
Thirty chemically synthesized γ-butyrolactone analogues with different C-2 side-chain lengths, 
different groups at C-1’ or different branching positions were tested. ScbR had a high affinity 
for a long C-2 side chain (C7-C10), a C-1’-β-hydroxyl group and a C-6’-methyl group (Chapter 
2). The highest binding affinity of ScbR was towards SCB1, SCB2 and SCB3, confirming the 
specificity between the receptor and its cognate signals (Chapter 2). A-factor and VB-D (the 
natural compound produced by S. virginiae) were detected by ScbR at 50- and 250-fold, 
respectively, higher concentration than SCB1. This difference in concentration of cognate and 
non-cognate signal molecules needed to promote activity is much lower than what has been 
published before. Existing γ-butyrolactone detection methods normally detect a non-cognate 
signal at a 103- to 104–fold higher concentration than cognate signals (Miyake et al., 1989, 
Hashimoto et al., 1992 and Nihira et al., 1988). The relatively higher specificity of the 
non-cognate signals measured in our work may be due to the kanamycin bioassay measuring 
the interaction of the receptor with the γ-butyrolactone, whereas other γ-butyrolactone detection 
methods measure the production of antibiotics, the end products of the signalling cascade, and 
thus may suffer from unknown influences. This high sensitivity of the kanamycin bioassay 
together with the advantage of easy manipulation makes this reporter system a powerful 
screening tool for potential signalling molecule producers (Chapter 2).  
This assay however does not provide any insight into how the γ-butyrolactones interact 
with the ScbR protein. The first crystal structure of a γ-butyrolactone receptor protein, CprB 
from S. coelicolor, reveals that the ligand-binding pocket is large enough to accommodate an 
entire γ-butyrolactone molecule (Natsume et al., 2004). Unfortunately, the ligand of CprB has 
not been identified and therefore the crystal structure of CprB with a γ-butyrolactone is not 





amino acid interactions of the γ-butyrolactone in the ligand-binding pocket and might serve to 
elucidate the regulatory mechanism involved.  
 
The role of ScbA in S. coelicolor 
(1)The enzymatic activity of ScbA in SCB biosynthesis 
In streptomycetes, the key proteins required for the synthesis of the γ-butyrolactones 
belong to the AfsA family, e.g. AfsA in S. griseus. AfsA was shown to be the key enzyme to 
synthesize A-factor by an in vitro biosynthetic experiment (Kato et al., 2007). An AfsA 
homologue, ScbA, was identified in S. coelicolor and a scbA deletion mutant failed to produce 
SCBs (Takano et al., 2001), suggesting the involvement of ScbA in SCB synthesis. The 
advanced remote homology detection tool HHpred results (see chapter 3 for details) suggested 
that ScbA has a remote similarity to FabA and FabZ which are fatty acid biosynthesis enzymes 
in Escherichia coli. An important active site amino acid residue, aspartate (Asp) in FabA and 
glutamate (Glu) in FabZ, is also conserved in the AfsA family, residing in the conserved 
duplicated AfsA repeat for ScbA and other AfsA homologues (Chapter 3). Therefore the Glu 
residues at position 78 and 240 in ScbA were mutated separately to create two different 
single-point mutants and together as a double-point mutant. An arginine (Arg) residue, which is 
conserved in the AfsA family and is at position 243 in ScbA, was also mutated. These four 
mutated scbA genes were introduced into the scbA deletion mutant in S. coelicolor, using an 
integrative plasmid. The resulting strains all had lost the ability to produce SCBs, suggesting 
that these mutated residues are essential in ScbA for the synthesis of SCBs. Mutagenesis of 
putative active site residues in ScbA thus strongly suggested that ScbA has enzymatic activity 
and also indicated that the ScbA and FabA/FabZ active sites are similar (Chapter 3). The 
precise catalytic mechanism of ScbA, and the other members of the AfsA family, is still unclear. 
To elucidate whether ScbA catalyzes a similar reaction as FabA/FabZ, the binding ability of the 
active ScbA with FabA/FabZ inhibitors (e.g. 3-decanoyl-N-acetylcysteamine) may be 
informative.  
The biosynthetic pathway for SCBs remains to be elucidated. However, from reports on 
the γ-butyrolactone system in different Streptomyces species, it is possible to speculate about a 
pathway for SCB synthesis. Based on the proposed A-factor biosynthetic pathway (Kato et al., 
2007), the putative SCB precursors, dihydroxyacetone phosphate (DHAP) and a β-keto acid 
derivative, are condensed by ScbA (SCO6266). The product formed is then reduced by ScbC 
(SCO6267), a protein homologous (76% identity in amino acid sequence) to BprA in S. griseus 
which was shown to catalyze this reaction (Kato et al., 2007), and dephosphorylated by an 
unknown phosphatase. This generates an A-factor like compound with a C-1’-keto group, 





sequence) to BarS1 in S. virginiae which was shown to reduce the C-1’-keto group into a 
C-1’-α-hydroxyl group (Shikura et al., 2002), resulting in SCBs (Fig. 1). In bacteria, 
functionally related genes are often found as neighbours. In this case, bprA is flanked by afsA 
in S. griseus and barS1 is located near to barX, the afsA homologue in S. virginiae. The scbB 
and scbC genes are adjacent to scbA and scbR, and therefore can potentially be involved in the 
biosynthesis of SCBs. Recently, we observed that a scbB and a scbC deletion mutant both 
failed to produce SCBs (Takano, unpublished data), thus confirming the involvement of ScbB 
and ScbC in SCB biosynthesis. The enzymatic activity of ScbA has been proven, but further 
studies are necessary to clarify whether ScbB and ScbC have the same functions as their 
homologues in S. virginiae and S. griseus, respectively.  
 
Figure. 1 A proposed SCB1 biosynthetic pathway. The condensation of precursors (e.g. dihydroxyacetone 
phosphate and a β-keto acid derivative) is catalyzed by ScbA, followed by a reduction step catalyzed by ScbC. A 
phosphate group is removed by a phosphatase, resulting in A-factor like compounds. The final reduction step is 
catalyzed by ScbB to yield SCBs. The name and chemical structure of SCBs (SCB1, SCB2 and SCB3) are shown.   
 
The AfsA homologue on SCP1 (S. coelicolor plasmid 1), MmfL, is suggested to have 
enzymatic activity and is involved in MMF biosynthesis (Corre et al., 2008). Corre and 





reactions which result in similar phosphorylated butanolide intermediates, subsequently 
modified by a different set of proteins (ScbB and ScbC for synthesis of SCBs and MmfH and 
MmfP for synthesis of MMFs; with <12% identity in amino acid sequence between ScbB and 
MmfH/MmfP, and between ScbC and MmfH/MmfP) to generate SCBs and MMFs, 
respectively (See Fig 4 in Chapter 1, Corre et al., 2008). They proved the involvement of 
MmfL, MmfH and MmfP in the biosynthesis of MMFs by introduction of these genes into a S. 
coelicolor strain lacking SCP1, resulting in the synthesis of MMFs (Corre et al., 2008 and 
O’Rourke et al., 2008). However, no enzyme reactions by in vitro synthesis were shown. The 
actual roles and the precise functions of these three proteins in the biosynthesis of MMFs 
therefore remain unclear. Expression of MmfL in E. coli caused the host to produce MMFs 
(and not γ-butyrolactones) (Corre et al., 2008). When AfsA was expressed in E. coli, the host 
was able to produce two A-factor analogues (Kato et al., 2007), suggesting that E. coli already 
encodes reductase and phosphatase activities required for γ-butyrolactone synthesis (see above 
for the proposed SCB biosynthetic pathway). If MmfL really synthesizes butenolide 
intermediates equivalent to that of the γ-butyrolactones, the E. coli carrying mmfL should be 
able to produce both MMFs and γ-butyrolactones. However, this was not the case.   
A new hypothesis may be drawn based on the active site similarity between ScbA and 
FabZ (Chapter 3). In the Gram-positive bacterium Enterococcus faecalis, two highly related 
FabZ homologues, FabZ and FabN, were identified (Wang et al., 2004). Although the two 
proteins have the same active site residues (histidine and glutamate) and share 58.7% amino 
acid identity, FabN has both dehydratase and isomerase activity while FabZ only has a 
dehydratase activity (Wang et al., 2004). Replacement of the FabZ β3 and β4 strands, which 
determine the orientation of helix α3 with the active site residue glutamate, with the 
corresponding β-strands from FabN, transformed FabZ to acquire a isomerase/dehydratase 
activity, indicating the importance of the shape of the substrate binding tunnel for enzymatic 
activity (Lu et al., 2005). The two important active site residues, glutamate and arginine, of 
ScbA are also conserved in MmfL (Chapter 3), but the overall amino acid identity between 
these two proteins is relatively low (30%, See Table 1 in Chapter 1). Although both ScbA and 
MmfL have an enzymatic activity, they may catalyze a different reaction due to variations 
generated by their amino acid sequences (i.e. 3D structure), and produce different products: 
compounds with a lactone ring generated by ScbA and compounds with a furan ring generated 
by MmfL. This hypothesis is contrary to the one suggested by Corre and coworkers (2008) and 
will need further experiments to prove this. To date, no crystal structure of ScbA or its 
homologues is available. Based on the crystal structures of FabA and FabZ, it was possible to 
propose a putative 3D structure of ScbA (Chapter 3). However, the real structure of ScbA 





experiments. An attempt to purify active ScbA protein was made (Chapter 5) but further work 
is needed here. Following successful purification of this protein and confirmation of its identity 
by MALDI-TOF analysis, attempts to obtain protein crystals are envisaged. This may result in 
high resolution crystal structures of ScbA, analysis of which may shed light on the differences 
between the ScbA and MmfL substrate binding tunnel structures.    
 
(2)The regulatory function of ScbA in its own transcription, and in antibiotic production 
and development 
ScbA is thought to also have a regulatory function, based on the observation that 
transcription of the scbA gene was barely detected in a scbA deletion mutant where the 
transcriptional start site was not deleted, and scbA transcription was not restored by addition of 
SCB1 (Takano et al., 2001). Strikingly, in all the scbA point mutants tested, transcription of the 
mutated scbA gene was readily detected by RT-PCR (Chapters 3 and 4). This suggests that 
these ScbA active site mutants are not affected in their ability to regulate their own 
transcription; the regulatory and enzymatic functions of ScbA thus are independent of each 
other. The transcription of the scbA gene was abolished in a scbR deletion mutant, indicating 
that ScbR may activate expression of the scbA gene; accordingly, the scbR mutant does not 
produce γ-butyrolactones (Takano et al., 2001). In S. virginiae, BarX, the ScbA homologue, 
was found to stabilize the DNA binding activity of BarA, the ScbR homologue in S. virginiae, 
through protein-protein interactions (Kawachi et al., 2000). Therefore, the interaction between 
ScbA and ScbR was tested by a gel retardation assay using purified ScbR and MBP-tagged 
ScbA proteins. However, no interaction between these two proteins was observed by gel 
retardation experiments (Bunet and Takano, unpublished data). Analysis of the amino acid 
sequence of ScbA also did not reveal any known DNA binding domain/motif. Thus, how ScbA 
and ScbR precisely are involved in the regulation of scbA transcription is still unclear.     
In the active site mutagenesis studies of ScbA, two out of four scbA point mutants elicited 
a precocious production of Act and Red, similar to observations made with a scbA deletion 
mutant (Chapter 4). The glutamate double-point mutant produced less Red in the R2 liquid 
medium while it was comparable to that of wild type in the R2 solid medium. For the arginine 
point mutant, Act and Red production was more than wild type in the R2 liquid medium but 
reduced in the R2 solid medium (Chapter 4). It is not clear why these two mutants have 
different antibiotic production profiles in solid and liquid medium. SCBs are known to regulate 
antibiotic production and ScbA acts as an enzyme in SCB synthesis. If this is the only role that 
ScbA has (as an enzyme), the scbA point mutants, which did not produce SCBs, should all give 
the same antibiotic phenotype. However, this was not the case which further suggests (as 






Other features of the glutamate double-point mutant are its development of aerial 
mycelium and spores on DNAgar and its slow growth on MS medium. These features were not 
observed in the other scbA point mutants, nor in the scbA deletion mutant or in the wild type. 
This suggests that this phenotype was not influenced by SCBs (Chapter 4). Glucose and sodium 
nitrate were found to be important for the formation of aerial mycelium in all the strains apart 
from the glutamate double-point mutant on DNAgar. How the glutamate double-point mutant 
managed to sporulate without addition of these two factors remains to be investigated. This 
phenotype suggests that ScbA has an unknown function in regulation of morphological 
development (Chapter 4). A few γ-butyrolactones previously were found to regulate 
morphological differentiation (for example A-factor), but none of the members of the AfsA 
family was found to have a direct involvement in development (Takano, 2006).  
In this work, the enzymatic function of ScbA has been proven clearly. In addition, 
evidence was obtained for a regulatory function of ScbA in its own transcription, and in 
antibiotic production and morphological development. Furthermore, overexpression of ScbA in 
Streptomyces resulted in slow growth of the host strain, suggesting that the precocious ScbA is 
somehow toxic to its native producer; this toxicity may connect to the various functions of 
ScbA (Chapter 5). Further detailed investigation of these potential regulatory functions or 
enzymatic activities of ScbA is needed in order to reveal the actual roles of ScbA in the 





















Nederlandse samenvatting en algemene discussie 
  
γ-Butyrolactonen zijn kleine signaal moleculen die voornamelijk geproduceerd worden 
door Streptomyces soorten. Zij hebben een belangrijke fysiologische rol omdat ze de productie 
van waardevolle secundaire metabolieten (bv. antibiotica) reguleren en in sommige gevallen de 
morfologische ontwikkeling. γ-Butyrolactonen worden geproduceerd in nanomolaire 
concentraties, voldoende om de signaaltransductie gebeurtenissen op gang te brengen die nodig 
zijn voor het secundair metabolisme (Takano, 2006). Doorgaans diffunderen deze 
γ-butyrolactonen vrijelijk over de celmembraan en door de celwand en binden aan hun 
bijbehorende receptor. Dit blokkeert de DNA-bindende activiteit van het receptoreiwit, hetgeen 
resulteert in de transcriptie van een target-gen en uiteindelijk in de productie van antibiotica 
en/of morfologische ontwikkeling (Takano, 2006). 
 
Streptomyces coelicolor produceert meerdere signaalmoleculen 
In het modelorganisme Streptomyces coelicolor werden met behulp van HPLC technieken 
ten minste drie kleine diffundeerbare factoren gedetecteerd met het vermogen 
antibioticaproductie te induceren. De meest overvloedige van deze factoren werd geïsoleerd 
waarna de structuur werd gekarakteriseerd als zijnde een γ-butyrolacton. Deze factor, die een 
lactonring bezit en een vertakte C-2 zijketen met acht koolstofatomen, wordt aangeduid als 
S. coelicolor butanolide 1, SCB1 (Takano et al., 2000). In het onderzoek beschreven in dit 
proefschrift zijn twee andere signaalmoleculen, genaamd SCB2 en SCB3, geïsoleerd en 
gekarakteriseerd. Deze factoren bezitten ook een lactonring, maar met een andere C-2 zijketen; 
een lineaire zijketen met acht koolstofatomen voor SCB2 en een vertakte zijketen met negen 
koolstofatomen voor SCB3 (hoofdstuk 2). Elk van deze drie SCBs kan de productie van de 
gepigmenteerde antibiotica actinorhodine (Act) en undecylprodigiosin (Red) induceren. 
Daarnaast zijn ze in staat om ScbR te binden, de γ-butyrolacton receptor in S. coelicolor, maar 
met een verschillende bindingsaffiniteit: SCB1 en SCB2 hebben dezelfde bindingsaffiniteit 
voor ScbR, terwijl SCB3 een ongeveer tweemaal hogere bindingsaffiniteit heeft (Hoofdstuk 2). 
Onlangs bleek S. coelicolor ook kleine diffundeerbare factoren met een furan ring te 
produceren, genaamd methylenomycin furanen (MMF1 tot MMF5), die tot de productie van 
methylenomycin leiden en die geen effect hebben op Act en Red productie (O'Rourke et al., 
2008 en Corre et al., 2008). Op deze manier heeft S. coelicolor ten minste twee onafhankelijke 
signaleringssystemen die beide meerdere signaalmoleculen produceren. 
 
De ligandvoorkeur van de γ-butyrolacton receptor, ScbR 





van het receptoreiwit voor het signaalmolecuul. De chemische structuurverschillen in 
γ-butyrolactonen bestaan voornamelijk uit de lengte van de C-2 zijketen en de groep die 
aanwezig is op de C’-1 positie van deze zijketen (zie figuur 3 in hoofdstuk 1). Deze verschillen 
zijn belangrijk voor hun bindingsaffiniteit zoals aangetoond is in S. coelicolor (door middel van 
een gel retardatie-experiment, Takano et al., 2001), S. virginiae (d.m.v. een virginiae butanolide 
bioassay experiment, Nihira et al., 1988) en S. griseus (d.m.v. een streptomycine inductie 
experiment; Khokhlov, 1980). 
ScbR heeft γ-butyrolacton-bindende activiteit (Takano et al., 2001) met een verschillende 
bindingsaffiniteit voor elk SCB (hoofdstuk 2). ScbR is in staat te binden in het promotorgebied 
van bepaalde targetgenen en onderdrukt zo de genexpressie van deze genen (zie hoofdstuk 1 
voor de details, Takano et al., 2001 en 2005). Gebaseerd op deze bevindingen, werd er een 
γ-butyrolacton detectiemethode ontwikkeld. Hiervoor werd de promoter van het cpkO gen, een 
van de targets van ScbR, gekloneerd voor een kanamycine resistentiegen. In de afwezigheid 
van γ-butyrolactonen zal ScbR binden aan de cpkO promoter om zo de expressie van het 
kanamycine reistentiegen te onderdrukken. Deze repressie kan worden opgeheven wanneer 
γ-butyrolactonen binden aan ScbR, wat zal leiden tot kanamycine resistentie. Op deze manier 
kan ScbR gebruikt worden als een sensor om de ligandvoorkeur van ScbR te onderzoeken, 
omdat de mate van ligandbinding zich direct vertaalt in verschillen in kanamycine resistentie. 
Dertig chemisch gesynthetiseerde γ-butyrolacton analogen met verschillende C-2 
zijketenlengtes, verschillende groepen op de C-1’ positie, of verschillende vertakkingsposities 
werden getest. ScbR had een hoge affiniteit voor liganden met een lange C-2 zijketen (C7-C10), 
een C-1’-β-hydroxyl groep en een C-6’-methyl groep (hoofdstuk 2). De hoogste 
bindingsaffiniteit van ScbR werd gevonden met SCB1, SCB2 en SCB3, wat het specifieke 
karakter tussen de receptor en zijn bijbehorende signalen bevestigt (hoofdstuk 2). Ook werden 
A-factor (geproduceerd door S. griseus) en VB-D (geproduceerd door S. virginiae) gebonden 
door ScbR bij een respectievelijk 50- en 250-maal hogere concentratie dan die van SCB1. Dit 
verschil in concentratie tussen een verwant signaalmolecuul en het echte signaalmolecuul 
(SCB1), nodig voor stimulering van de activiteit, is veel lager dan wat er al eerder is 
gepubliceerd. Bestaande γ-butyrolacton detectiemethoden detecteren normaliter verwante 
signalen bij een 1.000 tot 10.000–maal hogere concentratie dan die van het echte signaal 
(Miyake et al., 1989, Hashimoto et al., 1992 en Nihira et al., 1988). De hier gevonden hogere 
specificiteit voor verwante signalen kan te wijten zijn aan de kanamycine bioassay die de 
directe interactie meet van de receptor met het γ-butyrolacton, terwijl andere γ-butyrolacton 
detectiemethoden de vorming van antibiotica meten, de eindproducten van de soms complexe 
signalerings cascades, welke onderhevig kunnen zijn aan onbekende invloeden. Deze hoge 





ervoor dat dit reporter systeem een krachtige screeningstool is voor potentiële producenten van 
signaalmoleculen (hoofdstuk 2).   
Deze analyse geeft echter geen inzicht in de vraag hoe de γ-butyrolacton interactie met het 
ScbR eiwit verloopt. De eerste kristalstructuur van een γ-butyrolacton receptor, CprB uit S. 
coelicolor, laat zien dat de ligand-bindende pocket groot genoeg is om een heel γ-butyrolacton 
molecuul te herbergen (Natsume et al., 2004). Helaas is het ligand van CprB niet 
geïdentificeerd waardoor de kristalstructuur van CprB met het γ-butyrolacton niet beschikbaar 
is. Een 3D-kristalstructuur van ScbR met SCB1 zou waardevolle informatie kunnen geven over 
de aminozuur interacties in de γ-butyrolacton bindingspocket en zou kunnen bijdragen tot het 
ophelderen van het betrokken reguleringsmechanisme. 
 
De rol van ScbA in S. coelicolor 
(1) De enzymatische activiteit van ScbA in SCB biosynthese  
De belangrijkste eiwitten die nodig zijn voor de synthese van de γ-butyrolactonen in 
Streptomyceten behoren tot de AfsA familie, zoals AfsA in S. griseus. Uit een in vitro 
biosynthese experiment bleek dat AfsA een sleutelenzym is in de A-factor synthese (Kato et al., 
2007). Een AfsA homoloog, ScbA, werd geïdentificeerd in S. coelicolor en een scbA deletie 
mutant produceerde geen SCBs (Takano et al., 2001), hetgeen wijst op de betrokkenheid van 
ScbA in SCB synthese. Gebruikmakend van het homologie detectieprogramma HHpred (zie 
hoofdstuk 2 voor details) bleek dat ScbA een geringe gelijkenis heeft met FabA en FabZ, 
enzymen die betrokken zijn bij de synthese van vetzuren in Escherichia coli. Een belangrijk 
aminozuur aanwezig in het actieve centrum van FabA/FabZ (een aspartaat (Asp) voor FabA en 
een glutamaat (Glu) voor FabZ), bleek ook geconserveerd te zijn in de AfsA familie, met dit 
verschil dat het AfsA domein waartoe dit residue behoort gedupliceerd is (hoofdstuk 3). 
Daarom werden twee glutamaat residuen op posities 78 en 240 van ScbA zowel apart, als ook 
samen gemuteerd, resulterend in twee mutanten met een enkele puntmutatie, en een mutant met 
een dubbele. Daarnaast werd ook een arginine (Arg) gemuteerd, die geconserveerd is in de 
AfsA familie en zich bevindt op positie 243 in ScbA. Deze vier gemuteerde scbA genen werden 
geïntroduceerd in een scbA deletie mutant van S. coelicolor, met behulp van een integratief 
plasmide. Geen van de resulterende stammen bleek in staat SCBs te produceren, wat erop wijst 
dat deze gemuteerde aminozuren in ScbA essentieel zijn voor de synthese van SCBs. Dit 
mutagenese experiment met residuen uit het beoogde actieve centrum suggereert sterk dat 
ScbA enzymatische activiteit heeft en dat het actieve centrum van ScbA lijkt op dat van FabA 
en FabZ (hoofdstuk 3). Het is nog steeds onduidelijk wat het precieze katalytische mechanisme 
is van ScbA en de andere leden van de AfsA familie. Om op te helderen of ScbA een 





effect van FabA/FabZ remmers (bijv. 3-decanoyl-N-acetylcysteamine) is op de functie van 
ScbA (hoofdstuk 5). 
De biosynthetische route voor SCBs is nog onduidelijk en dient nader te worden 
bestudeerd. Echter, gebaseerd op de gegevens over γ-butyrolacton systemen in verschillende 
Streptomyces soorten, is het mogelijk hierover te speculeren. Op basis van de voorgestelde 
A-factor biosynthese route (Kato et al., 2007), worden de veronderstelde SCB precursors, 
dihydroxyaceton fosfaat (DHAP) en een β-keto zuur afgeleide, gecondenseerd door ScbA 
(SCO6266). Het product dat nu ontstaat wordt vervolgens gereduceerd door ScbC (SCO6267), 
een eiwit homoloog (76% identiteit in aminozuurvolgorde) aan BprA in S. griseus, en 
gedefosforyleerd door een nog onbekende fosfatase. Dit leidt tot de vorming van een soort 
A-factor-achtig molecuul met een C-1'-keto-groep, die wordt gereduceerd door ScbB 
(SCO6264), een eiwit homoloog (32% identiteit in aminozuurvolgorde) aan BarS1 in 
S.virginiae (Shikura et al., 2002), in een C-1’-β-hydroxyl -groep, wat resulteert in SCBs. In 
bacteriën worden functioneel gerelateerde genen vaak aangetroffen in elkaars nabijheid. In dit 
geval wordt bprA geflankeerd door afsA in S. griseus en barS1 ligt in de buurt van barX, de 
AfsA homoloog in S. virginiae. Daarom zijn scbB en scbC, die grenzen aan scbA en scbR, 
mogelijk betrokken bij de biosynthese van SCBs. Recentelijk hebben wij gevonden dat scbB en 
scbC deletie mutanten geen SCBs produceerden (Takano, ongepubliceerde gegevens), wat de 
betrokkenheid van ScbB en ScbC in de biosynthese van SCBs verder bevestigd. Hoewel de 
enzymatische activiteit van ScbA bewezen is, zijn verdere studies nodig om te verduidelijken 
of ScbB en ScbC dezelfde functies hebben als hun homologen in S. virginiae en S. griseus. 
Figure 1. Gepostuleerde route voor de biosynthese 
van SCBs. De condensatie van precursors (bijv. 
dihydroxyacetone fosfaat en een  β-keto zuur 
derivaat) wordt gekatalyseerd door ScbA, gevolgd 
door een reductie stap gekatalyseerd door ScbC. De 
verwijdering van een fosfaat door een fosfatase leidt 
daarna tot de vorming van een A-factor-achtige 
verbinding. De laatste reductie stap wordt 
gekatalyseerd door ScbB, resulterend in de vorming 
van SCBs. De naam en de chemische structuur van 





De AfsA homoloog gelegen op SCP1 (S. coelicolor plasmiede 1), MmfL, zou 
enzymatische activiteit hebben, met een rol in de MMF biosynthese (Corre et al., 2008). Corre 
en collega's hebben gepostuleerd dat ScbA en MmfL dezelfde precursors gebruiken en 
gelijksoortige reacties uitvoeren, resulterend in vergelijkbare gefosforyleerde butenolide 
tussenproducten. Deze worden vervolgens omgezet door verschillende eiwitten (ScbB en ScbC 
voor de synthese van SCBs en MmfH en MmfP voor de synthese van MMFs; met <12% 
identiteit in aminozuur volgorde) om respectievelijk SCBs en MMFs te maken (Zie figuur 4 in 
hoofdstuk 1, Corre et al., 2008). Hun experimenten bewezen de betrokkenheid van MmfL, 
MmfH en MmfP in de biosynthese van MMFs door de introductie van deze genen in een S. 
coelicolor stam waar SCP1 ontbrak, wat resulteerde in de synthese van MMFs (Corre et al., 
2008 en O'Rourke et al., 2008). Er werden echter geen in vitro enzym reacties uitgevoerd. De 
feitelijke rol en de precieze functie van deze drie eiwitten in de biosynthese van MMFs blijft 
daarom onduidelijk. Bovendien zorgde heteroloog geproduceerd MmfL in E. coli ervoor dat 
deze gastheer MMFs ging maken, maar geen γ-butyrolactonen (Corre et al., 2008). Toen AfsA 
werd geproduceerd in E. coli, was de gastheer in staat om twee A-factor analogen te vormen 
(Kato et al., 2007), wat suggereert dat E. coli wel degelijk reductase en fosfatase activiteiten 
bezit die noodzakelijk zijn voor γ-butyrolacton synthese (zie hierboven voor de gepostuleerde 
SCB biosynthese route). Als MmfL werkelijk butenolide tussenproducten synthetiseert, 
vergelijkbaar met die tijdens de vorming van γ-butyrolactonen, dan had een E. coli stam die het 
mmfL gen draagt zowel MMFs als γ-butyrolactonen moeten produceren. Dit was echter niet het 
geval. 
Een nieuwe hypothese kan worden geformuleerd op basis van de gelijkenis tussen de 
actieve centra van ScbA en FabA/FabZ (hoofdstuk 3). In de Gram-positive bacterie 
Enterococcus faecalis zijn twee sterk verwante FabZ homologen, FabZ en FabN, 
geidentificeerd (Wang et al., 2004). Deze twee eiwitten hebben dezelfde actieve centrum 
residuen (histidine en glutamaat) en 58,7% aminozuur identiteit. Opvallend is dat FabN 
dehydratase en isomerase activiteit heeft terwijl FabZ alleen dehydratase activiteit heeft (Wang 
et al., 2004). Vervanging van de FabZ β3 en β4 sheets, die de orientatie bepalen van helix α3 
met het actieve centrum residue glutamaat, door de overeenkomstige β-sheets van FabN, 
transformeerde FabZ in een enzym met isomerase/dehydratase activiteit; de vorm van de 
substraat-bindende tunnel lijkt dus belangrijk te zijn voor deze enzym activiteit (Lu et al., 
2005). De twee belangrijke residuen uit het beoogde actieve centrum van ScbA, een glutamaat 
en een arginine, zijn ook aanwezig in MmfL (hoofdstuk 3), ondanks dat de algehele aminozuur 
identiteit tussen deze twee eiwitten erg laag is (30%, zie tabel 1 in hoofdstuk 1), wat erop wijst 
dat de vorm van de substraat-bindende tunnel kan verschillen. ScbA en MmfL hebben beiden 





de vorm van de substraat-bindende tunnel, resulterend in verschillende producten: moleculen 
met een lactonring in het geval van ScbA, en moleculen met een furan ring in het geval van 
MmfL. Deze hypothese verschilt wezenlijk van die van Corre en collega's (2008) die 
suggereerden dat dezelfde gefosforyleerde butenolide tussenproducten worden gesynthetiseerd. 
Deze nieuwe hypothese zou ook verklaren waarom alleen MMFs worden gemaakt wanneer 
MmfL geproduceerd wordt in E. coli. Tot op heden is er geen kristalstructuur van ScbA of 
homologen hiervan beschikbaar. Gebaseerd op de kristal structuren van FabA en FabZ was het 
mogelijk om een hypothetische 3D structuur van ScbA op te stellen (hoofdstuk 3). Echter, de 
werkelijke structuur van ScbA moet nog worden bepaald, na zuivering van ScbA eiwit en 
verdere kristallisatie experimenten. Er is een poging gedaan om actief ScbA eiwit te zuiveren 
(hoofdstuk 5), maar hier zijn verdere inspanningen voor nodig. Na succesvolle zuivering van 
dit eiwit en bevestiging van zijn identiteit door middel van MALDI-TOF analyse, zal 
geprobeerd worden om eiwitkristallen te krijgen. Dit kan resulteren in een kristalstructuur van 
ScbA, waarvan de analyse licht kan werpen op verschillen in vorm en structuur van de 
substraat-bindende tunnels in ScbA and MmfL. 
 
(2) De regulerende functie van ScbA op zijn eigen transcriptie en op antibioticaproductie 
en ontwikkeling  
ScbA lijkt ook een regulerende functie te hebben, gebaseerd op de observatie dat de 
transcriptie van het scbA gen nauwelijks detecteerbaar is in een scbA deletie mutant waarvan de 
transcriptionele start site nog aanwezig is, en waarin scbA transcriptie ook niet hersteld werd 
door toevoeging van SCB1 (Takano et al., 2001). Opvallend is dat in alle scbA puntmutanten, 
transcriptie van de gemuteerde scbA genen aangetoond is met behulp van RT-PCR 
(hoofdstukken 3 en 4). Dit suggereert dat deze ScbA mutanten niet gestoord zijn in het 
vermogen hun eigen transcriptie te reguleren; de regulerende en enzymatische functies van 
ScbA zijn dus onafhankelijk van elkaar. Transcriptie van het scbA gen was uitgeschakeld in een 
scbR deletie mutant, suggererend dat ScbR de expressie van het scbA gen activeert; 
dienovereenkomstig produceert de scbR deletie mutant geen γ-butyrolactonen (Takano et al., 
2001). In S. virginiae bleek BarX, de ScbA homoloog, de DNA bindende activiteit van BarA, 
de ScbR homoloog te stabiliseren door eiwit-eiwit interacties (Kawachi et al., 2000). De 
interactie tussen ScbA en ScbR werd daarom door ons getest in een gel retardatie experiment 
met gezuiverde ScbR en MBP-ScbA eiwitten. Deze analyses lieten echter geen interactie zien 
tussen deze twee eiwitten (Bunet en Takano, ongepubliceerde gegevens). Verder liet de analyse 
van de aminozuurvolgorde van ScbA geen bekend DNA-bindend domein/motief zien. Het is 






In de studies van de belangrijke residuen in het actieve centrum van ScbA lieten twee van 
de vier scbA puntmutanten een vervroegde productie van Act en Red zien, vergelijkbaar met 
het effect van een scbA deletie mutant (hoofdstuk 4). Echter, de mutant met een dubbele 
puntmutatie produceerde minder Red in vloeibaar R2 medium, terwijl hij vergelijkbaar was met 
de wild-type stam op vast R2 medium. Voor de arginine puntmutant was de Act en Red 
productie hoger dan de wild-type stam in vloeibaar R2 medium, maar juist minder op vast R2 
medium (hoofdstuk 4). Het is niet duidelijk waarom deze twee mutanten verschillende 
antibiotica productieprofielen laten zien in vaste en vloeibare media. SCBs staan bekend om 
het reguleren van antibioticaproductie en ScbA fungeert als een enzym in SCB synthese. De 
ScbA puntmutanten, die geen SCBs produceerden, zouden allemaal hetzelfde antibioticum 
fenotype moeten geven als dit de enige rol is die ScbA heeft (als een enzym). Dit was echter 
niet het geval wat er verder op wijst (zoals aangegeven in de voorgaande paragraaf) dat ScbA 
een regulerende rol kan hebben in de productie van antibiotica. 
Andere kenmerken van de dubbele puntmutant zijn de opvallende ontwikkeling van 
luchtmycelium en sporen op DNagar en zijn trage groei op MS-medium. Deze functies werden 
niet waargenomen in de andere scbA puntmutanten, en ook niet in de scbA deletie mutant en in 
de wild-type stam. Dit suggereert dat dit fenotype niet beïnvloed werd door SCBs (hoofdstuk 5). 
Glucose en sodium natriumnitraat bleken van belang te zijn voor de vorming van 
luchtmycelium op DNagar van alle stammen, uitgezonderd de mutant met de twee puntmutaties. 
Hoe deze mutant erin geslaagd is om zonder toevoeging van deze twee componenten te 
sporuleren, moet nog worden onderzocht. Dit fenotype kan er echter op wijzen dat ScbA een 
onbekende functie heeft in de regulering van morfologische ontwikkeling (hoofdstuk 5). Al 
eerder bleken een paar γ-butyrolactonen morfologische differentiatie te reguleren (bijvoorbeeld 
A-factor), maar tot dusver is geen directe betrokkenheid van leden van de AfsA familie bij dit 
proces gezien (Takano, 2006). 
In dit werk is de enzymatische functie van ScbA duidelijk aangetoond. Daarnaast werd 
bewijs verkregen voor een regulerende functie van ScbA in zijn eigen transcriptie, op productie 
van antibiotica en bij morfologische ontwikkeling. Bovendien resulteerde overexpressie van 
ScbA in Streptomyces in een trage groei van de gastheerstam, wat suggereert dat vroegtijdige 
vorming van ScbA giftig is voor zijn natuurlijke producent; deze toxiciteit kan verbonden zijn 
met de verschillende functies van ScbA (hoofdstuk 5). Verder gedetailleerd onderzoek naar 
deze potentiële regulerende functies, of enzymatische activiteiten, van ScbA is nodig om te 
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Antibiotic production is regulated by numerous signals, including the so-called
bacterial hormones found in antibiotic producing organisms such as Strepto-
myces. These signals, the g-butyrolactones, are produced in very small quantities,
which has hindered their structural elucidation and made it difficult to assess
whether they are being produced. In this chapter, we describe a rapid small-scale
extraction method from either solid or liquid cultures in scales of one plate or
50 ml of medium. Also described is a bioassay to detect the g-butyrolactones
by determining either the production of pigmented antibiotic of Streptomyces
coelicolor or kanamycin resistant growth on addition of the g-butyrolactones.
We also describe some insights into the identification of the g-butyrolactone
receptor and its targets and also the gel retardation conditions with three
differently labeled probes.
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1. Introduction
Most secondary metabolites (including antibiotics) are the products of
complex biosynthetic pathways activated in the stationary phase or during
slow growth, which triggers the transition from primary to secondary
metabolism (Bibb, 2005). This switch is complex and poorly understood,
and involves many signals, including those by small signaling molecules
called g-butyrolactones. These signaling molecules, found mainly in Strep-
tomyces species, are considered to be ‘‘bacterial hormones’’ because they are
important in the regulation of antibiotic production and in some cases
morphological differentiation (Takano, 2006). The first g-butyrolactone,
A-factor, was identified from Streptomyces griseus in 1967 and was isolated as
a compound that could stimulate the production of streptomycin and
sporulation in a mutant defective in these characteristics (Khokhlov et al.,
1967) (Fig. 6.1). Subsequently, the group of Sueharu Horinouchi identified













































Figure 6.1 Chemical structures of the g-butyrolactones. SCB1, 2, and 3 are produced
by S. coelicolor; A-factor is produced by S. griseus;VB-A, B, C. D, and E are produced by
S. virginiae. Figure contributed byChristianHertweckwith permission.
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synthesis of A-factor (Horinouchi et al., 1985) and also the pathway by
which A-factor regulates streptomycin production (Ohnishi et al., 1999).
Other g-butyrolactones and its receptor systems were identified in Strepto-
myces virginae (Yamada, 1999 review), Streptomyces lavendulae FRI-5 (Kitani
et al., 2008), and Streptomyces coelicolor (Takano et al., 2005), the model
organism for Streptomyces genetics.
The number of identified receptor homologues has more than tripled in
recent years with the analysis of antibiotic biosynthetic gene cluster
sequences, suggesting that the g-butyrolactone system may be a widespread
regulatory component in controlling antibiotic production in the genus
Streptomyces and in other actinomycetes (Takano, 2006).
These signaling molecules are produced only in minute concentrations,
making them challenging to purify. However, their activity in nanomolar
concentration is helpful in bioactivity assays, which can be performed with
small quantities of material. In all the systems that have been reported, the
g-butyrolactones have been detected by such bioassays. For example:
A-factor in S. griseus is extracted with chloroform and detected by measur-
ing the induction of streptomycin production on a solid culture of a non-A-
factor producing mutant, S. griseus HHI (Hara and Beppu, 1982); virginiae
butanolides (VBs) in Streptomyces virginiae are extracted with ethyl acetate
from acidified cell-free supernatants of cultures and detected by measuring
the production of virginiamycin in a liquid culture of an S. virginiae mutant
(Nihira et al., 1988); IM-2 in S. lavendulae FRI-5 is extracted in the same
way as VBs and detected by the induction of a blue pigment (Sato et al.,
1989).
To quickly assess whether g-butyrolactones are a regulatory component
in the antibiotics of choice, a large-scale purification or structural elucida-
tion is not the first preference. This chapter describes the rapid small-scale
extraction and detection of g-butyrolactones in S. coelicolor which will aid in
solving this problem. We also aim to aid identification of g-butyrolactone
receptors and their targets.
2. Rapid Small-Scale g-Butyrolactone
Purification
Intracellularly produced g-butyrolactones are believed to diffuse pas-
sively out of the mycelium. In most protocols, liquid culture supernatants
are used for production. However, the amounts of g-butyrolactones
produced in liquid cultures vary with the growth of the mycelium and
extraction can be tedious. Therefore, we have developed a method using
plates of solid agar medium. Here, we describe extraction protocols for both
liquid and solid cultures.
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1. Grow the strain either on plates up to aerial mycelium formation or early
spore formation, or in liquid medium up to early stationary phase.
Note: Both minimal and rich media can be used in both cases; however,
the stability of the g-butyrolactones in rich media is much less than in a
defined medium and they must be extracted at an earlier time.
2. For plates, cut the agar into large pieces and place in a beaker. Add
30–40 ml ethyl acetate to cover the agar pieces, and shake gently.
Transfer the ethyl acetate into a rotary flask.
Note: Avoid breaking the agar into small pieces as this makes it difficult to
separate the agar from the solvent. Also, it is important to test the ethyl
acetate used for extraction beforehand as some ethyl acetate may already
have bioactivity.
3. For liquid cultures, add a 2–3-fold volume of ethyl acetate in a separation
flask. Shake 5–10 times, then separate the ethyl acetate phase from the
water phase and place the ethyl acetate phase in a rotary flask.
Note: If a small amount of second phase separates from the ethyl acetate
sample, remove it before evaporation. Normally, any second phase consists
of fatty acids which cannot be evaporated will affect the diffusion ability of
samples in the bioassay.
4. Evaporate all the ethyl acetate in a rotary evaporator and resuspend in
100% HPLC-grade methanol.
Note: From 3 plates or from 50 ml cultures, resuspend sample in 50 ml
of methanol.
3. Antibiotic Bioassay
The classical approach for the bioassay of g-butyrolactones is the obser-
vation or measurement of induced antibiotic production from an indicator
strain in response to the compound of interest. Based on this concept, the
antibiotic bioassay in S. coelicolor detects early production of the pigmented
antibiotics, blue actinorhodin, and red prodiginines (Takano et al., 2000).
1. Prepare spore stocks of the antibiotic bioassay indicator strain S. coelicolor
M145 (Kieser et al., 2000). Determine viable counts and store spores at
20 C in 20% glycerol.
2. Prepare supplemented minimal media solid (SMMS) plates (20 ml agar/
plate; Takano et al., 2001).
Note: The source of the agar strongly affects the timing and production of
the pigmented antibiotics. Try to use only agar from the same company
and the same batch.
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3. For each plate, add 1  107–108 M145 spores (so the plate is just about
confluent) in 60–100 ml of water. Using wet sterile cotton buds, spread
confluently onto the plates and dry in the laminar flow cabinet.
4. Spot a sample (<2 ml) in the middle of the plate and dry. Incubate plates
at 30 C, check them every 8–12 h and record the antibiotic production
by scanning the plates on a scanner (or take a photograph) (Fig. 6.2).
Note:
 Avoid dropping a sample before a plate is completely dry or dropping
more than 2 ml of the sample. If the sample volume is more than 2 ml,
spot in 2 ml aliquots several times after drying each time or concentrate
the sample before spotting.
 The extracted samples should be spotted onto the indicator plate
within 8 h of spreading, the sooner the better. No induction of the
pigmented antibiotics will be observed if the indicator is grown for
more than 8 h.
 The optimal amount of the positive control is 0.25 mg for the
g-butyrolactone SCB1. When using extracts made from S. coelicolor
M145, 20–30 ml out of the 50 ml of sample either from 50 ml liquid
cultures or from three plates should give bioactivity.
 To measure the approximate concentration of g-butyrolactones
isolated: for plates start the inoculum with the exact same number of
viable spore counts for each sample; for liquid cultures measure the
growth phase (by OD450 nm) convert into milligrams per dry weight
and also measure the volume of the supernatant; this amount then can
be used for comparison between samples.
 As seen in Fig. 6.2, the color may change depending on the amount of





Figure 6.2 An example of a typical bioassay. Extracts from solid plates of S. coelicolor
J1501and S. lividanswere spotted onto the indicator strain M145, then incubated for 36 h
at 30 C. The pigmented halos are the result of the butyrolactones stimulating
pigmented antibiotic production.
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4. Kanamycin Bioassay
The kanamycin bioassay was developed as an easy and direct method to
detect g-butyrolactone. It is based on the g-butyrolactone receptor, ScbR,
and its binding to the target DNA and the g-butyrolactones. ScbR represses
transcription of its own gene and that of cpkO, a pathway-specific regulatory
gene for the Cpk cluster, by binding to the promoter regions (Pawlik et al.,
2007; Takano et al., 2005). This repression is abolished by SCB1, resulting in
transcription of the target genes. Using these principles, a g-butyrolactone
detection plasmid, pTE134, was constructed which harbors scbR and its own
promoter region with the ScbR binding sites, together with the cpkO
promoter with the ScbR binding sites, fused to a promoterless-kanamycin
resistance gene (Fig. 6.3). pTE134, was transferred into S. coelicolor LW16
(scbA and scbR double deletion mutant) to obtain the kanamycin indicator
strain LW16/pTE134. LW16 was chosen as a host strain for the kanamycin
bioassay because it does not produce g-butyrolactones and it lacks scbR,
thus avoiding competition from endogenous ScbR. The kanamycin
bioassay indicator strain LW16/pTE134 is sensitive to kanamycin but


















Figure 6.3 Schematicmapof pTE134 used for the kanamycin bioassay. pTE134 has scbR
(open arrow) with its own promoter region, scbRp (black arrow) and a cpkO promoter,
cpkOp (black arrow) coupled with a promoterless kanamycin resistance gene (neo, solid
arrow). The light gray arrow indicates hyg (omega hygromycin resistance gene), the
deep gray arrow represents oriT (RP4 origin of single-stranded DNA transfer), the
hatched arrow represents int (phiC31 integrase), the shaded arrow indicates a partial
coding region (204 bp) of scbB and the attP site (phage phiC31 attP site) is indicated by
a vertical black line. Restriction sites used for cloning are indicated by black lines
(not allSacI andEcoRI sites are shownon themap).
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and the kanamycin resistance gene is transcribed, rendering the indicator
strain kanamycin resistant (Hsiao et al., submitted for publication).
This assay was also tested for its ability to detect other butyrolactones
than the ones produced by S. coelicolor. Though the sensitivity is weaker than
for the native g-butyrolactones, with enough material spotted to the plates,
kanamycin resistance can be observed. Furthermore, g-butyrolactones have
been identified from those antibiotic producing Streptomyces strains which
were not known to produce these molecules using this assay (Hsiao et al.,
submitted for publication).
1. Prepare spore stocks of the kanamycin bioassay indicator strain LW16/
pTE134 and stock spores in 50–100 ml aliquots at –20 C in 20% glycerol.
Note: Because this indicator strain is unstable, spores need to be collected
from MS plates (Kieser et al., 2000) containing 50 mg/ml hygromycin, then
aliquoted. Avoid thawing and refreezing the spore stocks.
2. Prepare fresh DNAgar (Difco Nutrient Agar) plates containing kanamy-
cin at a final concentration 3–5 mg/ml (20 ml per plate).
Note: Because the cpkO promoter has very low activity (conferring
resistance to <10 mg/ml kanamycin), the concentration of kanamycin
should not be higher than 5 mg/ml (Fig. 6.4).
3. To each plate, add 2.6  106 spores of the indicator strain in about
60–100 ml of water. Using wet sterile cotton buds, spread confluently
onto the plates and dry.
4. Spot the extract or sample (<2 ml) in the middle of the plate and dry.
Incubate plates at 30 C, check them after 2–3 days and record the growth
by scanning the plates on a scanner. The kanamycin resistant colonies will




Figure 6.4 The kanamycin bioassay using different kanamycin concentrations in the
indicator media. 0.1 mg of chemically synthesized SCB1 was spotted onto lawns of
LW16/pTE134 (2.6106 spores) onDNAgar plates containing 5,10, 25, or 50 mg/ml kana-
mycin, respectively.The plateswere incubated at 30 C for 3 days.
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Note:
 Again avoid spotting a sample before a plate is completely dry or
spotting more than 2 ml of the sample. If the sample volume is more
than 2 ml, spot in 2 ml aliquots several times after drying each time or
concentrate the sample before spotting.
 The optimal amount of the positive control is 0.1 mg for SCB1 and
0.25 mg for A-factor. To enhance the density of the growth halo,
a larger amount of indicator spores and a smaller amount of kanamycin
in the indicator plate can be used (Figs. 6.4 and 6.5).
5. Identification of g-Butyrolactone Receptors
Several groups have used different methods to identify the g-butyr-
olactone receptors. The first receptor to be identified was by Horinouchi
and co-workers using an A-factor affinity column and recovering
the receptor from the crude extract of S. griseus (Onaka et al., 1995).
The same technique was used to identify the g-butyrolactone receptors
from S. virginiae (Okamoto et al., 1995) and S. lavendulae FRI-5
(Ruengjitchatchawalya et al., 1995). Another approach was via PCR
using degenerate oligonucleotides to isolate the two receptor homologues
in S. coelicolor (Onaka et al., 1998). Interestingly, Onaka and co-workers
failed to identify ScbR with this approach. This may be due to the limited
homologous sequence information at the time.
1.48102
2.6106
Figure 6.5 The kanamycin bioassay using different amount of indicator strains. 0.1 mg
of chemically synthesized SCB1 was spotted onto lawns of LW16/pTE134 (2.6  106
or 1.48  107 spores) on DNAgar plates containing 5 mg/ml kanamycin, respectively.
The plateswere incubated at 30 C for 3 days.
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We have identified ScbR only by cloning the g-butyrolactone synthase
gene, ScbA, which lies divergent from the ScbR gene, using PCR (Takano
et al., 2001). In most of the g-butyrolactone systems identified (apart from
that in S. griseus) synthase and receptor genes are next to or very close to
each other. It is best to use this property and to identify the g-butyrolactone
synthase gene first using degenerate oligonucleotides or by an in silico
approach. The degenerate oligonucleotides should be designed near
the active sites we have identified by mutagenesis analysis, which also
correspond to the AfsA repeats (Hsiao et al., 2007).
Another approach is to use any sequence information available. These
g-butyrolactone receptors will resemble TetR repressors and may be found
especially concentrated close to antibiotic biosynthetic gene clusters. There
are usually several g-butyrolactone receptor homologues in one strain.
To determine the ‘‘real’’ receptor, the amino acid identity should be
more than 40% compared to the functionally proven g-butyrolactone
receptors, that is, ArpA, BarA, FarA, and ScbR. These proteins also will
have a pI of around 5–6 compared to the other ScbR homologues whose
pIs are much higher at around 9–11.
6. Identification of the g-Butyrolactone
Receptor Targets
The first target to be identified was from the A-factor system by use
of the genomic SELEX (systematic evolution of ligands by exponential
enrichment) system (Ohnishi et al., 1999). This method uses purified
g-butyrolactone receptor in gel retardation assays on partially digested
chromosomal DNA to find the binding sites. Several groups have now
proposed the target sequences for the g-butyrolactone receptors (Folcher
et al., 2001; Kinoshita et al., 1999; Onaka and Horinouchi, 1997) (Fig. 6.6).
However, these sequences are not sufficiently conserved compared with the
identified targets for ScbR (Fig. 6.6).
We have used the properties of the TetR receptor family, which the
g-butyrolactone receptors resemble. TetR proteins regulate their own
genes and/or the adjacent gene. By using this property, gel retardation
was performed to identify one of the ScbR targets. To identify another
target of ScbR, microarray analysis was performed, which did not result in
the identification of a direct target but rather the downstream genes which
represent the Cpk antibiotic biosynthetic gene cluster. But doing so, the
direct target, a pathway-specific activator, for the Cpk cluster was identified.
Surprisingly, of the four targets of ScbR that we have identified, two, site R
and site OA, have 100% consensus sequences at 6 bp at each ends. While the
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others, site A and site OB, only have 4 bp that are conserved with site R and
site OA. In contrast, within the pair, 11 bp are conserved out of 23 bp
(Fig. 6.6) (Takano et al., 2005).
To identify the g-butyrolactone receptor targets, first use the promoter
region itself, and also include the promoter region of the gene adjacent to it,
to perform a gel retardation assay with either a purified protein or a crude
extract. The activity of the protein is stabilized when the protein is still in
the crude extract and at a low concentration. As soon as the protein is
purified and concentrated, it tends to aggregate and will no longer be
suitable for any further experiments to analyze activity. Use the identified
target sequence to identify further targets in silico.
7. Gel Retardation Assay to Detect Target
Sequences of the g-Butyrolactone Receptors
Gel retardation is not a new technique and can be found described in
many publications (e.g., Folcher et al., 2001; Kinoshita et al., 1999; Onaka and
Horinouchi, 1997). However, we have experience in using three differently
labeled g-butyrolactone receptor target DNA fragments, and have optimized
the technique for each probe using pure protein and crude extracts from
either Escherichia coli or Streptomyces.
SiteA (scbA/R promoter region) GAAAAAAAACCGCTCTAGTCTGTATCTTAA
SiteOB (kasO promoter region)
SiteR (scbA/R promoter region)
SiteOA (kasO promoter region)
ScbR binding consensus
ArpA binding consensus































Figure 6.6 Consensus sequences of different g-butyrolactone receptors. The target
sequences found so far for ScbR and its consensus sequences in S. coelicolor are presented
on the top five lanes.The bottom three lanes are consensus sequences reported for the
different receptor proteins. ArpA: Onaka and Horinouchi (1997); BarA, FarA:
Kinoshita et al. (1999); SpbR: Folcher et al. (2001). Bold letters represent the conserved
base pairs in ScbRbinding sites.The base pairs in italic in siteA and siteOB represent the
conserved base pairs between these two sites.
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7.1. Labeling of DNA fragments
7.1.1. Radio-labeled probes
1. The oligo was first labeled at the 50 ends by incubation of 50 pmol
of oligo, 5 ml of [g-32P]ATP (10 mCi/ml), 1 ml of 10 kinase buffer,
and 1 ml T4 nuclease kinase in a total volume of 50 ml incubated at 37 C
for 30 min–1 h. The reaction was stopped and cleaned by addition of 1
volume of phenol/chloroform with vortexing, then the phenol was
extracted by addition of either 1 vol of chloroform or ether, twice.
The oligo were precipitated using 100% EtOH with 3 M NaoAc and
1 mg of glycogen at 20 C preferably O/N. The mixture was spun at
4 C for 30 min, then the supernatant discarded, and the pellet air dried.
2. PCR was conducted using labeled- and unlabeled-oligos. 60 ng of tem-
plate, 50 pmol of both unlabeled- and labeled-oligos, 200 mM dNTP, 5%
DMSO, and PCR buffer (commercial) together with Taq polymerase
were incubated to amplify in a total volume of 100 ml. The PCR condi-
tions are: 95 C for 5 min, then 30 cycles of 95 C for 50 s, 55 C for 40 s,
72 C for 40 s, then extend at 72 C for 5 min. Five microliters of the
reaction was loaded on a gel to assure amplification. If extra bands are
amplified, the fragment of interest can be purified using a commercial
gel-extraction kit. The final volume should be eluted in 50 ml.
3. Gel retardation was conducted with 2.5 ng of labeled DNA (about
10 cpm), pure protein or 0–15 ml crude extract from E. coli or Streptomy-
ces, 125 mMHEPES pH 7.5, 20 mM DTT, 20% glycerol, 200 mM KCl,
0.16 mg/ml calf thymus DNA in a final volume of 12.5–25 ml. The
mixture was incubated at room temperature for 10 min, then 2–4 ml of
loading dye (50%(v/v) glycerol, 0.25% (w/v) bromophenol blue, 10 mM
Tris–HCl, pH 8, 1 mM EDTA) was added. To detect the binding of the
receptor to the butyrolactones, the butyrolactones can be added either
before or 10 min after the incubation. In the case of SCB1, 1 mg was
added to see a release of the full shift.
Note:
 For the E. coli crude extract, a 10 ml LB overnight preculture of E. coli
harboring a plasmid with the g-butyrolactone receptor gene under the
control of the lacZ promoter was inoculated at a 1:100 dilution in
50 ml LB and grown at 37 C until OD600 0.7–0.8 when induced with
1 mM (final conc.) IPTG (Isopropyl b-D-1-thiogalactopyranoside).
After another 3 h of incubation, cells were harvested by centrifugation
and the cell pellet was washed twice with buffer (50 mM of Tris pH
7.0, 1 mM of EDTA, 1 mM of DTT, 100 mM of phenylmethylsulfo-
nylfluoride (PMSF)) and resuspended in 500 ml of the same buffer.
100 ml aliquots were stored at 80 C for later use. For crude extract
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preparation, the cells were immediately disrupted by sonication. The
cell lysate was clarified by centrifugation and the supernatant used as a
crude extract after determination of the total protein content.
 For the S. coelicolor crude extract, S. coelicolor was grown in 50 ml of
SMM then the same procedure as above was followed except the cells
were resuspended in 100 ml prior to sonication and 10 ml was used for
the gel retardation analysis. Due to the growth phase-dependent
expression of ScbR, the time point of growth when the cells were
harvested is crucial to detect any protein binding to the DNA.
 KCl was the best salt for this assay and MgCl was not suitable.
4. For detection of 100–300 bp DNA fragments, a 5% acrylamide gel
(5% acrylamide: bisacrylamide ¼ 37.5:1, 1.25 ml of 10 TBE, 15 ml of
TEMED, 87.5 ml of 10% AMPS in a total of 12.5 ml) was used in 1
TBE (90 mM Tris–HCl, 90 mM boric acid, 2 mM EDTA, pH 8.0)
running buffer. It is also possible to use a 3.5% acrylamide gel to
detect a longer DNA fragment. A Bio-Rad Mini Protean kit was used
for running the gel at 100 V constant for 1 h till the BPB just ran off
the gel.
5. The gel was then taken off the glass and wrapped in cling film (Saran
wrap) and directly placed onto an X-ray film (Super RX (Fujifilm)), and
exposed for 30 min at room temperature in a cassette. The film was
developed using an automated film developer (Fig. 6.7A).
Probes
Crude extract
R 2.5 ng DIG-X 0.23ng
4.0ml−
A B C D
130mg− − 130mg − 50mg
DIG-L 1.8 ng Cy 20ng
Figure 6.7 Gel retardation assay using differently labeled probes. Gel retardation
using: (A) Radio-labeled probes (R); (B) DIG-labeled probes with detection using
X-ray film (DIG-X); (C) DIG-labeled probes with detection using Lumi-imager
(DIG-L); (D) Cy3-labeled probes (Cy). All probes were made using a 146 bp DNA
fragment which includes the ScbR binding site Rwhich is situated at 68 to 42 nt
from the transcriptional start site (Takano et al., 2001).The amount of each probe used is
indicated next to each probe name. Crude extract (given in total protein as microl,
microg) from E. coli harboring pIJ6120 was used and the amount is indicated on the top
of the lanes.
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7.1.2. DIG-labeled probes
1. DNA fragments were first amplified by PCR using both unlabeled-
oligos using the PCR conditions mentioned in Point 2 of Section
7.1.1. Purified PCR product (either by a cleanup kit or by extracting
from a gel), 100 ng, was used in the DIG gel shift kit 2nd generation
(Roche) labeling procedure, steps 5–7 (p11 of Roche protocol). (Note:
this kit labels 30 ends.)
2. After labeling, the probes were incubated with the protein for gel
retardation assays as in Point 3 of Section 7.1.1.
Note:
 The labeled probes can be stored at 20 C for a very long time.
 Depending on the sensitivity of the detection method used (see
below), the amount of DIG-labeled probe may have to be varied.
In our case, eightfold less probe was used for detection with X-ray
films (we used 1.8 ng of labeled probe) compared to when a Lumi-
imager F1 (we used 0.23 ng labeled probe) was used for detection
(Fig. 6.7B and C).
 After optimization of the amount of probe used, the protein concen-
tration in the assay will have to be adjusted to keep the protein/DNA
ratio constant.
3. After running, the gel was taken off the glass plates for direct contact-
blotting (Roche protocol 3.7.2), further crosslinking (3.7.3), and chemi-
luminescent detection (3.8). The membrane was detected using an X-ray
film exposed for 20 min, then developed in an automated X-ray film
developer (Fig. 6.7B) or in a Lumi-imager F1 (Roche) for 40 min at
room temperature (Fig. 6.7C).
7.1.3. Cy3-labeled probes
The DIG-labeling protocol will take up to 2 days. To improve the effi-
ciency in time, Cy3-labeled oligos are now our preferred choice.
A preliminary protocol is described below.
1. 50-Cy3-labeled oligo was purchased from Sigma–Aldrich and used for
PCR along with the unlabeled-oligo as in Point 3 of Section 7.1.1. The
amplified product was purified and the concentration measured by
Nanodrop (Thermo scientific).
2. The gel retardation was conducted with 20 ng of Cy3-labeled DNA
fragment with 50–300 mg of crude extracts from Streptomyces as in Points
3 and 4 of Section 7.1.1. After running, the gel with the glass plate is
exposed for 30 s and detected in a LAS 4000 (Fujifilm) (Fig. 6.7D).
Note: A flourescence compound was detected in the Streptomyces crude
extract which may interfere with detection.
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8. Conclusions
The rapid small-scale purification of the g-butyrolactones and the
kanamycin assay have simplified the detection of the g-butyrolactones,
which are found to be one of the important factors in the regulation of
antibiotic production. From genome sequences and also from the sequence
of many antibiotic biosynthetic gene clusters many homologues to the
g-butyrolactone synthases and receptors have been identified, but the
number of g-butyrolactones elucidated has not increased since year 2000.
This method may provide an easy solution to detect the g-butyrolactones
from those strains which have the synthase and receptor homologues
and also to identify new organisms that may produce g-butyrolactones.
The binding sensitivity of the different g-butyrolactones to ScbR has been
tested and found to be lower; however, with enough material kanamycin
resistance was observed (Hsiao et al., submitted). Identification of the
receptor target is a major job. However, with the several hints obtained
from previous work and also from our experience with the gel retardation
assays, it may be possible to quicken the procedure.
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